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Abstract
The increase in bacterial resistances and the decrease in available antibacterial substances
against multi-drug resistant pathogens calls for an intensified search for novel antibiotics.
Therefore, in this study riboswitches were investigated as new antibacterial drug targets.
Riboswitches, which are RNA elements mostly found in the 5’ UTR of bacterial mRNA,
consist of a metabolite-binding aptamer domain and an expression platform. They regulate up
to 4% of all bacterial genes, either by inhibiting transcription or translation initiation. As many
of the genes regulated by riboswitches are essential for bacterial functioning, manipulation of
riboswitch activation may enable control over bacterial growth and viability. In this study, two
riboswitches with distinct regulatory mechanisms were investigated: the glmS ribozyme and
a thi -box riboswitch. The glmS riboswitch is a catalytically active RNA that regulates gene
expression by recognition of glucosamine-6-phosphate (GlcN6P), subsequent self-cleavage, and
degradation of glmS mRNA. Thi -box riboswitches recognize thiamine pyrophosphate (TPP)
and are involved in the regulation of TPP-biosynthesis genes. While TPP is a fundamental
cofactor for the crucial function of many bacterial proteins, GlcN6P is an important precursor
of cell wall biosynthesis.
Here, it was sought to identify modulators for these two riboswitch classes based on different
strategies. Firstly, in silico predicted riboswitch ligands were validated in vitro. Secondly, in
vitro and in vivo screenings were performed using rationally designed libraries of compounds
with structural analogy to their natural ligand. Finally, also natural products were investigated
for riboswitch modulation.
The screening of designed compound analogs identified carba-sugars as potent activators of
the glmS ribozyme of Staphylococcus aureus. These GlcN6P analogs activate the ribozyme to
a level comparable with the natural metabolite in vitro and revealed inhibition of bacterial
growth of a vancomycin-intermediate resistant S. aureus strain. Furthermore, compounds
suggested by virtual screening, and natural substances such as aminoglycosides were shown
to be inhibitors of glmS ribozyme cleavage. Finally, a natural GlcN-nitrosourea-derivative
revealed glmS ribozyme activating potential in vitro, albeit at higher concentrations than
carba-sugars.
The E. coli thi -box riboswitch thiM was shown to be modulated by triazolethiamine (TT)
and derivatives in vivo and increasing concentrations of TT led to a decrease in E. coli
growth. Additionally, thiamine analogs containing metal-chelating groups that mimic the
pyrophosphate moiety of TPP revealed efficient activation the thi -box riboswitch in vivo.
This study describes the discovery and characterization of the first glmS ribozyme activating
compound with effects on bacterial growth as well as thiM riboswitch activators that act
through a distinct mechanism in comparison to the already described thiamine analog
pyrithiamine (PT). The different screening assays applied as well as the compounds identified
in this study enabled a thorough investigation of riboswitches and their artificial regulation.
In the future, some of these promising riboswitch modulators may serve as lead structures for
novel antibacterials to combat the increasing number of multi-drug resistant pathogens.
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Zusammenfassung
Durch die Zunahme bakterieller Resistenzen stehen immer weniger antibiotisch wirksame
Substanzen gegen multiresistente Bakterienstämme zur Verfügung. Diese Tatsache begründet
die fortlaufende, intensive Suche nach neuen Antibiotika. Im Fokus dieser Suche liegen neben
Substanzen mit neuen Wirkungsmechanismen auch solche, die neue Zielstrukturen angreifen.
In der vorliegenden Arbeit wurden RNA-Schalter (Riboswitches) als neue Zielstrukturen für
die Entwicklung antibakterieller Wirkstoffe untersucht.
Riboswitches sind RNA-Elemente, die zumeist in der 5’ untranslatierten Region bakterieller
mRNA zu finden sind und aus einer Metabolit-bindenden Aptamerdomäne und einer Expres-
sionsdomäne bestehen. Diese RNA-Strukturen regulieren bis zu 4% aller bakteriellen Gene,
entweder durch vorzeitiges Beenden der Transkription oder Hemmung der Translationsinitia-
tion. Da viele Riboswitch-regulierte Gene essentiell für bakterielle Funktionen sind, ermöglicht
die Manipulation der Riboswitch-Aktivierung eventuell die Kontrolle von Bakterienwachstum
und -überleben.
In dieser Arbeit wurden zwei RNA-Schalter mit verschiedenen regulatorischen Mechanismen
untersucht: der glmS-RNA-Schalter sowie ein thi-Box Riboswitch. Der glmS Riboswitch
ist eine katalytisch aktive RNA (ein Ribozym), welche durch Erkennung von Glucosamin-6-
phosphat (GlcN6P), anschließender Selbstspaltung und Abbau der glmS mRNA die Genex-
pression reguliert. Thi-Box RNA-Schalter erkennen Thiaminpyrophosphat (TPP) und sind
an der Regulation von Genen der TPP-Biosynthese beteiligt. Während TPP ein wichtiger
Cofaktor für entscheidende Funktionen vieler bakterieller Proteine ist, spielt GlcN6P eine
bedeutende Rolle als Vorläufer der Zellwandbiosynthese.
In der hier vorliegenden Arbeit wurden verschiedene Strategien zur Identifikation von
Modulatoren dieser Riboswitch-Klassen genutzt. Zum einen wurden in silico vorhergesagte
Riboswitch-Liganden in vitro validiert. Zum anderen wurden in vitro und in vivo Screenings
mit designten Bibliotheken unternommen, die strukturelle Ähnlichkeit zum natürlichen
Liganden aufwiesen. Schließlich wurden auch natürliche Substanzen auf ihre Riboswitch-
modulierenden Wirkungen hin untersucht.
Im Screening der rational designten Substanzanaloga wurden Carba-Zucker als potente
Aktivatoren des glmS-Ribozyms von Staphylococcus aureus identifiziert. Diese GlcN6P-
Analoga aktivieren das Ribozym in vitro fast genauso stark wie der natürliche Metabolit und
hemmen das Wachstum eines intermediär Vancomycin-resistenten S. aureus Stammes. Darüber
hinaus konnte gezeigt werden, dass Substanzen, die im virtuellen Screening gefunden worden,
sowie bereits bekannte, natürliche Substanzen wie beispielsweise Aminoglycoside, die glmS-
Ribozym-Selbstspaltung hindern können. Außerdem zeigte eine Glucosamin-Nitrosoharnstoff-
Verbindung glmS-Ribozym-Aktivierung in vitro, jedoch bei höheren Konzentrationen als die
Carba-Zucker.
Desweiteren wurde gezeigt, dass der E. coli thi-Box Riboswitch thiM in vivo durch Tria-
zolthiamin (TT) und Derivate moduliert wird und steigende Konzentrationen von TT zu einer
Verminderung des Bakterienwachstums führen. Zusätzlich aktivierten Thiaminanaloga mit
Metall-chelatierenden Gruppen, welche möglicherweise das Pyrophosphat von TPP imitieren,
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den ThiM Riboswitch in vivo.
Diese Arbeit beschreibt die Entdeckung und Charakterisierung der ersten synthetischen
Substanz, die das glmS Ribozym aktiviert und Bakterienwachstum hemmt, sowie thiM
Riboswitch-Aktivatoren, die wahrscheinlich über einen vom bekannten Thiaminanalogon
Pyrithiamine (PT) abweichenden Mechanismus auf den Riboswitch wirken. Die genutzen,
unterschiedlichen Screening-Systeme sowie die in dieser Studie entdeckten Substanzen er-
möglichen eine fundierte Untersuchung von Riboswitches und ihrer künstlichen Regulation.
In Zukunft könnten einige dieser vielversprechenden Substanzen als Leitstrukturen für neue
Antibiotika genutzt werden, um die steigende Zahl an multi-resistenten Pathogenen zu
bekämpfen.
4
1 Introduction
Genetic control has been presumed to result mostly from protein factors that act as tran-
scriptional repressors or activators. However, over the past 15 years the role of non-coding
RNAs (ncRNAs) in the control of bacterial gene expression has been unraveled (Dambach
and Winkler, 2009). Among them are ncRNAs acting in trans, such as small RNAs (sRNAs),
which interact with their target mRNAs through base-pairing (Repoila and Darfeuille, 2009),
or affect gene expression by associating with RNA-binding proteins (Babitzke and Romeo,
2007) or with RNA polymerase (Storz et al., 2006). Furthermore, the 5’ untranslated region
(5’UTR) of the mRNA can often contain cis-acting regulatory elements which respond to many
different types of effector signals (Figure 1.1). These include the recognition of metabolites
(Figure 1.1 A), or metals (Figure 1.1 B), the detection of fluctuations in temperature (Figure
1.1 C, Narberhaus et al. (2006)), the recognition of RNA-binding proteins or trans-encoded
RNAs (Figure 1.1 D & J, Irnov et al. (2006); Grundy and Henkin (1998); Dambach and
Winkler (2009)) or combinations of these recognition mechanisms (Figure 1.1 E-J).
The metabolite-sensing RNAs which modulate many fundamental biochemical pathways
and essential cellular functions constitute a major class among these cis-regulatory RNAs
(Figure 1.1 A, B, E-I and Section 1.1). They are referred to as riboswitches (Section 1.1)
and will be in the focus of this work. The detailed understanding of their structures and
differential architectures, phylogenetic conservation and distribution, as well as the regulatory
systems they use, will form the foundation for understanding the application of riboswitches
as antibacterial targets particularly with respect to multi-drug resistant pathogens evolving
(Section 1.4).
Figure 1.1: Posttranscrip-
tional regulation of gene
expression in bacteria.
Increased (+) or decreased
(-) gene expression by cis-
regulatory RNAs (depicted as
hairpins) in response to cognate
stimulus (A-E). Hypothetical
cis-regulatory RNA responding
to a combination of metals
and metabolite concentrations
(F). Tandem riboswitches that
respond to the same (G) or
different metabolites (H, I).
Possibly multiple, distinct
posttranscriptional regulatory
mechanisms cooperate in con-
trolling downstream expression
(J). Figure taken from Dambach
and Winkler (2009).
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1.1 Riboswitches
Riboswitches are RNA elements found in mRNAs and efficiently regulate gene expression
within many fundamental metabolic pathways (Mandal et al., 2003). They have been identified
not only in bacterial, but also in archaeal and eukaryotic genomes (Rodionov et al., 2002;
Sudarsan et al., 2003a). Riboswitches consist of an aptamer domain and an expression
platform. The natural aptamer recognizes the cognate ligand with high affinity and specificity.
Binding of the ligand to this sensory domain induces a global secondary structure change,
that also influences the expression platform of the riboswitch. These changes mostly lead
to repression of gene expression by transcription termination or inhibition of translation
initiation.
1.1.1 Classes of riboswitches
Riboswitches are grouped into different classes according to their sequence and structure
conservation within the aptamer domain. At present more than 20 riboswitch classes are known,
some of which represent orphan riboswitches, whose natural ligands remain unidentified to
date. Among the known riboswitch classes are seven which respond to enzymatic cofactors, like
adenosyl-cobalamine (AdoCbl, Nahvi et al. (2004)), thiamine pyrophosphate (TPP, Winkler
et al. (2002a)), flavin mononucleotide (FMN, Winkler et al. (2002b)), S-adenosylhomocysteine
(SAH, Wang and Breaker (2008); Wang et al. (2008)), molybdenum cofactor (Moco, Regulski
et al. (2008)), S-adenosylmethionine (SAM, Grundy and Henkin (1998); Winkler et al. (2003))
and tetrahydrofolate (THF, Ames and Breaker (2010)). Three riboswitches were described
that sense amino acids (glycine, glutamine, lysine Mandal et al. (2004); Ames and Breaker
(2011); Sudarsan et al. (2003b)) and one recognizes an amino sugar, glucosamine-6-phosphate
(GlcN6P, Winkler et al. (2004)). Moreover, there are several of these RNA elements that
react to purines (adenine, Mandal and Breaker (2004) & guanine, Batey et al. (2004)) or
other nucleobase containing ligands like deoxyguanosine (dG), prequeuosine ( preQ1, Roth
et al. (2007)) or cyclic di-GMP (c-di-GMP, Sudarsan et al. (2008); Lee et al. (2010)). Finally,
also ions like Mg2+ and F− can trigger riboswitch mediated gene regulation (Ramesh and
Winkler, 2010; Baker et al., 2012).
The aptamer domains which determine the riboswitch class vary in length from about
30 nt (preQ1 riboswitch, Roth et al. (2007)) to approx. 150 nt (TPP riboswitch), and also in
secondary structure complexity (Dambach and Winkler, 2009). Some riboswitch sequences
and structures are exceedingly well conserved among different species, e. g. the TPP riboswitch
class (Breaker, 2011; Barrick and Breaker, 2007). Nevertheless, other metabolites can be
recognized by several distinct aptamer folds. There are, for example, two different preQ1
(Roth et al., 2007; Meyer et al., 2008) and two kinds of c-di-GMP riboswitches (Shanahan
et al., 2011). However, the riboswitch that probably best exemplifies this variation in aptamer
structure is the SAM-responsive element for which at least six subtypes are known (Winkler
et al., 2003; Weinberg et al., 2008, 2010; Corbino et al., 2005; Poiata et al., 2009; Fuchs et al.,
2006).
The specific discrimination of the appropriate riboswitch ligand under a pool of many, often
very similar, metabolites is neccessary to allow precise gene regulation (Barrick and Breaker,
2007). Riboswitches are capable of this high selectivity through shape complementarity, and
specific interactions (Serganov and Patel, 2012). The latter are usually established through
numerous hydrogen bonds between aptamer and ligand, but can also include electrostatic,
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van der Waals and stacking interactions. Riboswitch aptamers bind their target with high
affinities that extend from the mid micromolar (glmS ribozyme, Winkler et al. (2004)) to the
mid picomolar range (TPP, Welz and Breaker (2007) or FMN, Lee et al. (2009)). Finally,
aptamers can be structurally preorganized in the absence of ligand, but because riboswitch
ligands are usually well buried within a binding pocket (Breaker, 2008), ligand binding often
induces structural rearrangement or stabilization of aptamer substructures (Breaker, 2010).
Frequently, cations aid in ligand recognition by shielding negative charges of the cognate
molecule. Examples include the negatively charged pyrophosphate group of TPP which is
coordinated by two Mg2+ ions (Edwards and Ferré-D’Amaré, 2006), or flouride which is only
recognized by its riboswitch, when it interacts with three Mg2+ ions (Ren et al., 2012). Other
cations, like potassium can also be required for metabolite binding as shown for the lysine
riboswitch (Serganov et al., 2008).
1.1.2 Mechanisms of riboswitch-mediated gene control
Riboswitch-mediated gene regulation is facilitated by the concerted communication between
aptamer domain and expression platform. Whereas the well-conserved aptamer domain is
even used to categorize these RNA elements, the expression platforms are far less conserved.
This is mainly due to the fact, that they harness folding differences which enable several
different processes to interfere with gene expression efficiency (Breaker, 2010).
One of the most common mechanisms of riboswitch control involves the manipulation of
transcription termination (Figure 1.2 A). Here, ligand binding induces a conformational change
in the expression domain that creates a terminator stem followed by a stretch of five to nine
uridines. Upon encountering this structure, the RNA polymerase pauses and eventually falls
off its template, thus prematurely ending transcription. In the absence of ligand, a competing
second structure or anti-terminator is formed that allows efficent mRNA production. Some
riboswitch-RNA fragments generated by premature transciptional arrests have been shown to
be prone to degradation by specific RNases (Spinelli et al., 2008; Shahbabian et al., 2009).
Similarly to the transciption termination mechanism, gene expression can be regulated by
riboswitches on the translation initiation level. Here, two altering RNA folds control ribosome
access to the ribosome binding site (or Shine-Dalgarno (SD) sequence). In the presence of
ligand, the anti-SD-sequence sequesters the ribosome binding site, which prevents association
of the small ribosomal subunit and hence translation start. This mechanism of gene regulation
by riboswitches is more commonly found in organisms that also make extensive use of the
protein factor Rho (Figure 1.2 B, Barrick and Breaker (2007); Roth and Breaker (2009)),
which is an RNA binding protein that enhances transcript termination in regions that are not
masked by ribosomes (Ciampi, 2006).
In addition to these widespread mechanisms, there are riboswitches known that regulate
splicing (Figure 1.2 C, Croft et al. (2007)), or gene expression via transcription interference
or antisense action (Figure 1.2 D Breaker (2010); André et al. (2008)), dual transcription and
translation control (Figure 1.2 E, Rodionov et al. (2004); André et al. (2008)) as well as RNA
cleavage (Figure 1.2 F, Winkler et al. (2004)).
Splicing was found to be regulated by TPP riboswitches in plants and fungi (Figure 1.2 C,
Sudarsan et al. (2003a); Cheah et al. (2007); Wachter et al. (2007); Kubodera et al. (2003)).
Thi-box RNAs will be discussed in greater detail in Section 1.3 as will be the detailed gene
regulatory mechanism employed by glmS ribozyme self-cleavage (Section 1.2, Figure 1.2 F,
Winkler et al. (2004); Collins et al. (2007)).
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Figure 1.2: Established and predicted mechanisms of riboswitch-mediated gene reg-
ulation. Most common mechanisms are transcription termination (A), translation initiation –
perhaps accompanied by Rho, which recognizes nascent mRNA that is not actively translated,
thus causing transcription termination– (B), and splicing control in eukaryotes (C). More rare
mechanisms observed or predicted in some bacterial species include transcription interference or
possibly antisense action (D), dual transcription and translation control (E), and ligand-dependent
self-cleaving ribozyme action (F). Figure taken from Breaker (2010).
Not depicted in detail is the mechanism of a SAM-I riboswitch in Clostridium acetobu-
tolyticum. This special riboswitch is encoded in trans downstream of an operon involved in the
conversion of methionine to cysteine (Rodionov et al., 2004) and confers its gene regulatory
function by controlling the production of antisense transcripts in cis, which interact with the
mRNA like sRNAs to downregulate gene expression (André et al., 2008).
Riboswitches most often provide the means for negative feedback regulation of metabolic
pathways, being placed upstream of those genes that produce the ligand by which they
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are triggered. This allows the organisms to quickly react to changes in their environment.
However, there are also two examples of positive feedback regulation: the glycine and adenine
riboswitches. The latter RNA element, for example, is often found in front of genes that are
only required when high adenine concentrations are encountered in the cell, such as adenine
transporters or adenine deaminase (Mandal and Breaker, 2004; Mandal et al., 2004).
1.1.3 Stacking of riboswitch components
In addition to the varieties of aptamer structures and ligand specificities, the repertoire of gene
regulatory function by riboswitches can be expanded to more complex architectures consisting
of, e. g. several riboswitches in tandem (Figure 1.1 F-I), or multiple aptamer domains followed
by a single expression domain. These sensory domains could recognize the same or a different
ligand and bind them independently or in a cooperative manner. All these scenarios will
influence gene regulation efficiency (explained in detail in Breaker (2010)).
Under the simplest conditions, where a gene is controlled by a riboswitch carrying only a
single aptamer and expression platform, an 81-fold change in ligand concentration is needed to
progress from 10% to 90% gene expression (Welz and Breaker, 2007; Breaker, 2010). When
two or more riboswitches that sense the same ligand are placed in series, the system requires
only a 40-fold change in ligand concentration to elicit the same change in gene expression
(Breaker, 2008). However, this is merely the case if these tandem riboswitches are triggered
with near-identical ligand concentrations and if triggering either one independently represses
gene expression (Breaker, 2008).
Even more complex is the natural example of a Boolean operator, which consists of two
different riboswitches specific for two different ligands. Binding of either ligand will cause the
activation of gene regulatory processes. This case of riboswitch stacking has been observed
for the metE mRNA in Bacillus clausii (Sudarsan et al., 2006).
A glycine riboswitch from Vibrio cholerae provides yet another example of architectural
complexity, as it carries two similar aptamers and one expression platform (Barrick and
Breaker, 2007; Mandal et al., 2004). If perfectly cooperative, then the riboswitch could
overcome the 10% to 90% gene expression range with only a factor of 9 change in glycine
concentration (Breaker, 2008). In this case perfect cooperativity means that ligand binding
at either side improves affinity at the other.
1.1.4 Riboswitch folding and function
Riboswitch folding in bacteria is tightly coupled to transcription (Serganov, 2010) and was
shown to contribute greatly to the efficiency of riboswitch mediated gene control. Hence, it is
not surprising to find some aptamer domains that bind their ligand only when the expression
domain has not yet been transcribed. However, there are two extremes of how riboswitches
handle the concerted action of ligand binding and folding. The one extreme is represented by
riboswitches which exist in a fairly well-defined, pre-organized conformation in the absence of
ligand. Ligand-dependent conformational changes are limited to a region within or adjacent to
the binding pocket (Montange and Batey, 2008). The glmS, purine and SAM-II riboswitches
belong to this category. Even though the glmS and SAM-II riboswitches are rather rigid,
there is a certain degree of pre-organization in apo-state of purine riboswitches, which oscillate
between different non-binding structures and then likely use conformational selection for
ligand recognition (Liberman and Wedekind, 2012). Therefore, when the ligand binds, the
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aptamer structure continues to envelope the ligand by folding.
The other extreme of riboswitch folding is represented by those RNA structures that will
undergo extensive changes in secondary and tertiary structure upon ligand recognition in
addition to local changes near the binding pocket (Montange and Batey, 2008). The TPP,
M-box and SAM-I riboswitch classes are members of this group. As binding pockets of these
riboswitches are often split, significant conformational changes in the RNA are necessary
to bring together distal elements of tertiary structure (Montange and Batey, 2008). These
extensive structural changes are often supported by cations such as Mg2+, which aid the
folding of ligand-binding conformations and assist in ligand recognition, e. g. by the alignment
of helical segments and thus the promotion of base pairing (Serganov and Patel, 2012).
1.1.5 Phylogenetic distribution of riboswitches
Since the aptamer domain has to use the limited diversity of only four nucleobases for target
recognition, it is not surprising that its sequence is often well conserved. This sequence and
structure conservation is used to assign riboswitches to distinct classes, but can also be used
Figure 1.3: Ri-
boswitch dis-
tributions and
phylogenetic
conservation.
Depicted is the
phylogenetic tree
with standard
accepted branch-
ing for different
organisms. The
size of squares
illustrates the
frequency with
which a given
riboswitch oc-
curs in the
corresponding
taxonomic group.
The bar diagram
on the right
demonstrates
the total number
of nucleotides
from each tax-
onomic division
in the sequence
databases that
were searched.
Figure taken
from Barrick et
al. (2007).
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to estimate the phylogenetic distribution and conservation of these RNA elements (Figure
1.3, Barrick and Breaker (2007)).
The TPP riboswitch is the only class known to date that can be found in all three
domains of life: bacteria, archeae and eukarya. The AdoCbl riboswitch is widely distributed
among eubacteria and seems to be a key-regulator of this metabolite’s biosynthesis. The
glmS ribozyme recognizing GlcN6P is mainly found in Gram-positive bacteria, where it was
predicted to exist in at least 18 other species apart from Bacillus subtilis (Barrick et al.,
2004). Purine riboswitches are the least distributed and the preQ class is only found in
proteobacteria. Interestingly, the distribution of SAM-I and SAM-II classes overlaps only
slightly and indicates how these two classes rather complement each other in a variety of
organisms. In proteobacteria for example, SAM-II dominates over the occurance of SAM-
I, which is preferably found in firmicutes, fusobacteria, actinobacteria, cyanobacteria and
acidobacteria, that do not regulate their SAM levels by SAM-II riboswitches. Although in
some bacteria both SAM-sensing classes are found, no single bacterium carries both SAM-I
and SAM-II riboswitch classes (Barrick and Breaker, 2007). Additionally, SAH riboswitches
are predicted to be present in proteobacteria and SAM-IV RNA elements in actinobacteria
(Weinberg et al., 2007).
Firmicutes, fusobacteria and γ-proteobacteria use riboswitch regulation extensively, even
though the latter carry fewer representatives of each class (Barrick and Breaker, 2007).
Although, the appearance of these distributions may shift as new genomes are constantly
sequenced and several new riboswitch classes have been discovered since this description was
published by Barrick in 2007, Figure 1.3 still demonstrates how commonly riboswitches are
used as regulatory tool in bacteria.
1.1.6 Riboswitches as new antibacterial drug targets
Antibiotics known to date address a relatively concise spectrum of targets (Figure 1.4). They
interfere with important cellular processes like transcription (rifampicins), translation (amino-
glycosides, macrolides, tetracycline, oxazolidinone), metabolic pathways, e. g. tetrahydrofolate
synthesis (sulfonamides) as well as cell wall biosynthesis (β-lactam antibiotics, glycopeptides).
Despite this collection of means employed and targets addressed, the development of resis-
tances hampers the use of several antibiotics today. This rise in antibiotic resistances creates
an urgent need for the development of antibacterial substances that address new targets and
use novel modes of action.
Riboswitches constitute such a new promising target. This is not only due to the fact that
structured RNA is a druggable entity in general (e. g. rRNA binding by aminoglycosides),
but also because riboswitches naturally bind low molecular weight ligands with a distinction
similar to that known by proteins (Blount and Breaker, 2006). Moreover, they are known to
regulate up to 4% of all bacterial genes, many of which are essential. Finally, exept for TPP,
riboswitches have mainly been identified in bacteria. And the TPP recognizing RNA elements
present in eukarya exert regulatory mechanisms very distinct from the ones used by eubacteria
(Section 1.1.2). In an agonistic fashion, riboswitch targeting compounds are thought to
permanently activate the riboswitch and hence repress gene expression even under starvation
from that metabolite (Blount et al., 2007), provided that the mimic cannot functionally
replace the natural ligand. However, many of the essential metabolites whose production is
regulated by riboswitches are also needed by mammals, e. g. the vitamin B1, TPP. Hence,
ligand analogs could not only act on riboswitches but also interfere with mammalian enzymes,
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Figure 1.4: Antibiotic drug targets in bacteria. Schematic representation of a bacterial
cell to illustrate different modes of action employed by known classes of antibiotics (black) with
some substance representatives in brackets, and their most frequently used resistance mechanisms
(red). Arrows point at target structures. The novel, promising target represented by riboswitches
is highlighted in orange.
as known for pyrithiamine (PT, Koedam (1958)) and L-aminoethylcysteine (AEC, Girolamo
et al. (1986)). Nevertheless, evidence exist that there are differences in recognition of cognate
ligands by enzymes and riboswitches (Serganov et al., 2006; Lim et al., 2006), which opens
up the possibility of finding compounds that only interact with the bacterial riboswitch. As
riboswitches can also be located in front of several genes or controlling entire operons, the
collective repression of these genes within a certain metabolic pathway could be deleterious.
Depending on their natural distribution substances targeting riboswitches could be used
as broad-spectrum antibiotics (such as TPP or FMN riboswitches, Section 1.1.5) or as more
selective drugs (like preQ or purine riboswitches, see Figure 1.3, Section 1.1.5).
Moreover, these RNA elements are compatible with the establishment of high-throughput
screening systems (HTS) as shown for the glmS ribozyme by Blount et al. (2006); Mayer and
Famulok (2006). Additionally, rational design approaches have proven to be indispensible for
identifying novel riboswitch modulators (Blount et al., 2006; Lünse et al., 2011).
1.1.6.1 Riboswitch-targeting compounds
When searching for riboswitch activating drugs one has to overcome the challenge of finding
chemical entities that are still close enough to the natural riboswitch ligand to be recognized,
but as much dissimilar as possible to avoid resistance mechanisms or side effects.
The thiamine analog pyrithiamine (PT, Figure 1.5, A), whose mode of action remained
elusive for decades, was finally shown to exert at least parts of its toxic effects by the
interaction with thi -box riboswitches. Like thiamine, PT is taken up and phosphorylated to
pyrithiamine pyrophosphate (PTPP, Iwashima et al. (1976)). As such, it acts on the riboswitch
and represses the expression of thiamine biosynthesis and transport genes (Sudarsan et al.,
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2005). PT resistant bacteria have been shown to contain mutations in the aptamer domain of
thi -box riboswitches, which result in the inhibition of proper ligand recognition and efficient
metabolite binding.
Screening of lysine related compounds resulted in the identification of several lysine analogs,
e. g. L-aminoethylcysteine (AEC) and DL-4-oxalysine, able to repress gene expression (Blount
et al., 2007). These compounds show affinities similar to that of the natural riboswitch ligand
and the ones with Kd values closest to lysine revealed bacterial growth inhibition in the
micromolar range (4-140 µg/ml, Figure 1.5, B). Point mutations in the aptamer domain of
the lysine riboswitch upstream of lysC render B. subtilis cells resistant against riboswitch
targeting compounds (Blount et al., 2007; Ataide et al., 2007).
Additionally, several guanine riboswitch targeting purine analogs (Figure 1.5, C) were
described that do not only bind to the riboswitch in vitro but also inhibit bacterial growth in
vivo (Kim et al., 2009; Mulhbacher et al., 2010).
Figure 1.5: Array of non-metabolite riboswitch modulators. Shown are compounds
acting on four different riboswitch classes. TPP with its analog pyrithiamine pyrophosphate
(PTPP) (A). Amino acid analogs acting on the lysine riboswitch (B). Guanine and its analogs
(C). Ligand for the FMN riboswitch and a naturally synthesized analog, Roseoflavin (D). Minimal
inhibitory concentrations are stated below the riboswitch activating analog with the according
microorganism in brackets.
Finally, the riboflavin analog Roseoflavin which is synthesized by Streptomyces davawensis
has one additional dimethylamino group (Figure 1.5 D, Ott et al. (2009)) that is well
accommodated by a space in the binding pocket of FMN riboswitches (Serganov et al., 2009).
This provides evidence for the action of naturally occurring substances that act on riboswitches
to interfere with bacterial growth.
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1.2 The glmS ribozyme
In the following sections the gene regulatory mechanism of the glmS ribozyme is described in
more detail. Special emphasis is put on riboswitch structure for ligand recognition and cofactor
aided cleavage catalysis (Sections 1.2.2 and 1.2.3). Their precise knowledge is prerequisite
for the successful identification of novel substances activating this riboswitch, which is able
to discriminate close analogs of its cognate metabolite not only by potential differences in
binding affinity, but also by requiring the ligand to catalyze RNA cleavage (Breaker, 2008).
1.2.1 Mechanism of glmS ribozyme-mediated gene regulation
Among the different classes of riboswitches introduced in Section 1.1.1, the glmS riboswitch
assumes a unique role, as it does not only regulate gene expression in response to increasing
metabolite concentrations, but it does so by an enzymatic activity. The glmS riboswitch is
actually a ribozyme, i. e. a catalytically active RNA (Winkler et al., 2004) that irreversibly
cleaves itself upon encountering its ligand. Depending on the experimental conditions the
glmS ribozyme can enable a change in rate constants of 107 (Brooks and Hampel, 2009; Klein
et al., 2007b).
The cognate ligand, glucosamine-6-phosphate (GlcN6P), is a central metabolite needed for
bacterial cell wall assembly as it is the precursor of peptidoglycan biosynthesis (Section 1.2.4).
When GlcN6P binds to the glmS ribozyme the RNA cleaves itself. This scission produces a
short RNA fragment bearing a 2’,3’-cyclic phosphate in addition to its 5’ triphosphate, which
caps all intact mRNAs, as well as a second product with a characteristic 5’ hydroxyl terminus.
These products are analogous to the ones produced by other ribozymes like the hammerhead,
hairpin or hepatitis delta virus (HDV). This newly freed 5’-OH group is recognized by RNase
J1, an RNase conserved among bacteria, which degrades the glmS mRNA (Collins et al.,
2007). As the glmS protein is a preferred substrate for ClpP and hence for protein degradation
(Kock et al., 2004), the down-regulation of its mRNA levels by glmS ribozyme activation
Figure 1.6: GlmS ri-
bozyme consensus
model and crystal
structure. Consensus
sequence and secondary
structure model for glmS
ribozymes (A). The asterisk
denotes the site of ribozyme
self-cleavage. Optional
hairpins (i) or (ii) are
present in some represen-
tatives. Figure adapted
from McCown et al. (2011).
Crystal structure of glmS
ribozyme from Klein and
Ferré-D’Amaré (2006) (B).
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results in a decrease of enzymatic activity. This allows for negative feedback regulation by
the glmS ribozyme.
Collins et al. impressively demonstrated the importance of glmS ribozyme cleavage in vivo,
as ribozyme mutants incapable of self-cleavage resulted in a sporulation deficient phenotype
in Bacillus subtilis. Additionally, Watson et al. showed that the glmS riboswitch is capable
of integrating two signals: it is activated by GlcN6P, but at high concentrations of Glc6P,
this metabolite can occupy the binding pocket and inhibit ribozyme mediated gene repression
(Watson and Fedor, 2011).
Interestingly, ribozyme-dependent GlmS regulation seems to be fairly restricted to Gram-
positive organisms (Barrick et al., 2004). Today 463 glmS riboswitch variants have been
predicted of which only five were identified in Gram-negative species (mainly belonging to
the phylum of synergestetes, McCown et al. (2011)). The paralogous GlmS enzymes of Gram-
negative bacteria and eukaryotes are controlled on the protein level by the allosteric action of
GlcN6P (Milewski, 2002; Ferré-D’Amaré, 2010). Moreover, trans-acting non-coding RNAs
regulate the expression of GlmS in Escherichia coli (Görke and Vogel, 2008; Reichenbach
et al., 2008).
1.2.2 Structure of the glmS ribozyme
The crystal structure revealed that the glmS ribozyme consists of three parallel helical stacks
comprising three pseudoknots. The minimal functional core (Section 1.2.3) includes helices P1,
P2, P2.1 and P2.2 (Figure 1.6), of which P1, P2 and P2.2 stack coaxially and pack side-by-side
with the short P2.1 helix (Ferré-D’Amaré, 2010; Klein and Ferré-D’Amaré, 2006). The four
helices of this compact, contiguous structure are connected by four strand crossovers that
define two nested pseudoknots (Ferré-D’Amaré, 2010). GlcN6P and the scissile phosphate lie
engulfed in the core structure. The exact metabolite binding site lies within the major groove
of P2.2, also suggested by the highly conserved nucleotides in P2.1, P2.2 and the segments
connecting the two helices (Klein and Ferré-D’Amaré, 2006).
The core domain of the riboswitch is stabilized by the associated peripheral domain (dark
blue, Figure 1.6 B), which is formed by the coaxially stacked helices P4 and P4.1, which are
covalently connected to the ribozyme core through helices P3 and P3.1. These interactions are
supported by tertiary contacts, i. e. by helices P3 and P3.1 which form an H-type pseudoknot,
that is defined by two helices and three connecting loops (Aalberts and Hodas, 2005).
1.2.3 The glmS ribozyme catalytic core & ribozyme action
Based on biochemical and structural data, GlcN6P acts as a cofactor in the glmS ribozyme
catalysis rather than through an allosteric activation that would lead to a conformational
change in the RNA structure (refer to Section 1.1.4, Klein and Ferré-D’Amaré (2006);
McCarthy et al. (2005); Cochrane et al. (2007, 2009)). Three different experimental set-ups
for glmS ribozyme crystallization yielded precisely superimposed structures for the ribozyme:
I) in the absence of ligand, II) in the presence of glucose-6-phosphate (Glc6P), which does
not activate the riboswitch, or III) in the presence of GlcN6P, however using an RNA
construct point-mutated to be incabable of self-cleavage (Klein and Ferré-D’Amaré, 2006;
Klein et al., 2007a). The structures show that an open, hydrated binding site, which is lined
with phylogenetically conserved residues, accommodates GlcN6P thereby burying about 80%
of its solvent-accessible surface area (Klein and Ferré-D’Amaré, 2006). The fact that Glc6P,
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which differs from GlcN6P only by having a hydroxyl group at the C2 position instead of an
amine group, is not capable of activating the glmS ribozyme, points at the critical function of
the amine group (Winkler et al., 2004; McCarthy et al., 2005).
The active site within the glmS ribozyme core brings the reactive groups of the substrate
in a near in-line conformation. Since the conserved nucleobase A-1 makes a hydrogen bond to
G65, the exchange of this adenosine for a guanosine results in a steric clash with G65 (Figure
1.6 A). Hence, this point mutation is often used to generate a minimally altered, but inactive
glmS ribozyme variant (see Section 5.1.2).
GlcN6P binds to the glmS ribozyme exclusively in the α-anomeric conformation (Lim
et al., 2006), which is supported by the fact that only compounds with the stereochemical
arrangement of the anomeric hydroxyl group and the amine at position 2 are able to activate
the RNA enzyme (e. g. ethanol vs. ethanolamine, McCarthy et al. (2005)). These groups
make extensive use of hydrogen bonds to nucleobases in the ribozyme structure (Figure
1.7). Substituting the G1 residue with a series of natural and unnatural purine nucleotides
revealed the importance of this imine-phosphate-group interaction. When G1 was replaced by
inosine, GlcN6P was still able to activate the ribozyme. However, the use of 2-aminopurine or
6-dimethyladenine, whose N1 position is not protonated at neutral pH, rendered the ribozyme
more active in the presence of GlcN instead of GlcN6P (Klein et al., 2007b). It is thought
that the unprotonated imine results in a steric clash with the phosphate of GlcN6P. Therefore,
GlcN can be bound more efficiently and lead to stronger activation of the mutated ribozyme.
Complex RNAs require divalent metal ions for folding and Mg2+-ions have been shown to
adopt this functional role for the glmS ribozyme. However, Mn2+, Ca2+ and cobalt hexamine
(trivalent) can substitute the role of Mg2+. These ions which show a higher charge density
than monovalent ions, solely support folding (Roth et al., 2006) and not catalysis. In part
this is evidenced by the fact that no metal ions bind in the immediate vicinity of the scissile
phosphate (Klein and Ferré-D’Amaré, 2006). Although it was shown that many riboswitches
bind anionic ligands (Baker et al., 2012) as chelates of divalent cations, this does not seem to
be the case for the phosphate group of GlcN6P in the glmS ribozyme. There are Mg2+ ions
in the vicinity of the GlcN6P phosphate moiety, but the cations do not make inner-sphere
(direct) coordination (Ferré-D’Amaré, 2010). Furthermore, the GlcN6P binding site is heavily
hydrated, and the Mg2+ ions in it are surrounded by well-ordered water molecules, yet they
do not have a largely preferred arrangement. Finally, none of the Mg2+ ions in this binding
Figure 1.7: Recognition of GlcN6P by
the glmS ribozyme. Schematic depiction of
interaction responsible for GlcN6P recognition
by glmS ribozyme. Hydrogen bonds are shown
as two-headed arrows. Stacking interaction
occurs between the nucleobase of G1 and the
sugar. Figure adapted from Ferré-D’Amaré
(2010).
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pocket have ligands that complete their octahedrical coordination shell with good geometry
(Klein et al., 2007b). This is in contrast to the higly ordered Mg2+ ion that coordinates the
phosphates of C2, C36 and G37.
The necessity of GlcN6P for the scission is undoubtedly evident from the fact that despite
the well pre-organized active site, in which the substrate is distorted to a near in-line
conformation, no cleavage can be observed in the absence of GlcN6P. Nevertheless, there are
different theories on how GlcN6P supports the glmS ribozyme cleavage reaction. According
to the first theory GlcN6P could act as general acid-base catalyst (Figure 1.8 A). Here, it
is thought to deprotonate the 2’OH nucleophile of A-1 through a proton relay employing
two tightly bound water molecules. The resulting ammonium form of GlcN6P functions to
stabilize the transition state as electrostatic catalyst. Additionally, the ammonium group
could donate a proton to the 5’oxo leaving group thereby stabilizing it (Figure 1.8 A, Klein
and Ferré-D’Amaré (2006); Ferré-D’Amaré (2010)). Another theory involves the G40 residue
of which the N1 imine could function as general base catalyst deprotonating the A-1 2’OH
nucleophile, whereas the ammonium form of GlcN6P functions as an electrostatic and/or
general acid catalyst (Figure 1.8 B). This is supported by a G40A mutation which renders
the ribozyme inactive even in the presence of GlcN6P, even though for the glmS ribozyme
catalytic activity an interdependency seems to exist between GlcN6P and G40, as neither is
functional in the absence of the other (Ferré-D’Amaré, 2010).
Figure 1.8: Catalytic mechanisms of the glmS ribozyme. GlcN6P deprotonates the 2’-OH
nucleophile through a proton relay employing two tightly bound water molecules, functioning
as a general base catalyst. The resulting ammonium form of GlcN6P functions to stabilize the
transition state electrostatically and also donates a proton to the 5’-oxo leaving group, functioning
as a general acid catalyst (A). The N1 imine of G40 functions as a general base catalyst (B).
GlcN6P, in its ammonium form, functions as an electrostatic and general acid catalyst. The
ribozyme is inactive in the absence of GlcN6P or if a G40A mutation is made. Figure adapted
from Ferré-D’Amaré (2010)
Even though an RNA sequence ranging from nucleotide -1 to 75 has been shown to be able
to perform the GlcN6P aided self-cleavage reaction, an RNA structure including nucleotides
-1 to 145 will exhibit maximal activity (Figure 1.6 A). These observations led to the definition
of the ribozyme core region (for the short RNA) and the glmS ribozyme motif (for the
longer sequence). Furthermore, the glmS ribozyme can be split at L1 (Figure 1.6 B) into a
bimolecular RNA construct allowing the performance of multiple turnover reactions in the
presence of GlcN6P (Brooks and Hampel, 2009).
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1.2.4 The GlmS protein
The glmS ribozyme regulates the expression of the enzyme glucosamine-6-phosphate synthase
(Figure 1.9, (3), GlmS, L-glutamine:D-fructose-6-phosphate amidotransferase). This key
enzyme of hexosamine metabolism is responsible for the utilization of the amide nitrogen of
glutamine in the biosynthesis of amino sugars (Zalkin and Smith, 1998). GlmS catalyzes the
conversion of fructose-6-phosphate (Fru6P) into glucosamine-6-phosphate (GlcN6P) in the
presence of glutamine (Badet et al., 1987). The resulting GlcN6P is then isomerized into
D-glucosamine-1-phosphate (GlcN1P) by the phosphoglucosamine mutase (Figure 1.9, (4)
glmM) and further converted into uridine diphospho-N-acetyl-D-glucosamine (UDP-GlcNAc)
by the GlcN1P acetyltransferase (Figure 1.9, (5) glmU, bi-functional N-acetylglucosamine-1-
phosphate uridinyltransferase) via the intermediate N-acetyl-glucosamine-1-phosphate (Glc-
NAc1P). UDP-GlcNAc itself is an essential precursor of peptidoglycan biosynthesis in Gram-
positive organisms (as well as lipopolysaccharide biosynthesis in Gram-negative bacteria).
Figure 1.9: GlcN6P biosynthesis pathway in S. aureus Mu50. nagB codes for
glucosamine-6-phosphate isomerase (2) which converts access GlcN6P to Fru6P. For further
detailed description of GlcN6P biosynthesis and annotation of numbers refer to main text.
These pathways are fuelled by glucose (Glc), which is taken-up by S. aureus Mu50 via the
ptsG phosphotransferase system (Figure 1.9, (6)) and thereby phosphorylated to glucose-6-
phosphate (Glc6P). The glucose-6-phosphate isomerase (Figure 1.9, pgi, (1)) converts Glc6P
to fructose-6-phosphate (Fru6P). When glucosamine (GlcN) is taken up by the glcA PTS
transporter (Figure 1.9, (7)) it is directly phosphorylated to GlcN6P.
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1.3 thi-box riboswitches
Thiamine pyrophosphate (vitamin B1) is an essential cofactor for several important enzymes
of the carbohydrate metabolism. As a result the production of this vitamine has to be tightly
regulated and many organisms employ regulatory RNAs, namely thi-box riboswitches for
exactly this purpose.
Thi -box riboswitches belong to the most widespread class of regulatory RNAs. They are not
only found in α-, β-, γ- and �-proteobacteria, in cyanobacteria, the CFB group (Cytophaga-
Flavobacteria-Bacteroides group), the Thermus/Deinococcus group, the Bacillus/Clostridium
group, in actinomycetes and thermotogales (Figure 1.3, Rodionov et al. (2002)), but also
in archeae (Miranda-Ríos et al., 2001), and they represent the only class also abundant in
eukarya, were they were identified in fungi (Sudarsan et al., 2003a) and plants (Kubodera
et al., 2003).
This riboswitch class controls the expression of genes involved in the biosynthesis, salvage
and transport of thiamine and its precursors (Section 1.3.3) through a variety of different
control mechanisms (Section 1.3.1). The higly conserved RNA structure (Section 1.3.2), which
regulates gene expression differently in the absence or presence of thiamine, was first described
by Miranda-Rios and co-workers in 2001. Later, Winkler et al. brought biochemical evidence
of aptamer domains within bacterial mRNA that specifically bind to TPP, leading to a direct
modulation of gene expression (Winkler et al., 2002a).
1.3.1 Mechanisms of thi-box riboswitch-mediated gene regulation
This riboswitch class concentrates the wealth of regulatory mechanisms that can be employed
by these entirely RNA-based regulatory elements. There are thi-box riboswitches which
inhibit translation initiation or stop transcription prematurely, others control splicing or
processing and stability of mRNAs (Figure 1.10).
In eubacteria the most commonly encountered regulatory mechanisms comprise either
the formation of a terminator stem or the sequestration of the SD-sequence (Section 1.1.2,
Figure 1.10 A & B). However, in a variety of plant species TPP riboswitches were found to
reside in the 3’UTR of thiC genes and it was shown that thiC transcripts with alternating
3’UTR lengths were produced dependent on riboswitch function (Figure 1.10 C, Wachter
et al. (2007)).
Apart from the TPP riboswitch-mediated regulation of splicing and 3’ end processing in
plants, thi-box riboswitches in fungi, like Neurospora crassa, regulate the splicing of introns
(Cheah et al., 2007). Metabolite binding alters the availability of alternative splice site and
branch site components of an intron within the NMT1 mRNA, which codes for a protein
involved in TPP metabolism (Figure 1.10 D).
1.3.2 Structure of thi -box riboswitches
Two crystal structures have been solved for the TPP riboswitch. The TPP-responsive
regulatory element in front of thiM in Escherichia coli was crystallized by Serganov and
coworkers, whereas Thore et al. obtained the thi-box riboswitch structure of thiC from
Arabidopsis thaliana (Serganov et al., 2006; Thore et al., 2006).
The structures show a strong similarity and both fold into a tuning fork-like conformation
that binds the ligand between its prongs. Five base-paired helical stems (P1-P5) are connected
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Figure 1.10: Mechanisms of riboswitch control employed by thi-box riboswitches. In
bacteria, thi -box riboswitches usually reside in the 5’UTR and regulate gene expression either by
inhibition of translation initiation through the sequestration of the Shine-Dalgarno sequence (A)
or they prematurely halt transcription by enabling the formation of a terminator hairpin (B). In
eukaryotes TPP riboswitches control splicing (C) or 3’ end processing/RNA stability (D). Figure
adapted from Sudarsan et al. (2003a).
via non-base-paired junctions and loops (Figure 1.11). The helix P1 is formed by the 5’ and
3’ end of the riboswitch RNA. Helices P1, P2, P4 and junctions J1/4 and J2/4 form a central
three way junction (Thore et al., 2006). The two parallel helices each function by recognizing
one part of TPP. Helix P2, J3/2, P3, L3 represents the pyrimidine sensor helix and helix P4,
J4/5, P5, L5 comprises the pyrophosphate sensor helix. The actual binding sites are found in
deep pockets which orient TPP perpendicular to the helices. Eukaryotic TPP riboswitches
often contain variable lengths of the P3 stem, whereas in bacterial representatives a P3a stem
is frequently present, but neither P3 nor P3a is directly involved in TPP binding (Edwards
and Ferré-D’Amaré, 2006; Thore et al., 2006).
The pyrimidine part of vitamine B1 is sensed by the J3/2 bulge within helix P2/3, which
contains a conserved sequence (UGAGA, nucleotides 39-43, Figure 1.11 B, C, D). Residues
U39 and A43 form a trans-Watson-Crick/Hoogsteen base pair that causes the extrusion of
residues G40, A41 and G42. The pyrimidine ring itself is held between residues G42 and A43
by stacking interactions and the formation of two hydrogen bonds with residue G40 and one
hydrogen bond between the N1 position of the TPP pyrimidine ring and the 2’ oxygen of
residue G19. Triples (G19·A47)·G42 and (G18·C48)·A41 further stabilize these arrangements
(Serganov et al., 2006).
Using chemical and enzymatic probing analysis Rentmeister et al. showed that the pyrimi-
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Figure 1.11: Crystal structure of the E. coli thiM riboswitch. Overall structure indicating
helical, loop and junction regions of the E. coli thiM riboswitch (A). Gray structure indicates
the A. thaliana thiC riboswitch (Thore et al., 2006). Close ups of TPP (B), TMP (C) or PT
(D) binding contacts within the aptamer domain. Pyrimidine sensor helix colored in red and
pyrophosphate sensor helix represented in blue. Metal ions are shown in light blue and water
ions in red. Hydrogen bonds are represented as dashed and inner sphere metal coordinations as
solid lines. Figures taken from Edwards and Ferré-D’Amaré (2006).
dine sensor helix was preformed to recognize the HMP moiety of TPP with the stem region
P2/3 (Rentmeister et al., 2007). Once this part of the molecule is bound, a structural
rearrangement that draws the pyrophosphate sensor helix near, is initiated. However, in the
absence of a phosphate or pyrophosphate group this global conformational change does not
occur (Rentmeister et al., 2007).
The pyrophosphate group of TPP is recognized by its according sensor helix in the J4/5
internal loop through interaction with divalent cations and their corresponding coordinated
water molecules (Figure 1.11). Even though conflicting data exists, the current hypothesis
involves the aid of two divalent ions for this interaction (Serganov et al., 2006; Edwards and
Ferré-D’Amaré, 2006). The only residue making direct contact with the phosphate group
is the highly conserved G78, which forms a hydrogen bond between its N1 proton and a
nonbridging oxygen of the β-phosphate of TPP. Two more divalent ions are involved in correct
folding of the RNA structure.
Finally, two tertiary interactions bring the pyrimidine and pyrophosphate sensor helix
together. This is achieved by base-pairing between L5 & P3 on top of the helices, whereas the
parallel alignment of both helices is due to a kink at residue A53 in the J2/4 bulge. This kink
also allows the adaptation of the two helices to accommodate the ligand. Therefore, thiamine
monophosphate (TMP) will lead to a more compact fold of the riboswitch’s aptamer domain
in comparison to TPP.
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1.3.3 TPP biosynthesis and metabolism
Synthesis of the coenzyme thiamine pyrophosphate is accomplished in bacteria by the coupling
of a pyrimidine and thiazole moiety (Figure 1.12). Each of these molecules is produced
separately and then finally united.
Figure 1.12: Schematic of the TPP biosythesis pathway in bacteria. For a detailed
description refer to main text.
The biosynthesis of the pyrimidine moiety starts with aminoimidazole ribotide (AIR), an
intermediate of the purine biosynthesis pathway. ThiC converts AIR to hydroxymethyl-
pyrimidine-phosphate (HMP-P), which is then phosphorylated by the bifunctional HMP
kinase/HMP-P kinase ThiD to yield hydroxymethyl-pyrimidine-pyrophosphate (HMP-PP,
Figure 1.12).
In E. coli, the thiazole moiety of thiamine is derived from tyrosine, cysteine, and 1-deoxy-D-
xylulose phosphate (DXP). An unresolved chain of reactions involving the thiF, thiS, thiG,
thiH, and thiI gene products converts these reactants to the hydroxyethyl-thiazole phosphate
product (HET-P). Thiazole synthase (ThiG) catalyzes an Amadori-type rearrangement of
DXP via an imine intermediate (Dorrestein et al., 2004). DXP, whose production is catalyzed
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by the dxs gene product, is also used in the nonmevalonate pathway and the pyridoxal
biosynthesis (Begley et al., 1999; Rodionov et al., 2002). ThiF catalyzes adenylation of the
sulfur carrier protein ThiS by ATP. In addition, ThiI and IscS, enzymes shared by the thiamine
and 4-thiouridine biosynthetic pathways, may play a role in the sulfur transfer chemistry
(Figure 1.12).
HMP-PP and HET-P are joined by one enzymatic step mediated by the ThiE protein,
followed by phosphorylation of the formed TMP by ThiL to create TPP. Moreover, three
distinct kinases, ThiM, ThiD, and ThiK, are involved in the salvage of HET, HMP, and
thiamine, respectively, from the culture medium. Thiamine, thiamine phosphate, and thiamine
pyrophosphate are actively transported in enteric bacteria using the ABC transport system
ThiBPQ (Webb et al., 1997). At present, no other distinct thiamine transporters, neither
HET nor HMP transport systems, have been identified in bacteria (Rodionov et al., 2002).
1.4 Multidrug-resistant pathogens
Antibiotics have become a valuable, yet habitually used defense against microbial infections.
Hence, resistances have evolved to every antibiotic placed into clinical practice, irrespective of
the chemical class or molecular target of the drug (Payne et al., 2007). The appearance and
further evolution of multidrug-resistant (MDR) pathogens almost puts us into the perspective
of the pre-antibiotic era, because only limited antibiotic means for sufficient cure exist against
many of these pathogens. It seems nearly impossible to undertake today’s surgical procedures,
transplantations, cancer chemotherapy, or care of the critically ill or HIV-infected without
effective antimicrobial agents (Arias and Murray, 2008). Bacteria have proven to be champions
of evolution by adapting not only to challenging natural circumstances (extreme pH, salt,
temperature), but also by establishing resistance strategies to circumvent the action of harmful
substances targeted at them.
Among the Gram-positive organisms, especially methicillin-resistant Staphylococcus aureus
and vancomycin-resistant enterococci impose therapeutic challenges, whereas multidrug-
resistant Pseudomonas aeroginosa and acinetobacter, klebsiella, enterobacter and Escherichia
coli assume this role for Gram-negatives.
As bacterial infections are the third-leading cause of death world wide (WHO, 2008), the
search for novel antibacterial substances has to continue to provide the means for sufficient
defense, not only, but particularly, against MDR pathogens.
1.4.1 Resistance mechanisms and the need for new antibacterial targets or
compounds with new mechanisms of action
Resistance mechanisms are classically divided into two categories: Intrinsic resistance, which
refers to a resistance against an antibacterial agent that is inherently present in a microorgan-
ism. This may be due to the drug-susceptible target not being present in the species (e. g.
resistance of the penicillin-binding proteins of enterococci to the effects of cephalosporins), or
an inherent characteristic of the organism may prevent the agent from reaching the target
(e. g. resistance of Gram-negative bacteria to vancomycin because of the drug’s inability
to penetrate the Gram-negative outer membrane). The second, and most often referred to
resistance mechanism in the discussion of MDR pathogens are acquired resistances. These
occur from a change in the genetic composition of the microorganism either by mutation of
important cellular structures or by changes in physiological processes. Genetic composition
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can also be altered by acquisition of foreign resistance genes, so that a drug that once was
effective is no longer active (Kaye and Kaye, 2000; Neu, 1992).
To combat or avoid these resistances which render many antibiotics useless, efforts have
been focused on
• finding inhibitors of the enzymes that confer resistance
• chemically modifying existing antibiotic structures to prevent enzymatic modification
• designing inhibitors of bacterial efflux pumps
• developing new antibiotics with new modes of action (MoAs, Roemer et al. (2012);
Payne et al. (2007)).
Nevertheless, these strategies should be aided by a prudent use of antibiotics, as it may avoid
overmortality associated with infections due to MDR bacteria. Thus, the restrictive use of
empirical antimicrobial therapy, short-duration treatments, and knowledge of pharmacological
models, need to be encouraged in order to break the vicious circle of antibiotic overuse (Alvarez-
Lerma et al., 2006; Leone et al., 2003, 2007). In addition, microbiological documentation
before initiating empirical antimicrobial therapy should be an obligatory prerequisite to avoid
fostering of new resistance development.
1.4.2 Staphylococcus aureus - a multi-drug resistant pathogen
Staphylococcus aureus, first isolated by Alexander Ogston in 1880 (Ogston, 1882), is a Gram-
positive, facultative anaerobic, coccal bacterium that is frequently found as part of the normal
skin flora and nasal passages (Kluytmans et al., 1997). Even though about one-fifth of
the human population is a permanent carrier of this bacterium, some S. aureus strains can
cause severe opportunistic, difficult to treat infections, due to their resistance against most
antibiotics in use (methicillin-resistant or multi-drug resistant Staphylococcus aureus (MRSA)).
Methicillin resistance is now a common problem for many hospitals around the world, and
the recent emergence of community strains of S. aureus that are methicillin resistant, but also
harbor genes associated with increased virulence impose the latest concern (Chambers, 2001,
1997). In 2002, an MRSA strain was isolated that is resistant against vancomycin, one of the
last resort antibiotics applicable against these top causes for nosocomial infections (Weigel
et al., 2003).
This rapid development of resistances calls for an ongoing search for alternative antibacterial
substances that address novel targets and employ new modes of action. This is why RNA
elements should be explored as antibacterial targets in these organisms which appear most
difficult to target and most needy in obtaining adequate defense against.
1.4.3 Vancomycin-resistant Staphylococcus aureus
Vancomycin resistant Staphylococcus aureus (VRSA) evolved by acquisition of the vanA gene
from enterococci, which are of significance as reservoir of resistance genes among Gram-
positive bacterial pathogens (Leclercq et al., 1988). After the isolation of vancomycin-resistant
Staphylococcus aureus (VRSA) in Japan in 1997 (Hiramatsu et al., 1997), several methicillin-
resistant S. aureus (MRSA) strains with similar levels of vancomycin resistance have been
isolated in other countries (Ploy et al., 1998; Boyle-Vavra et al., 2001; Chesneau et al., 2000;
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Ferraz et al., 2000; Tenover et al., 1998; Walsh, 1999). The term VRSA is based on the
vancomycin breakpoint set by the British Society for Chemotherapy, where a strain for which
the minimal inhibitory concentration (MIC) is 8 µg/ml is defined as resistant. Since the same
MIC is defined as an indicator for intermediate susceptibility by the Clinical and Laboratory
Standards Institute (CLSI), these VRSA strains are called vancomycin-intermediate S. aureus
(VISA) or glycopeptide- intermediate S. aureus (GISA) in the United States (Tenover et al.,
1998). Both terms, GISA and VISA, have been used in the literature and in essence are
interchangeable. Here, the CLSI classification and terminology is going to be used (Table
1.1).
Susceptibility classification Vancomycin [µg/ml]
susceptible (VSSA) ≤ 2
intermediate (VISA) 4 - 8
resistant (VRSA) ≥ 16
Table 1.1: Terminology for S. aureus strains with reduced vancomycin susceptibility.
A subclass of VISA is formed by heterogeneous vancomycin-intermediate resistant S. aureus
(hVISA), that show a vancomycin MIC within the susceptible range when tested by routine
methods, but a proportion of the population of cells are in the vancomycin-intermediate range
(Hiramatsu, 2001).
1.4.3.1 Resistance mechanisms
Main resistance mechanisms of VISA include changes in cell wall architecture, autolytic
activity, and metabolism. Cell wall thickening is a consistent feature of VISA strains that
may be associated with activated cell wall synthesis (Hanaki et al., 1998a), and is reduced
when isolates are serially passaged in vancomycin free medium and resistance levels drop
(Cui et al., 2003). Although the exact mechanisms leading to cell wall thickening have not
been determined yet, the thickness is thought to prevent vancomycin from reaching its target
(Sieradzki and Tomasz, 2003). In most isolates studied, common changes in cell wall structure
include
• increased levels of abnormal muropeptides (Sieradzki and Tomasz, 1999)
• overexpression of PBP2 and PBP2’ (Moreira et al., 1997; Hanaki et al., 1998a)
• reduced PBP4 expression levels (Sieradzki et al., 1999)
• increased levels of D-Ala-D-Ala residues
• increased glycan chain length (Komatsuzawa et al., 2002)
• decreased levels of the muropeptide amidation (Boyle-Vavra et al., 2001)
• reduced levels of peptidoglycan cross-linking (Moreira et al., 1997; Pfeltz et al., 2000;
Sieradzki and Tomasz, 2003; Sieradzki and Tomasz., 1997).
For some VISA isolates a small increase in peptidoglycan cross-linking was found (Boyle-Vavra
et al., 2001; Reipert et al., 2003). Additional common characteristics are a reduced growth
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rate (Chuard et al., 1997) and reduced whole-cell lysostaphin susceptibility (Cui et al., 2006;
Daum et al., 1992; Moreira et al., 1997). Furthermore, VISA strains often show a reduced
acetate catabolism, which could lead to altered growth characteristics, antibiotic tolerance,
changes in cell death, and increased polysaccharide intercellular adhesin synthesis according
to Nelson et al. (2007). Finally, reduced autolytic activity is yet another mutual attribute of
hVISA and VISA strains (Boyle-Vavra et al., 2001, 2003; Hanaki et al., 1998a; Koehl et al.,
2004).
1.4.3.2 Mu50
In this study, the VISA strain Mu50 was used for all in vivo investigations related to the
glmS ribozyme (Section 3.1.5 and 3.1.6).
Mu50 (ATCC 700699, vancomycin MIC of 8 µg/ml) was isolated in 1997 from a surgical
wound infection from a 4-month-old individual who had undergone cardiac surgery, where
vancomycin failed to cure the infection (Hiramatsu et al., 1997). Mu50 and its putative
precursor strain Mu3, a hVISA (Hiramatsu et al., 1997), show increased cell wall synthesis.
When compared with vancomycin-susceptible control strains (VSSA), they have enhanced
incorporation of N-acetylglucosamine (GlcNAc) into the cell wall, an increased pool size
of the cytoplasmic murein monomer precursor (UDP-N-acetylmuramyl-penta-peptide), an
increased cell wall turnover rate, and increased production of penicillin-binding proteins
PBP2 and PBP2’ (Hanaki et al., 1998a,b; Hiramatsu, 1998). In addition to these shared
features with hVISA strain Mu3, VISA strain Mu50 displays about a twofold increase in cell
wall thickness, increased synthesis of nonamidated muropeptides and reduced peptidoglycan
cross-linking which additionally contribute to vancomycin resistance as they enhance the
affinity for trapping vancomycin (Cui et al., 2000). Subsequent investigation of isogenic cells
with different cell wall thicknesses prepared from single colonies of Mu50 cells demonstrated
that the cell wall thickening is the major contributor to vancomycin resistance of Mu50 (Cui
et al., 2000).
Interestingly, Mu50 displays prolinged doubling times which suggests that their resistance
comes at a great biological fitness cost. Compared with VSSA strains, Mu50 incorporates
2.3 times more glucose molecules into the cell wall peptidoglycan, where they constitute the
aminosugar components of thickened cell wall (Cui et al., 2000). Although it was described
that the rates of growth and cell wall synthesis of S. aureus are not correlated with each other
(Wong et al., 1978), it might be that the increased use of glucose for cell wall components
depletes the organism of energy and important metabolites. The prolonged doubling times of
VISA strains explain why they do not quickly prevail in health care facilities and their detection
is mostly confined to patients with MRSA infection undergoing long-term vancomycin therapy
(Tenover, 1999).
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In the 1960’s many antibiotics were discovered and their mode of action elucidated. In this
Golden age of antibiotic research it was generally believed that the problem of bacterial
infections was solved. This is why this research field was soon deserted and many pharmaceu-
tical companies abandonned their anti-infectives programs. However, today the search for
antibacterials has appeared back on the agenda, as resistances have evolved against every
chemical entity in use as antibiotic. In this regard, bacterial species emerged, which have
accumulated a variety of resistance mechanisms. These multi-drug resistant bacteria used to
be confined to hospitals, although they are now increasingly found in community settings as
well.
This combination of events calls for an ongoing search for new antibiotic substances that
address novel targets and/or employ new modes of action. A quite recently discovered class
of non-coding RNAs, coined “riboswitches”, regulates gene expression in bacteria in response
to binding to a cognate ligand. In this study, these riboswitches are investigated as promising,
new antibacterial drug targets.
For this, two complementing strategies are followed: On the one hand a riboswitch class
mainly found in Gram-positive organisms is investigated - the glmS riboswitch, whereas on
the other hand a more widespread riboswitch class is studied for its use as antibacterial target
- namely that of the thi -box riboswitches.
Different means were utilized to enable the identification of potential riboswitch modulators.
In silico predictions and screenings of concise, rationally designed libraries of ligand analogs
aimed at the detection of compounds that could interfere with riboswitch-mediated gene
regulation. Furthermore, libraries of chemically synthesized, artificial entities as well as
natural compounds were used for these investigations.
Newly identified compounds targeting riboswitches may provide a new class of antibacterial
substances, employing novel modes of action and hence evading common resistance mechanisms.
Therefore, these substances spur the hopes of defining a new class of last resort antibiotics
urgently needed to fight multi-drug resistant pathogens.
Moreover, the identified riboswitch-targeting compounds can be used as tools for the inves-
tigation of RNA-small molecule interactions. Chemically and structurally related compounds
and their potential of riboswitch modulation will provide a more detailed understanding of
riboswitch-ligand recognition and tolerance. Furthermore, these riboswitch modulators can
be used to investigate bacterial metabolic pathways and their regulatory networks. This could
in turn aid in exploring riboswitch related virulence factors or resistance mechanisms in MDR
pathogens.
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This chapter describes the search for artificial as well as natural riboswitch modulators. The
validation of the in silico predicted glmS riboswitch is outlined in the first part (Section 3.1.1
and 3.1.2), culminating in its use for a screening system utilized to search for chemically
synthesized glmS ribozyme activators (Section 3.1.3.1 and 3.1.3.2) as well as the testing of
naturally occuring RNA interactors for their effect on ribozyme cleavage (Section 3.1.7.1 and
3.1.7.2).
The second part of this chapter applies concepts of riboswitch modulator identification to
the most wide-spread class of riboswitches, namely the thi-box riboswitches (Section 3.2.1).
Here, the validation and characterization of triazolethiamine compounds as thiM riboswitch
activators is described (Section 3.2.2 and 3.2.3).
The chapter concludes with introducing a proof-of-principle study to enable the identification
of preQ1 riboswitch modulators (Section 3.3) by applying previously employed screening
set-ups to new riboswitch classes.
3.1 The glmS ribozyme of Staphylococcus aureus Mu50 as
antibacterial drug target
As the increasing occurence of bacterial resistances and the decrease of novel antibacterial
structures imposes a serious threat on public health, there is an urgent need for the ongoing
search for new antibiotics with novel modes of action. Therefore, the vancomycin-resistant
staphylococcal strain Mu50 was used in this study as model organism for the screening and
in vitro as well as in vivo characterization of compounds that modulate the glmS ribozyme.
The glmS ribozyme regulates expression of the enzyme glucosamine-6-phosphate synthase
(GlmS), which catalyzes the conversion of fructose-6-phosphate to glucosamine-6-phosphate
(GlcN6P, Section 1.2.4). Since GlcN6P is an important precursor of cell wall biosynthesis,
manipulating the concerted synthesis of this essential metabolite promises maximal interference
with bacterial growth and/or survival. Hence, targeting the regulatory element of the glmS
gene, the glmS ribozyme, is a promising route for the development of novel antibacterial
measures.
3.1.1 Validation of in silico predicted glmS ribozyme of S. aureus Mu50
Riboswitches usually reside in long intergenic regions (IGRs) and are characterized by their
relatively well conserved aptamer domain. The Breaker laboratory created a database known
as the Breaker Laboratory Intergenic Sequence Server (BLISS; http://bliss.biology.yale.edu)
that integrates sequence similarity between IGRs from 91 microbial genomes (in 2004) with
uniform predictions of gene functions and intrinsic transcription terminators to identify new
riboswitches (Barrick et al., 2004). Riboswitch sequence alignments generated by BLISS
usually show a collection of base-paired stems that are often supported by the presence
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of nucleotide covariation. Moreover, search algorithms that use this secondary structure
information and allow for the insertion of variable loops and incorporate predictions of intrinsic
terminators, have been successfully employed to identify new examples of these RNA elements
(Barrick et al., 2004).
Barrick et al. used this computational method not only for the discovery of a number of
new riboswitches in IGRs, but also for the prediction of the presence of validated riboswitch
structures in other organisms. Figure 3.1 shows the phylogenetic distribution of the glmS
ribozyme which, according to their prediction, can be found in at least 18 other Gram-positive
bacterial species. Among them is Staphylococcus aureus (secondary structure prediction
shown in Figure 3.2 A), which allowed us to use the sequence alignment published in 2004
for the design of primers suitable for amplification of the putative glmS ribozyme sequence
from S. aureus Mu50 genomic DNA (refer to Table 7.10 for primer sequences). The resulting
genomic PCR product (217 bp) of the wild type glmS ribozyme version is shown in Figure 3.2
B. Additionally a longer version of the glmS ribozyme was designed (248 bp) and used for all
following metabolite-induced self-cleavage assays (primers: 5’+T7 glmS Sau long & 3’Sau
glmS neu) as this elongation allowed better separation and thus visibility of the cleavage
fragment (Figure 3.2 C).
The RNA, which had been in vitro transcribed from the amplified DNA product, was
subsequently dephosphorylated, radioactively labeled at its 5’ end and finally tested in the
so-called metabolite-induced self-cleavage assay for ribozymatic activity (Figure 3.2 C). In
this assay, the RNA is incubated in the absence and presence of magnesium chloride as well
as glucosamine-6-phosphate (GlcN6P), the natural ligand of the glmS ribozyme, and its
Figure 3.1: Phylogenetic distribution of the glmS ribozyme. Sequence alignment of the
conserved element residing upstream of glmS gene homologs. Nucleotides shaded with purple, blue,
green, and orange identify putative base-paired regions P1 through P4, respectively. Lowercase
and uppercase letters of the consensus identify nucleotides that are conserved in 80% and 95% of
the representatives. Nucleotides highlighted in red differ between the database sequence and the
ones determined by the sequencing of clones for Bce and Bsu prepared by the Breaker laboratory.
For each representative the organism and gene name are provided. Organism abbreviations:
Bce, Bacillus cereus; Bha, B. halodurans; Bsu, B. subtilis; Cpe, Clostridium perfringens, Lpl,
Lactobacillus plantarum; Lin, Listeria innocua; Oih, Oceanobacillus iheyensis ; Sau, Staphylococcus
aureus; Tte, Thermoanaerobacter tengcongensis; Fnu, Fusobacterium nucleatum (taken from
Barrick et al. (2004)).
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Figure 3.2: Amplification
and verification of glmS ri-
bozyme in S. aureus Mu50.
Secondary structure of glmS
riboswitch sequence including
the ribozyme core (-10-145 nt,
A, blue sequence) according to
glmS consensus by McCown et al.
(2011). Agarose gel analysis of
glmS ribozyme amplification
from genomic DNA of S. aureus
Mu50. Primers 5’Sau glmS+T7
and 3’Sau glmS neu used for
this PCR (B) were designed
according to conserved sequences
shown in Figure 3.1. GlmS
ribozyme self-cleavage assay
is shown in (C). GlmS RNA
undergoes self-cleavage upon
incubation with either its natu-
ral metabolite GlcN6P or the
unphosphorylated aminosugar
GlcN in the presence of MgCl2.
PAGE quantification results
obtained by evaluation of band
intensities of full length RNA
(FL) and cleavage product (Clv)
using AIDA software (D).
self-cleavage can be monitored by separating the labeled RNA fragments by PAGE (Figure
3.2 C). The predicted sequence from Barrick et al. showed enzymatic activity dependent on
the presence of GlcN6P and Mg2+-ions in vitro.
3.1.2 Characterization of the glmS ribozyme of S. aureus Mu50
The metabolite-induced self-cleavage assay was also employed to investigate certain charac-
teristics of the S. aureus glmS riboswitch in comparison to its already described counterpart
in B. subtilis (Winkler et al., 2004). Both riboswitches revealed very similar behaviour in
their optimal cleavage temperature, the used pH for cleavage and their activating metabolites
(Table 3.1 and compare to primary data shown in Figure 8.2 A-D). In summary, the optimal
activity for the glmS ribozyme occurs under near physiological conditions for Mg2+, pH and
cleavage temperature. However, even though most of their properties were alike, the S. aureus
glmS ribozyme needed higher magnesium chloride concentrations (9mM) for cleavage than B.
subtilis (5mM, see Table 3.1 and Section 8.1 Figure 8.2 F), respectively. Furthermore, Co2+
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cannot replace Mg2+ in the self-cleavage reaction in S. aureus (Table 3.1 and Figure 8.2 E),
whereas the divalent metal ions Ca2+, Mn2+ and Sr2+ were able to substitute for Mg2+ in
both organisms, however with decreasing potency.
Parameter S. aureus Mu50 B. subtilis
pH 7 7
EC50 MgCl2 9mM 5mM
Divalent cations Ca2+, Mg2+, Mn2+, Ca2+, Co2+, Mg2+,
accepted Sr2+ Mn2+, Sr2+
Activating metabolites GlcN6P, GlcN, GlcN6P, GlcN
GlcN6S, GlcNAc6P GlcN6S, GlcNAc6P
Optimal temperature 37 °C 37 °C
Table 3.1: Characteristics of glmS ribozymes of S. aureus and B. subtilis. Comparison
between parameters influencing glmS cleavage such as optimal pH, MgCl2 concentration, divalent
cations accepted, activating metabolites and optimal reaction temperature is shown. All para-
meters for the S. aureus glmS were determined using the metabolite-induced self-cleavage assay
(Section 6.2.4.1) and are compared to published results from Winkler et al. (2004), where same
assay conditions were used. GlcN6P= glucosamine-6-phosphate, GlcN= glucosamine, GlcN6S=
glucosamine-6-sulfate, GlcNAc6P= N-acetyl-glucosamine-6-phosphate.
The half maximal effective concentration (EC50) was determined for the most potent glmS
ribozyme activators (Table 3.2). For this, self-cleavage assays were performed with increasing
concentrations of activator, and cleavage was stopped after 30 minutes of incubation. A
dose-response curve was plotted and EC50-values were calculated from non-linear regression,
three-parameter fits (Section 6.2.4.2). The natural activator of the glmS riboswitch, GlcN6P,
revealed the lowest EC50-value of 3.6 µM. The unphosphorylated amino sugar GlcN, which has
been known to activate the glmS ribozyme to a lesser degree, has an EC50-value of 189 µM.
This about 50 fold decrease in EC50 demonstrates the importance of the phosphate group for
glmS ribozyme activation. Glucosamine-6-sulfate (GlcN6S), which contains a sulfate instead
of a phosphate group, has a half maximal effective concentration in the same range as GlcN
(160 µM, Table 3.2). This exchange of phosphate for sulfate also results in a decrease of
EC50-values (Table 3.2).
Activator EC50 [ µM]
GlcN6P 3.6 ± 0.4
GlcN 189 ± 22
GlcN6S 160 ± 14
Table 3.2: EC50-values for S. aureus glmS riboswitch activating metabolites. Percent-
age of glmS cleavage was plotted against the logarithm of metabolite concentration used in the
cleavage reaction, leading to a sigmoidal dose-response curve (Figure 8.1, Table 8.1 and Section
6.2.4.2).
3.1.3 Screening for artificial activators of S. aureus Mu50 glmS ribozyme
Different approaches can be employed when searching for chemical entities that activate
riboswitches. One can search known metabolites and natural products to identify “natural”
riboswitch activators or inhibitors (see Section 3.1.7.2 and 3.1.7.1). Or one could search
through compounds that are not part of the metabolome of organisms, which would lead to
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the identification of “artifical” riboswitch modulators. This approach can be pursued using a
variety of strategies, such as the screening of libraries containing small molecules with certain
characteristics, e. g. drug-like (Mayer and Famulok, 2006), FDA-approved (Blount et al., 2006;
Lim et al., 2006), or in silico predicted (see Section 3.1.3.1). Furthermore, libraries can be
screened that contain analogs of the cognate riboswitch ligand (Blount et al. (2006); Lünse
et al. (2011), see Sections 3.1.3.2, 3.2.2 and 3.2.3).
In the following sections the search for artificial glmS ribozyme modulators will be discussed
using in silico predicted (Section 3.1.3.1), as well as concise, rationally designed compound
libraries (Section 3.1.3.2).
3.1.3.1 Screening of compounds with three-dimensional shapes similar to GlcN6P
Using the concept of 3D similarity, a virtual screening of commercially available compounds
was performed in collaboration with Jean-Louis Reymond’s group at the University of Berne.
Their approach is distantly comparable to the already published strategy of “rapid overlay of
chemical structures” (ROCS, (Nicholls et al., 2010)), which is a state-of-the-art 3D similarity
method that allows the identificaton of the most active compounds in virtual screenings and
having those molecules be diverse (Nicholls et al., 2010; McGaughey et al., 2007). Compared
to ROCS however, Reymond’s algorithm integrates the entire molecule shape instead of only
matching atomic centers. Furthermore, hydrophobic areas as well as hydrogen acceptors and
donors are taken into consideration by the program, but ionic interactions are disregarded.
In this in silico screening, 57 structures appeared as hits whose binding characteristics
and molecular shape mimicked that of GlcN6P in three dimensional space (unpublished
algorithm, personal communication Lars Ruddigkeit). These compounds, which are hereafter
referred to as “Reymond compounds”, were obtained from Princeton Biomolecular Research
and subsequently tested for induction of glmS ribozyme cleavage, or for inhibition of GlcN6P-
mediated glmS ribozyme activation. The metabolite-induced self-cleavage assay (see Sections
6.2.4.1 and 6.2.4.2 for experimental details) was utilized for these screenings.
Before screening the Reymond compound library, the assay was analyzed for its DMSO
tolerance (Figure 8.3 E). Increasing concentrations of DMSO were tested and demonstrated
that this solvent can be used to up to 2% without strong effects on assay performance.
Screening for the activation of S. aureus Mu50 glmS ribozyme was performed in the presence
of 2mM compound in 2% DMSO. Six hits were identified (compounds D4, D7, E5, E6, E9
and F5) that showed at least 2 fold increase in cleavage above background cleavage in the
absence of any metabolite (Figure 3.3 and Table 8.3). Compound E6 (as well as C6, even
though this compound did not appear as hit, compare percent glmS cleavage in Figure 3.3)
showed RNase contamination or some kind of unspecific RNA interaction causing a smear of
the full length glmS RNA in the polyacrylamide-gel (PA-gel). These two effects could lead to
an artificial increase in band intensity, either for the cleavage product or the full length RNA,
resulting in false positive hit-detection in the screening evaluation from quantification analysis
data. Increased glmS cleavage detected for compounds D4, D7, E5, E9 and F5 (see Figure
3.3 for chemical formulas) was not due these effects. As compounds D7 and E5 showed
highest activities, they should be investigated further, e. g. for concentration dependent and
glmS ribozyme-specific cleavage activation. Furthermore, compounds structurally similar to
the ones found in this screening should be investigated for their effects on ribozyme activation.
The screening was repeated under more stringent conditions, meaning at lower compound
concentrations (500 µM compound) which also decreased the total DMSO content (0.5%
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Figure 3.3: Screening of Reymond compounds for activation of S. aureus Mu50 glmS
ribozyme. Screening outcome with controls as black bars on the left (reactions without metabolite
and without MgCl2 as negative control, reactions with divalent ions and metabolite as positive
control). Chemical formulas of hit compounds are shown as inset. Compounds that were
considered as hits after PAGE and band quantification analysis are marked with an asterisk.
DMSO, see Table 8.3). Those compounds revealing more than five fold background cleavage
were deemed hits, namely C1, C11, D1, D3 and F2 (Figure 3.4, again background cleavage
was defined as glmS cleavage in the absence of metabolite). Interestingly, not even the
strongest activators from the first screening, compounds D7 and E5, were confirmed under
these conditions. This may be due to the decreased DMSO concentrations used here and the
resulting changes in compound solubility (see detailed discussion in Section 4.2.1).
Additionally, a screening was performed using 20 µM compound in 2% DMSO (Figure 8.7).
Here, the compound concentration was decreased further to identify inhibitors in the low
micromolar range. At the same time the DMSO concentration was increased to the maximum
of 2%, that is tolerable in terms of assay performance, to secure best-possible compound
solubility. Under these conditions no compounds were identified that activated glmS ribozyme
cleavage above background levels (Figure 8.7).
Moreover, a screening of Reymond compounds (2mM) in competition with GlcN6P (200 µM)
in a final DMSO concentration of 2% was undertaken (Figure 3.5 A, and Table 8.3). Using a
rather broad cut-off for hit definition at 40% cleavage, substances were detected that reduce
cleavage by at least 50% compared to glmS activation observed in the mere presence of
200 µM GlcN6P. In this respect, 13 compounds were deemed hits, namely B7, C3, C6, C8,
C9, D2, D6, D8, E6, E8, F6 as well as an accidential mixture of F7/8 (Figure 3.5 B).
However, the effect observed for compound E6 and C6 was found to be unspecific as it was
most likely due to an RNase contamination that diminished band intensity, and compound
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Figure 3.4: Screening of Reymond compounds for activation of S. aureus Mu50 glmS
ribozyme. Screening outcome with controls on the left (black bars). Assay conditions are as
described above (Figure 3.3), yet using 500 µM compound in 0.5% DMSO instead of 2 µM in
2% DMSO. Chemical formulas of hit compounds are shown as insets. The black line shows the
cut-off for hit definition at about 12.5% glmS cleavage. Compounds that were considered as hits
after PAGE and band quantification analysis are marked with an asterisk.
D8 caused unspecific interactions with the RNA, so that the full length glmS could only be
detected in the PA-gel pocket. This is why these compounds were excluded from the primary
hits.
Due to structural similarity to C9 and high activity, D9 was also included in further
characterizations of cleavage inhibition (Figure 3.5).
In addition to all the substances identified that block glmS cleavage, it was striking to find
compound D4 to increase glmS scission above percentages observed in the mere presence of
GlcN6P (Figure 3.5). This compound had also been identified in the 2mM in 2% DMSO
screening approach (see also Table 8.3). However, in a concentration dependent study of
D4 influence on glmS cleavage, no enhancement was observed (Figure 8.6 F). This finding
suggests that the increased cleavage rates monitored in the presence of D4 are merely due to
unspecific effects (see detailed discussion Section 4.2.1).
Compounds B7, C3, C6, C8, C9, D2 and D4 were tested for effects on glmS cleavage
in the presence of compound concentrations ranging from 25nM to 2mM (Figure 8.6 in
Section 8.1). Compounds were not tested at concentrations exceeding 2mM as this would
have increased the final DMSO concentration above 2%. In order to reach saturation, a
lower concentration of GlcN6P was used, that is closer to the EC50-value for glmS ribozyme
activation of 3.6 µM. Under these conditions only B7, C3, C6, C8 and D2 revealed a
concentration dependent cleavage inhibition in competition with 4 µM GlcN6P (Figure 8.6
A-E). For compound D2 a dose-response curve could be fitted (R2= 0.94) yielding an IC50-
value of 488 µM (Figure 8.6 E). For the other compounds a decrease in cleavage was observed
at high compound concentrations, indicating a weaker affinity within the millimolar range.
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Figure 3.5: Screening of Reymond compounds for competition with GlcN6P in glmS
ribozyme cleavage activation. Screening outcome with controls on the left (black bars). Assay
conditions are as described above (Figure 3.3). 200 µM GlcN6P were used in all competition
reactions with 2mM Reymond compound (2% DMSO final). Black lines show the cut-off for hit
definition at 40% glmS cleavage. Compounds that were considered as hits after PAGE and band
quantification analysis are marked with an asterisk (A). Chemical formulas of hit compounds
are shown in (B). Due to structural similarity to C9 and high activity, D9 was also included in
further characterizations of cleavage inhibition.
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3.1.3.2 Screening of GlcN6P analogs for ribozyme activation
Several strategies have already been employed to search for glmS ribozyme activators. In
2006, Mayer et al. described a fluorescence polarization-based high-throughput-compatible
screening assay to monitor GlcN6P-dependent glmS ribozyme self-cleavage of the minimal
riboswitch from B. subtilis (Mayer and Famulok, 2006). A diverse library of small molecules
was assembled to include mainly compounds that follow Lipinski’s rule of five, thereby
increasing the chances to obtain orally active drugs (Lipinski et al., 2001). However, none of
the 5000 drug-like compounds showed activation of the glmS ribozyme (Lünse et al., 2011).
At the same time, Blount et al. performed a FRET-based screening to identify inhibitors of
a bimolecular glmS ribozyme from S. aureus (Blount et al., 2006). A collection of rationally
designed GlcN6P analogs as well as a library of 960 bioactive compounds was screened.
Within the GlcN6P analog library, several substances with a potential for glmS ribozyme
activation were discovered. Although the bioactive compound library was quite diverse, only
one valuable hit was identified, whose binding and activation of the ribozyme was not due to
unspecific RNA interactions (Blount et al., 2006). This compound was glucosamine - again a
sugar, in structure very similar to the natural ligand of the glmS ribozyme.
Figure 3.6: Screening of GlcN6P analogs for S. aureus Mu50 glmS ribozyme activa-
tion. Library of glucosamine-6-phosphate analogs used in this screening (A). Performance
of glucosamine-6-phosphate and derivatives in the metabolite-induced self-cleavage assay (B).
Cleavage of the glmS riboswitch induced by GlcN6P and GlcN (black bars, 0.2mM) compared to
a panel of compounds 1-9 (gray bars, concentration as indicated).
These different approaches indicate that screening distinct libraries of metabolite analogs
can be very effective in riboswitch activator identification. Thus, a novel GlcN6P analog library
was designed (Figure 3.6 A, compounds 1-9). Compounds 1-4 were based 1-deoxyglucosamine-
6-phosphate which has been shown previously to activate the glmS-riboswitch from B. cereus
(Lim et al., 2006). Compounds 1-4 as well as the methyl glycosides 5-7 were designed to
investigate the importance of the C-3 and C-4 hydroxy groups for S. aureus glmS ribozyme
activation. Additionally, carba-sugars 8 and 9 were synthesized to address the role of the ring
oxygen in riboswitch activation. This small compound library was synthesized by Valentin
Wittmann’s lab at the University of Konstanz. The synthesis of CGlcN6P (Figure 8.4) is
described in detail in Schmidt (2010).
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This series of structural and stereochemical GlcN6P isomers was subsequently investigated
for glmS ribozyme activation using the metabolite-induced self-cleavage assay (Figure 3.6
B). Most strikingly, compound 8 activated the riboswitch to a comparable extent as does
GlcN6P (control bar) demonstrated by 80% cleavage at 200 µM. Compound 9, which is
the unphosphorylated form of compound 8, activates glmS cleavage to about 20%, yet at
100 fold higher concentrations (20mM). Finally, compound 2, which contains the minimal
requirements for glmS ribozyme activation (Lim et al., 2006), also revealed a slight increase in
ribozyme activity above background levels (approx. 10%), that was found to be concentration
dependent (Figure 8.3 D).
The other compounds tested revealed no significant increase in ribozyme activity. The
derivatives of 1-deoxy-GlcN6P lacking the equatorial 4-hydroxy group are not active anymore
(Figure 3.6, compound 4). Similarly, variants with a cyclic phosphate (Figure 3.6, compound
3) or a methylation at the 1-hydroxy functionality (Figure 3.6, compounds 5-7) are also not
effective in inducing glmS riboswitch hydrolysis.
3.1.4 Characterization of carba-sugars as novel glmS ribozyme activators
Carba-sugar 8, from here on referred to as carba-glucosamine-6-phosphate (CGlcN6P) was
shown to efficiently induce glmS riboswitch self-cleavage. Therefore, its cleavage characteristics
were further investigated in vitro.
For this, EC50-values for GlcN6P and GlcN as well as their carba-analogs were calculated
by plotting the ratio of glmS cleaved against the logarithm of metabolite concentration used in
the cleavage reaction, leading to a sigmoidal dose-response curve (Figure 8.1). In comparison
to GlcN6P (Section 3.1.2), carba-glucosamine-6-phosphate’s EC50-value is less than two fold
higher (EC50 GlcN6P= 3.6 µM vs. EC50CGlcN6P= 6.2 µM, see also Table 3.2). Due to
Figure 3.7: Concentration dependent cleavage of S. aureus Mu50 glmS ribozyme.
GlcN6P, GlcN and artificial metabolite Carba-GlcN6P trigger concentration dependent cleavage
of glmS ribozyme of S. aureus Mu50 (A). Dose-response curves from at least three independent
experiments were used to calculate the EC50. Error bars are omitted for clearer representation,
but can be found in Figure 8.1. (B) Chemical formulas for natural metabolite GlcN6P (upper
left) and its carba-analog CGlcN6P (upper right) as well as for the amino sugar GlcN (lower
left) and its analog CGlcN (lower right). Differences in chemical structure from GlcN6P are
highlighted in light blue.
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Figure 3.8: Determination of observed rate constant for glmS cleavage. Kobs determi-
nation of S. aureus Mu50 (A) and B. subtilis (B). Cleavage rates of the glmS-riboswitch at different
concentrations (circles 2 µM; squares 20 µM; triangles 200 µM) of GlcN6P (blue), CGlcN6P (cyan),
and GlcN (red). Plots of the fraction cleaved as a function of time are shown. Experiments were
carried out in triplicates.
the mere exchange of the ring oxygen for a CH2 group in the carba-sugar (Figure 3.7 B),
the interaction the oxygen formes with the riboswitch is the only one lost in comparison
to the natural metabolite. This most likely accounts for the similarity in half-maximal
ribozyme activation. When the phosphate group is missing, like in GlcN (Figure 3.7 B), the
concentration of half-maximal activation is about 50 fold higher. For its carba-analog, CGlcN,
no EC50-value could be determined as the assay set-up did not permit the use of compound
concentrations high enough to reach saturation levels of maximal ribozyme cleavage. The
highest CGlcN concentration assayed was 10mM, which indicates that half maximal CGlcN
triggered ribozyme activation must be in the millimolar range. Interestingly, the half maximal
ribozyme activation by CGlcN6P is about three fold enhanced in B. subtilis (2.1 µM) in
comparison to S. aureus (6.2 µM).
In order to evaluate how efficiently the glmS ribozyme cleaves upon encountering its cofactor
or analogs, kobs values were determined. By monitoring ribozyme cleavage over a time course
of 90 minutes at defined metabolite concentrations, rate constants (kobs) were determined
using the fit for a one phase exponential association (Section 6.2.4.3).
The rate constants (kobs) of metabolite-induced cleavage of the S. aureus glmS-riboswitch
were found to be comparable for GlcN6P and CGlcN6P at all concentrations tested (200, 20,
2 µM, Table 3.3). For example, GlcN6P cleaves the S. aureus ribozyme at 200 µM with a rate
constant of 0.18min−1 and the carba-analog at a rate of 0.15min−1. These data indicate
Concentration S. aureus kobs [min−1] B. subtilis kobs [min−1]
[µM] GlcN6P CGlcN6P GlcN6P CGlcN6P
200 0.18 0.15 1.75 1.2
20 0.11 0.095 0.4 0.22
2 0.07 0.060 0.14 0.083
Table 3.3: kobs values determined for glmS ribozyme cleavage of S. aureus and
B. subtilis.
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that the potential of CGlcN6P for riboswitch activation is very similar to that of the natural
metabolite (Figure 3.8 A). The overall cleavage rates of the S. aureus glmS-riboswitch were
found to be slower than those reported for glmS-riboswitches from other bacteria (kobs at
200 µM GlcN6P 0.18min−1 in S. aureus and 1.75min−1 in B. subtilis, Table 3.3, Winkler et al.
(2004)). Interestingly, the activation of the B. subtilis glmS-riboswitch was more disturbed
by CGlcN6P as kobs- values decreased in comparison to GlcN6P (kobs at 200 µM CGlcN6P
1.2min−1 vs. 1.75min−1 for GlcN6P, Figure 3.8 B). Similarities in kobs values determined
for S. aureus GlcN6P versus CGlcN6P dependent cleavage are also reflected in obtained
EC50-values (see above). The three fold difference in EC50 of CGlcN6P between S. aureus
and B. subtilis hints at the about 10 fold higher kobs values determined for B. subtilis.
3.1.5 Antibacterial effects of carba-sugars on S. aureus Mu50
After CGlcN6P had shown similar behaviour to GlcN6P in activating the glmS ribozyme in
vitro, the effect of carba-sugars on growth of the VISA strain Mu50 was investigated.
For these in vivo studies the use of CGlcN6P is not indicated because it is not very likely
to pass the cell membrane due to its charged phosphate moiety (Figure 3.7 B). Different
strategies will have to be utilized to possibly enable direct CGlcN6P take-up (McGuigan
et al., 2008).
Gram-positive bacteria usually take up sugars by active transport through sugar specific
phosphoenolpyruvate transfer systems (PTS, Reizer et al. (1988)). Staphylococci have PTS
transporters for a variety of sugars, among them also glucosamine. Under the hypothesis that
the PTS transporters responsible for GlcN uptake can also accept CGlcN, this carba-sugar
was used for all in vivo investigations. When transferred across the cell membrane via a PTS,
GlcN, and likely CGlcN, is phosphorylated at its C-6, resulting in GlcN6P or CGlcN6P, the
more potent glmS ribozyme activator (Figure 3.9 A).
Two standard microbiological evaluations were performed to investigate and define an-
Figure 3.9: Effect of CGlcN on S. aureus Mu50 growth. Schematic of hypothesized
carba-sugar transport and action inside bacteria (A). Increasing concentrations of CGlcN are
shown in shades of blue, bacterial growth without compound is depicted in red and growth in the
presence of high doses of vancomycin are orange (B).
40
3.1 The glmS ribozyme of Staphylococcus aureus Mu50 as antibacterial drug target
tibacterial potency of CGlcN. On the one hand, the influence of CGlcN on S. aureus Mu50
growth was assessed by determining its minimal inhibitory concentration (MIC, experimental
details are found in Section 6.3.5). The MIC marks the lowest compound concentration at
which bacterial cells do not show growth after 24 h of incubation. This figure is often used
to compare potencies of antibiotics with each other. Cells were grown in a chemical defined
medium (CDM, Section 7.4) where amino acids were the sole carbon source. An inhibition in
growth was observed at concentrations of 625 µM carba-glucosamine (133 µg/ml).
On the other hand, bacterial growth was measured directly upon addition of the carba-
compound over a time course of 24 h. Vancomycin, used at elevated, clinically irrelevant,
concentrations in this experiment, is a bactericidal antibiotic. Its killing effect is evident from
the fact that the orange line, resembling S. aureus growth in the presence of vancomycin,
only slightly elevates and then remains at the same absorption value (Figure 3.9 B). The
CGlcN growth curves revealed that with increasing concentrations (40 µM-80mM) a decrease
in optical density was observed, which suggests that Staphylococcus aureus Mu50 cell count
descreases (Figure 3.9 B). Whether this is due to a bactericidal or bacteriostatic effect needs
to be further investigated (Section 5.1.5).
3.1.6 Synergistic effect of carba-sugars and vancomycin on S. aureus Mu50
growth inhibition
The vancomycin-resistant Staphylococcus aureus strain Mu50 shows increased cell wall synthesis
(Section 1.4.3.2, Hanaki et al. (1998a)). The thickened cell wall of this strain is seen as a
major contributor to vancomycin resistance (Breukink et al., 1999). In order to be able to
synthesize a stronger cell wall, more precursors are needed. Several components of pathways
involved in the making these precursors were shown to be upregulated in S. aureus Mu50 (Cui
et al., 2000). This strain shows an increased uptake of GlcNAc, which can easily be converted
to GlcN6P. Moreover, higher levels of glutamate synthase are found increasing the production
of glutamate, which is necessary for the synthesis of GlcN6P from Fru6P with the help of
Figure 3.10: Synergistic effect of sub-inhibitory concentrations of vancomycin in
combination with CGlcN. Bar graph depicts cell growth in the presence of either sub-
inhibitory concentrations of vancomycin (2.5 µM) in combination with increasing concentrations
of CGlcN (light gray) or increasing CGlcN concentrations (gray). Bacterial growth in chemically
defined medium without any compound present (black) or upon addition of 2.5 µM vancomycin
are shown as controls (dark gray).
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glmS. And finally this enzyme, the GlcN6P synthase, has also been found to be more active
thus producing more GlcN6P, which is the precursor of UDP-GlcNAc (Cui et al., 2000).
Therefore, sub-inhibitory concentrations of vancomycin were tested in combination with
CGlcN to investigate any synergistic effects. A concentration of 2.5 µM vancomycin did not
show any reduction in cell growth and was hence used as “sub-inhibitory” concentration
(Figure 3.10). A decrease in cell growth was observed in the presence of 5-40mM CGlcN in
combination with 2.5 µM of the glycopeptide antibiotic, with the greatest difference to be
observed at 10mM CGlcN (Figure 3.10). In comparison to this, the mere use of CGlcN did
not lead to such a strong abatement in bacterial growth. These results are preliminary, as
this experiment could only be carried out once. Since CGlcN is not commercially available,
but rather had to be synthesized, only limited amounts of compound were at hand for
experimentation. However, the synergistic CGlcN-Vancomycin tendencies call for further
evaluation of this phenomenon by future experiments.
3.1.7 Screening for natural activators of vancomycin-intermediate resistant
S. aureus Mu50 glmS ribozyme
Apart from screening synthetic small molecule libraries or chemically synthesized metabolite
analogs, natural products should be considered for interfering with glmS ribozyme activation.
Hence, this Section will describe the investigation of aminoglycosides as glmS ribozyme
regulators (Section 3.1.7.1) as well as the exploration of the naturally occuring substance
Streptozotocin in its role of glmS riboswitch activation (Section 3.1.7.2).
3.1.7.1 Screening of aminoglycosides for activation or inhibition of the glmS ribozyme
Aminoglycosides are oligosaccharide antibiotics that were first discovered in 1944 in the group
of Selman Waksman (Jones, 1944). These antibiotics are multiply charged compounds of
high flexibility. Their positive charges are attracted to the negatively charged RNA backbone
(Hermann and Westhof, 2000; Tor, 2003). The flexibility of the aminoglycosides facilitates
accommodation into a binding pocket within internal loops of RNA helices or into ribozyme
cores (Schroeder et al., 2000).
The conserved elements among aminoglycosides are highlighted in Figure 3.11 for To-
bramycin. The 2-deoxystreptamine ring is common to all aminoglycosides. Moreover, the
aminogroups at position 1 and 3 are conserved, as these elements are essential for binding to the
decoding site of the 16S rRNA (Schroeder et al., 2000). Furthermore, the 2-deoxystreptamine
ring is most commonly substituted, usually via O-glycosidic bonds, at positions 4 and 5, as
in the neomycin class (Figure 3.11 H-L), or at positions 4 and 6, as in the gentamicin and
kanamycin classes (Figure 3.11 A-D and Figure 3.13 B).
Aminoglycosides interact with ribosomal RNA at the A-site (Fourmy et al., 1996; Vicens
and Westhof, 2002), which is the entry site for aminoacyl tRNAs (except for the first aminoacyl
tRNA fMet, which enters at the P-site). Binding of the antibiotic induces a conformational
change in the RNA, thereby switching the A-site into a high affinity state for mRNA–tRNA
recognition and reducing the rejection rate of near-cognate tRNAs (Karimi and Ehrenberg,
1994; Fourmy and Puglisi, 1998). This increased affinity of the A-site for tRNAs in the
presence of antibiotics results in misreading of the genetic code (Davies et al., 1964, 1965;
Schroeder et al., 2000). In the presence of aminoglycosides, the level of translational accuracy
was estimated to decrease from a normal frequency of 1 × 10−3–10−4 misincorporation events
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Figure 3.11: Chemical structures of aminoglycosides tested for glmS ribozyme in-
terference in this study. In (A) the conserved streptamin ring is highlighted in orange, the
O-glycosidic bonds in red.
per codon to as much 1 in 10−1-10−2 (Zaher and Green, 2009).
Aminoglycosides are also known for interacting with catalytically active RNAs. Extensive
studies have been performed on their influence on the hammerhead ribozyme, RNase P
cleavage (Stage et al., 1995; Vioque, 1989), or group I intron splicing (von Ahsen et al., 1991).
Hence, aminoglycosides were tested for their ability to enhance or inhibit the activation
of the glmS ribozyme of S. aureus Mu50. For this, the ribozyme was either incubated
with the aminoglycoside alone or additionally in the presence of 200 µM GlcN6P. None of
the aminoglycosides investigated showed any activation of glmS ribozyme cleavage (Figure
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3.12). However, there were some amino sugars that interfered with proper ribozyme cleavage
triggered by GlcN6P, namely Paromomycin, Tobramycin, Hygromycin B, and Neomycin.
Although from the quantification data analysis it appears that Netilmicin decreases cleavage
significantly, PAGE showed that this is merely due to unspecific interactions with the RNA,
which retain it in the gel pockets (Figure 3.12 A).
The most prominent decrease in metabolite-induced self-cleavage showed Neomycin (Figure
3.12 B, Figure 3.11 I), which is similar in structure to Ribostamycin, Paromomycin and
Framycetin (Figure 3.11 M, J & K and Figure 3.12 B). Paromomycin (Figure 3.12 A)
and Ribostamycin (Figure 3.12 C, Schüller (2012)) revealed a slight inhibition of glmS
cleavage. Framycetin was not available for testing, but should be investigated for its effect
on glmS ribozyme inhibition. Tobramycin also interfered with ribozyme activity, however
aminoglycosides similar in structure, like Gentamicin and Kanamycin A did not show any
effect (Figure 3.11 A, B and 3.13 B). Slightly less closely related Sisomycin revealed moderate
glmS cleavage inhibition (Figure 3.12 C and Figure 3.11 C, (Schüller, 2012)). Although,
future experiments will have to uncover whether these effects are due to the same unspecific
interactions observed for the structurally very closely related Netilmicin (Figure 3.11 D).
Moreover, Spectinomycin did not show any effect in glmS ribozyme cleavage inhibition
(Figure 3.12 A and Figure 3.11 H). Compared to the aforementioned aminoglycodsides, it
uses different mode of action on bacterial translation by inhibiting the translocation process
(Brink et al., 1994). However, Hygromycin B which employs this mode of action also (Peske
et al., 2004), revealed a very strong effect on ribozyme inhibition (Figure 3.12 A and Figure
3.11 E). Hence, those groups conferring the inhibition of the translocation process are either
not necessarily the same ones that interfere with ribozyme action, or possibly secondary or
tertiary RNA structures targeted by Spectinomycin and Hygromycin B in rRNA are not
equally found in the glmS ribozyme.
Because different influences on ribozyme activation have been described in the literature for
Kanamycin A and B, the latter was also tested for its ability to interfere with glmS ribozyme
cleavage (Figure 3.13). Although the only difference between these antibiotics is the exchange
of a hydroxyl group for an amino-group, this slight difference in structure leads to a strong
reduction of glmS ribozyme cleavage by Kanamycin B (to about 20%), whereas Kanamycin
A shows no effect (Figure 3.13 A). In this regard, Kanamycin C (Figure 3.13 B) should be
tested for its influence on ribozyme cleavage. This would allow to conclude whether the
number or the position of amino-groups is critical for cleavage inhibition. Kanamycin B is
also interesting, as it is very close in structure to Tobramycin (Figure 3.13 B and Figure 3.11
A), which contains a single hydroxy-group less.
To further investigate these observed phenomena, all aminoglycosides that revealed an
inhibitory effect on cleavage were tested in a concentration dependent manner in competition
with GlcN6P. Table 3.4 shows half-maximal inhibitory concentrations obtained from dose-
response curves (Figure 8.11). Neomycin inhibited cleavage most potently of all examined
aminoglycosides displaying an IC50 of 28.7 µM. Ribostamycin lacks one of the amino sugar
rings compared to Neomycin, it has a less pronounced inhibitory activity (IC50 2.03mM).
Interestingly, Paromomycin, which differs from Neomycin by the exchange of one amino-group
for a hydroxyl group, is able to reduce ribozyme cleavage, but too subtle to determine IC50-
values from a proper dose-response curve. This indicates that its IC50-value is more than 100
fold reduced compared to Neomycin. These findings underline the importance of the number
of amino-groups carried by the aminoglycoside. A decrease in amino-groups is correlated
with a decrease in ribozyme cleavage inhibition. Tobramycin inhibits glmS cleavage with an
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Figure 3.12:
Screening
of aminogly-
cosides for
inhibition and
activation of
S. aureus glmS
ribozyme
cleavage.
Aminoglyco-
sides Netilmicin,
Paromomycin,
Spectinomycin,
Streptomycin,
Tobramycin and
Hygromycin B
were tested for
activation of the
glmS ribozyme
at compound
concentrations
of 200 µM or
for inhibition of
glmS ribozyme
cleavage in the
presence of
200 µM GlcN6P
(A). The same
experimental set-
up as described
in (A) was used
to investigate
characteristics
of Amikacin,
G418, Gentami-
cin, Isepamicin,
Kanamycin A
and Neomycin
(B) as well as
Ribostamycin
and Sisomycin
(C). Experiments
carried out by
Anna Schüller
are marked with
an asterisk.
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Figure 3.13: Influence of Kanamycin A and B on glmS ribozyme clevage. Metabolite-
induced self-cleavage of glmS ribozyme in the presence of either aminoglycoside alone (200 µM)
or in the presence of 200 µM GlcN6P (A). This assay was performed by Anna Schüller. Structure
of Kanamycin A, B and C (B).
Aminoglycoside IC50 [µM]
Neomycin 28.7
Tobramycin 55.4
Paromomycin n.a.
Ribostamycin 2030
Sisomycin n.d.
Kanamycin B 43.4
Table 3.4: IC50-values of aminoglycoside mediated glmS ribozyme inhibition.
Kanamycin B and Ribostamycin values were calculated from aminoglycoside concentration
dependent glmS ribozyme cleavage experiments performed by Anna Schüller. n. a.= not applica-
ble, where fits could not be applied to insufficient dose-response curves, n. d.= not determined.
IC50-value of 55.4 µM, thus about two fold less effectively than Neomycin. However, its value
of half-maximal ribozyme inhibition lies in the same range as that observed for Kanamycin B,
which was found to be 43.4 µM (Table 3.4). These two aminoglycosides are very similar in
structure and only differ by an additional hydroxyl group carried by Kanamycin B (Figure
3.13 B and Figure 3.11 A).
The half-maximal inhibitory concentration of Sisomycin has not yet been determined, even
though this aminoglycoside, in structure closely related to Netilmicin and quite similar to
Tobramycin and Gentamicin (Figure 3.11 A-D), did show glmS cleavage inhibition comparable
to Kanamycin B (Figure 3.12).
Additionally, cleavage rate contants were determined by Anna Schüller for GlcN6P induced
glmS ribozyme cleavage in the presence of increasing concentrations of aminoglycosides (Table
3.5). These kobs values indicate the change in speed of the cleavage reaction in the presence of
the antibiotic. In general, for all aminoglycoside antibiotics tested, increasing concentrations
led to a decrease in the observed rate constants. Moreover, the differences in kobs are in line
with inhibition tendencies observed in IC50 measurements (Table 3.4).
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Aminoglycoside Concentration [µM] kobs [min−1]
GlcN6P 2 0.068
20 0.107
200 0.177
Neomycin 2 0.155
20 0.0726
50 0.0414
100 n. a.
Tobramycin 2 0.167
20 0.098
200 0.034
2000 n. a.
Paromomycin 20 0.29
200 0.22
2000 0.151
Ribostamycin - n. d.
Sisomycin 20 0.193
200 0.058
2000 n. a.
Kanamycin B 20 0.154
50 0.115
100 0.039
Table 3.5: kobs values determined for glmS cleavage reaction. kobs measurements and
calculations were performed by Anna Schüller (Schüller, 2012). Observed rate constants were
obtained for reactions containing 200 µM GlcN6P and varying concentrations of aminoglycoside
antibiotic (2 µM-2mM). Metabolite-induced self-cleavage was monitored over a time course of
90min (Figure 8.10 and Figure 8.9). n. d.= not determined, n. a.= not applicable, where fits
could not be applied because of (near)-complete cleavage inhibition.
Exemplarily, an aminoglycoside concentration of 20 µM is chosen for comparison of kobs
values obtained in the presence of 200 µM GlcN6P. Under those conditions, observed rate
constants for Sisomycin (0.193min−1) or Kanamycin B (0.154min−1) remain comparable
to that observed for 200 µM GlcN6P alone (0.177min−1, Table 3.5). The cleavage rate for
Tobramycin (0.098min−1) and Neomycin (0.0726min−1) is 1.8-2.4 fold lower. Interestingly,
Paromomycin enhances glmS ribozyme cleavage 1.6 fold, even though increasing Paromomycin
concentrations still lead to a decrease in kobs values.
The decreases in kobs is even more pronounced at equimolar concentrations of aminoglycoside.
At these concentrations the kobs values are in the range of natural glmS ribozyme activation
at 2 µM GlcN6P (Table 3.5).
3.1.7.2 Streptozotocin
This section describes the investigation of a naturally occurring GlcN analog, Streptozotocin,
for its potential in glmS riboswitch activation. Streptozotocin (also known as Streptozocin
and abbreviated Stz) is a monofunctional nitrosourea compound that was first isolated from
Streptomyces achromogenes ssp. streptozoticus (C. Lewis, 1959/1960) and has been used as
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broad spectrum antibiotic that is active against many Gram-positive and -negative bacteria.
Streptozotocin or [2d-2-(3-methyl-3-nitrosoureido)-D-glucopyranoside] (Figure 3.14 A) is a
derivative of 2d-glucose and similar in structure to D-glucosamine and N-acetyl-D-glucosamine
(GlcNAc) (Ross R. Herr, 1967; Wiley, 1979). Stz is described as a mutagen, cancerogen, an
antitumor agent (Wiley, 1979) and is also a widely distributed diabetogen (Rakieten and
Nadkarni, 1963; Junod et al., 1967).
Stz is taken-up by Escherichia coli and other sensitive bacteria via a PTS transporter,
nagE, which is naturally involved in N-acetyl-glucosamine (GlcNAc) uptake (Lengeler, 1979).
Bacteria that show a mutation in the pts-operon transport enzyme or the gene nagE are not
susceptible to Streptozotocin anymore (Ammer et al., 1979; Lengeler, 1980). This nitrosourea
compound relies on its ability to be taken-up into cells, where it is broken down to yield the
highly toxic compound diazomethane, which kills cells by excessive DNA alkylation (Wiley,
1979). Additionally, the phosphorylated derivative of Stz accumulates intracellularly, since it
can neither be dephosphorylated nor deacetylated by metabolic enzymes.
3.1.7.2.1 In vitro activation of the glmS ribozyme of S. aureus Mu50 and B. subtilis by
Streptozotocin
Considering the similarity in structure between glucosamine and Streptozotocin we hy-
pothesized that this antibiotic might also affect glmS ribozyme cleavage. Therefore, the
previously described riboswitches from B. subtilis and S. aureus, were used to assess ribozyme
activation by increasing concentrations of Streptozotocin (Figure 3.14 B, C). Indeed, this
antibiotic revealed concentration dependent effects leading to a half-maximal glmS activation
of 104mM in S. aureus and 956mM in B. subtilis. It is not unexpected that these values lie
in the millimolar range. Apart from the structural changes at the C-2 position, it is also
known that the lack of the phosphate group at C-6 causes a significant decrease in ribozyme
activation for GlcN and GlcN6P which differ 50 fold in EC50-value (Table 3.2). Therefore,
although these results do not appear promising at first sight, the phosphorylated variant
might be interesting to investigate in vitro, especially since it is known that Streptozotocin is
present in its phosphorylated form in vivo.
3.1.7.2.2 Antibacterial effects of Streptozotocin
To investigate the influence of Streptozotocin on bacterial growth, minimal inhibitory
concentrations as well as growth curves were obtained for the VISA Mu50 strain. As a
vancomycin susceptable control strain, SG511-Berlin was used, which displays increased
sensitivity to antibiotic treatment (Sass and Bierbaum, 2009).
Minimal inhibitory concentrations (MICs) of Streptozotocin were determined as described
before in different growth media, namely 2× chemically defined medium (2×CDM), 0.5×
Mueller-Hinton (0.5×MH) broth, and brain-heart infusion (BHI).
BHI is a highly nutritious general purpose growth medium for fastidious as well as nonfas-
tidious bacteria and is the richest medium used in this MIC-investigation. Mueller-Hinton
medium consists of beef extract and acid hydrolysate of casein, which provide nitrogen,
vitamins, carbon, and amino acids. Starch is added to absorb any toxic metabolites produced.
Because of its composition and its use as half-concentrated solution, this medium is lower
in glucose than the BHI-broth (Mueller and Hinton, 1941). The chemically defined medium
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Figure 3.14:
Activation
of the glmS
ribozyme by
Streptozoto-
cin. Studies
of metabolite-
induced self-
cleavage by
S. aureus (B) and
B. subtilis (C)
glmS ribozyme
in the presence
of controls GlcN
and GlcN6P
(black bars) as
well as increasing
concentrations
of Streptozo-
tocin (gray
bars, 2-600mM).
Dose-response
curves were used
for EC50-value
determination
as described
before. S. aureus
dose-response ex-
periment marked
with an asterisk
was performed by
Anna Schüller.
does not contain any glucose. Here, the bacteria use aminoacids as sole energy source.
In general, it can be observed that the richer the medium in aminosugar equivalents, like
GlcN, the higher is the MIC (GlcN concentration in BHI > 0.5×MH > 2×CDM and according
MICs are 18.75 > 9.4 > 0.29 µM, Table 3.6). This can be explained by the competition of
(amino-) sugars with Streptozotocin for take-up by the same PTS transporters.
Strikingly, the vancomycin-resistant Mu50 strain has four fold lower MICs than the sensitive
SG511 strain, which is known to be very susceptible to cell wall targeting antibiotics (e. g. in
BHI 18.75 µM in Mu50 vs. 75 µM in SG511).
MIC Streptozotocin
Medium Mu50 [µM] SG511 [µM]
BHI 18.75 75
0.5×MH 9.4 37.4
2×CDM 0.29 1.17
Table 3.6: Minimal inhibitory concentrations of Streptozotocin in different media in
S. aureus Mu50 or SG511.
49
3 Results
Figure 3.15:
Growth of S. au-
reus Mu50 and
SG511 in the pres-
ence of increasing
Streptozotocin con-
centrations in BHI.
Graphs show optical
density measured at
600 nm plotted against
the time. Bacterial
growth without Strep-
tozotocin added is
shown in magenta and
contamination controls
of BHI and Strepto-
zotocin solutions are
depicted in black and
gray.
Measuring bacterial growth with increasing Streptozotocin concentrations revealed a strong
inhibition at concentrations higher than 37.5 µM in the vancomycin-susceptible strain SG511
as well as the VISA strain Mu50 (Figure 3.15). In 0.5×MH or 2×CDM bacterial growth
could be inhibited at even lower concentrations (Figure 8.12). However, with decreasing
aminosugar concentrations in the medium, bacterial growth rates decrease as well. This is
why, determinations of minimal inhibitory concentrations in 2×CDM were incubated for 48 h
(Section 6.3.5 for experimental details).
3.2 The thi-box riboswitch as antibacterial drug target
Thi -box riboswitches are phylogenetically the most widely distributed (Rodionov et al., 2002),
as they are found in all three domains of life (Miranda-Ríos et al., 2001; Sudarsan et al., 2003a;
Kubodera et al., 2003). Therefore, they constitute a valuable target for the identification of
novel antibacterial substances addressing a broad range of bacterial species.
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So far, a pyrimidine analog of thiamine called pyrithiamine (PT, Figure 3.17 E) has been
shown to bind to (Figure 1.11 D) and activate thi -box riboswitches in its phosphorylated form
pyrithiamine pyrophosphate (PTPP, Sudarsan et al. (2005)). The phosphorylation of PT to
PTPP is most likely accomplished with the help of thiamine pyrophosphorylase (thiK, Melnick
et al. (2004)). This compound was synthesized and first described as means to study thiamine
metabolism (Tracy and Elderfield, 1941), as it induces thiamine deficiency in mice and pigeons
(Koedam et al., 1956). PT and PTPP are known to compete for thiamine and TPP binding
sites on proteins (Woolley, 1951). Quickly after its discovery, PT was shown to be toxic in
small doses to bacteria and fungi which need thiamine supplementation (Woolley and White,
1943; Robbins, 1941). At present, it is known that at least part of this antibacterial and
antifungal activity is due to action on the riboswitch and interference with proper protein
expression, because PT-resistant bacteria have mutations in their TPP riboswitch aptamer
domain (Sudarsan et al., 2005).
3.2.1 Screening for thiM riboswitch activators
In order to screen for thi-box riboswitch activators, a reporter gene assay was designed,
in which the thiM riboswitch from E. coli (Figure 3.16 A, Mayer et al. (2007)) was cloned
into the 5´-UTR of the lacZ gene, coding for β-galactosidase (Figure 3.16 B, Simons et al.
(1987)). Thiamine addition to the growth medium, leads to absorption and conversion to
thiamine pyrophosphate (TPP). TPP binds to the aptamer domain of the thiM riboswitch,
which induces a change in secondary structure that sequesters the Shine-Dalgarno sequence
and subsequently downregulates reporter gene expression. The amount of β-galactosidase
produced is measured by a colorimetric assay (see Section 6.3.7) in which the amount of
cleaved O-nitrophenyl-β-galactopyranoside is detected by measuring absorption at 420 nm.
Two E. coli strains were transformed using the pRS414-thiM plasmid: the MG1655 strain,
which is often referred to as the E. coli wild-type laboratory strain due to its few mutations
(Table 7.5), and DH5αZ1 cells which are rendered dependent on thiamine uptake from the
growth medium, because of the thi−1 mutation (Table 7.5). In these cells the amount of TPP
is dependent on the amount of thiamine added to the growth medium. This enables direct
external control of the availability of this vitamine. In MG1655 cells however, TPP amounts
cannot be controlled from the outside, as these bacteria can synthesize it themselves from
precursors.
Subsequent monitoring of β-galactosidase activity in the presence and absence of thiamine
revealed a concentration dependent decrease in β-galactosidase expression with increasing
amounts of thiamine (Figure 3.16 C & D, black curve). Evaluation of dose-response curves
gave comparable IC50-values for both strains in the nanomolar range (15 nM for DH5αZ1
and 21 nM for MG1655). For thiamine as well as pyrithiamine it is thought that they are
likely to be taken-up and phosphorylated by the bacteria, hence probably act as TPP or
PTPP on the riboswitch (Iwashima et al., 1976). However, both strains differ in the effect
seen for pyrithiamine. Whereas this thiamine analog decreases reporter gene expression in
MG1655 cells at concentrations above 50 µM, it does not show any influence on β-galactosidase
expression in the thiamine dependent strain (Figure 3.16 C & D, gray curve).
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Figure 3.16: In vivo screening system for thiM riboswitch activators. Secondary
structure prediction of E. coli thiM riboswitch (A). Shine-Dalgarno sequence is highlighted in
orange and thiM mutation site is colored in red. Schematic representation of plasmid construct
used for thiM riboswitch activator screening (B). pRS414 plasmid containing an ampicillin selection
marker was used to construct a lacZ-fusion with the thiM riboswitch sequence. Transformed
E. coli strains DH5αZ1 (C) and MG1655 (D), were utilized to report thiM riboswitch activation.
TPP binds to and activates the thiM riboswitch, which results in a decrease in reporter gene
expression measured by a colorimetric assay (6.3.7), whereas PT only decreases β-galactosidase
expression in MG1655 cells.
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3.2.2 Identification of triazolethiamine and close derivatives as new thiM
riboswitch activators
The thi-box riboswitch has been shown to allow a greater degree of variation in its ligand
interaction as exemplified by the TPP analog pyrithiamine (Thore et al., 2008). Therefore,
thiamine analogs bearing a 1,2,3-triazole group instead of the thiazole heterocyclic moiety in
thiamine were investigated for in vivo thi -box riboswitch activation using the aforementioned
reporter gene assay (Section 3.2.1). Synthesis of these compounds was achieved using a
“click” chemistry approach utilizing a common azide intermediate which was then reacted
with the appropriate substituted alkyne (Figure 8.5). All triazolethiamine (TT) analogs, were
synthesized by Colin Suckling’s group (University of Strathclyde, Glasgow, UK, for detailed
synthesis schemes refer to Scott (2012)).
Figure 3.17 A & B shows reporter gene activity in E. coli upon addition of thiamine,
PT or the synthesized triazolethiamine compounds in relation to maximum β-galactosidase
expression monitored without thiamine. These data indicate that TT (10) is able to repress
reporter gene activity to about 5% in the thiamine dependent strain or about 10% in MG1655.
As PT and TT-variants are likely to be phosphorylated in vivo, and thus activated to interact
with the thiM riboswitch, they are capable of inducing the necessary conformational changes
in the RNA to downregulate gene expression. In DH5αZ1 cells, triazolethiamine compound
11 reduces β-galactosidase expression to 40%, compound 12 to 60% and compound 13 to
only about 80% (Figure 3.17 A). Even though effects were pronounced in the wt E. coli
strain, a reduction in reporter gene expression was observed for compounds 12 and 13
(Figure 3.17 B). Therefore, shortening (11) or elongating the alkyl side chain (12 and 13)
results in a loss of activity. This is most likely due to reduced uptake and/or phosphorylation
of these compounds in vivo. Interestingly, compound 14, which bears an amino group
instead of a hydroxyl residue on the ethyl-alkyl side chain of TT, also represses reporter gene
activity to about 20% (Figure 3.17 A) or 10% (Figure 3.17 B). In order to efficiently activate
the thiM riboswitch this compound would have to be phosphorylated, however by which
biochemical pathways this is possibly achieved, remains to be elucidated. Compound 15
with its terminal carbonyl group reveals neither in E. coli wild-type MG1655 cells nor in the
thiamine auxotrophic DH5αZ1 strain a strong thiM riboswitch activation. This compound
was not further investigated, neither for concentration dependent effects in the reportger gene
nor growth assay (for comparison of chemical formulas refer to Figure 3.17 E).
Except for the strikingly different effect of PT, the investigated compounds show similar
tendencies of activating the riboswitch in both E. coli strains. However, in DH5αZ1 cells the
compounds revealed a clear structure-activity relationship at concentrations of 500 µM (Figure
3.17 A), whereas in the strain MG1655 almost every compound was active with a slight
decrease of activity when elongating the alkyl-side chain of TT (Figure 3.17 B). Generally,
the triazolethiamine-analog-effect is always more pronounced for concentrations of 500 µM in
E. coli MG1655 cells.
In order to evaluate whether the observed effects on β-galactosidase expression are solely
due to activation of the riboswitch, a thiM riboswitch variant (thiM mut, Figure 3.16 A) was
used. It has an alteration in its aptamer domain disrupting the P2 helix and has previously
been described as rendering this riboswitch incapable of controlling β-galactosidase expression
(Mayer et al., 2007). In both bacterial strains, thiamine and compound effects were abolished
when the thiM mut construct is used in the reporter gene assay (Figure 3.17 C & D).
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Figure 3.17: In vivo screening of triazolethiamine analogs using a thiM riboswitch-
dependent reporter gene assay. β-galactosidase assay in DH5αZ1 (A) and MG1655 cells (B)
in the presence of thiamine, PT or triazole compounds 10-15 shown as relative expression. C
& D depict control assays using a reporter construct with a mutated thiM sequence. Chemical
formulas for thiamine, pyrithiamine and triazole thiamine analogs (10-15) (E).
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3.2.2.1 Concentration dependent influence of triazole-compounds on reporter gene
expression in DH5αZ1 and MG1655
In support of the observed thiM riboswitch activation by TT compounds, IC50-values were
determined. All compounds (10-14) clearly indicated a concentration dependent repression
of gene expression, however TT (10) revealed the strongest effect with an IC50-value of
8.0 µM (Table 3.7) in DH5αZ1. For compounds with increasing alkyl-chain length (12 and 13)
inhibition curves in DH5αZ1 cells did not reach maximum inhibition, hampering IC50-value
determination (Supplementary Figure 8.14). Where dose response fits were not applicable,
the IC50-value is above 500 µM. Also in wt E. coli only comparatively high IC50-values were
observed (213.5 µM for 12, Table 3.7, Supplementary Figure 8.15). As expected, PT did not
show any concentration dependent effect on β-galactosidase expression in DH5αZ1 cells, but
in MG1655 cells repression of gene expression was detectable at concentrations above 100 µM
(Table 3.7, Figure 3.17 B and C).
Compound IC50 [µM] DH5αZ1 IC50 [µM] MG1655
thiamine 0.015 ± 0.001 0.021 ± 0.006
10 (TT) 8.01 ± 3.64 38.36 ± 4.7
11 38.95 ± 8.4 106.44 ± 23.98
12 n. a. 213.50 ± 2.69
13 n. a. n. a.
14 73.59 ± 5.8 123.00 ± 28.99
PT n. a. n. a.
Table 3.7: IC50-values for thiM riboswitch activating compounds 10-14. IC50-values
were calculated from dose-response curves of the inhibition of reporter gene expression in DH5αZ1
and MG1655 cells. Means and standard deviations of at least three independent experiments,
measured in duplicates, are shown. n. a. = not applicable, TT = triazolethiamine, PT =
pyrithiamine.
Furthermore, IC50-values for TT compounds were found to differ 2-4 fold between both
strains, which is likely to be caused by the differences in genetic background (Section 4.2.5).
However, the relative order of half maximal inhibitory concentrations within the strains is the
same (IC50 thiamine < TT < 11 < 14 < 12, Table 3.7).
3.2.2.2 Influence of TT compounds on bacterial growth in E. coli and H. influenza cells
The finding that triazolethiamine and some TT-based compounds activate the thi-box ri-
boswitch and act as inhibitors of gene expression in E. coli, led to the investigation of their
impact on bacterial growth (Figure 3.18).
Monitoring the ratio of bacterial growth in E. coli DH5αZ1 (growth in the presence of
triazolethiamine derivative versus cell growth in the absence of compound) showed concentra-
tion dependent inhibition of bacterial growth by TT (Figure 3.18 A). It is noteworthy that
this property was not seen for the shortened TT-variant 11 (Figure 3.18 B), even though
this compound revealed moderate downregulation of reporter gene expression (Figure 3.17
A). In contrast, elongation of the alkyl-side chain renders 12 and 13 capable of interfering
with bacterial growth. It is interesting that especially compound 13 whose activity in thi-
box-dependent repression of gene expression was less prominent, still inhibits cell growth
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Figure 3.18: E. coli DH5αZ1 growth in the presence of triazolethiamine compounds.
Bacterial growth is shown as ratio of growth in the presence of TT-compound versus growth
in the absence of any compound. Graphs A-E show assay results for indicated compound or
thiamine (F). Compound concentrations between 500 µM- 32mM at 495min are shown.
(Figure 3.18 C and D). The amine-compound (14) did not interfere with bacterial growth at
concentrations tested (Figure 3.18 E), which is surprising taking into account its strong effect
on riboswitch activation in the reportergene assay. Interestingly, the same effect was observed
for thiamine itself, which was expected to support growth in this thiamine auxotrophic strain
(Figure 3.18 F). However, it is possible that critical thiamine concentrations that would yield
to a concentration dependent growth are below the 500 µM tested. E. coli MG1655 cells
showed similar tendencies in triazole compound effects on bacterial growth, however they
were more subtle (Figure 8.13). This leads to the assumption that bacteria whose thiamine
biosynthesis is intact, somehow gain advantages in tolerating these thiamine analogs and
potentially even use parts of them as precursors for their own thiamine biosynthesis (Section
4.2.5).
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PT did not show any effect on bacterial growth in DH5αZ1 cells (Figure 8.8), which is in
line with its inability in activating the thiM riboswitch in the reporter gene assay (Figure
3.17). Most likely PT is degraded into thiamine precursors by a tenA activity (Sudarsan et al.,
2005). However, in MG1655 cells, whose reporter gene expression could be downregulated by
PT, this compound induces a decrease in bacterial growth (Figure 8.8).
Additionally, minimal inhibitory concentration determinations were conducted, that show a
decrease in growth (displayed by smaller cell pellets) but no complete growth inhibition at
concentrations up to 1mM.
The Gram-negative bacterium Haemophilus influenza bears the thiM riboswitch upstream of
an essential gene for thiamine biosynthesis. Thus, interfering with the riboswitch in regulating
this gene, may cause severe effects on bacterial growth. Therefore, H. influenza was tested for
TT-compound effects.
Normally, the fastidious H. influenzae are cultivated on bacitracin chocolate agar, made
from red blood cells, which have been lysed by heating very slowly to 65 °C. Hence, it
contains the required factor X (hemin) and factor V (NAD) for Haemophilus growth, but
also undefined amounts of thiamine. The addition of bacitracin renders this medium selective
for the Haemophilus genus (Kilian, 2001). It has been shown that H. influenza, whose shape
ranges from cocobacilli to filamentous rods, grows better in humid atmosphere with added
5-10% of CO2 and temperatures between 33-37 °C (Kilian, 2001).
However, under minimal conditions the cultivation of these nonmotile, nonsporeforming,
facultative anaerobes is rather demanding. No chemically defined media have been described
before, that would allow sufficient testing in the presence of thiamine or TT-compounds under
defined parameters. Similar to the chemically defined medium used for Staphylococcus aureus
growth, a minimal H. influenza medium (CDM-HI) was created, which contains factor V and
X, but no thiamine or glucose (Section 7). This allows the separate addition of the vitamin
and sugar depending on the experimental set-up, i. e. vitamin deprived for TT-compound
testing, sugar deprived for possible carba-sugar off-target tests.
However, growth tests in liquid culture were not successful. CDM-HI cultures containing
glucose and thiamine, glucose but no thiamine, and neither glucose nor thiamine were
inoculated with Haemophilus influenzae of an OD600 of 0.65 in a ratio of 1:100. Optical
density was measured every day for a week, but did not indicate any growth. This could be
due to the medium’s nutrient content being insufficient or because cell growth is too slow
to enable any OD600 detection after this incubation period. Yet, repetition of this set-up
by inoculating the culture to a starting OD of 0.1 did not reveal any growth within seven
days of monitoring either. This suggests that cultivation procedures are not yet optimal to
support bacterial growth, either because essential components for H. influenza growth are
absent from the minimal medium or that other conditions, such as incubation without shaking
are deleterious.
As an alternative to cultivation in liquid culture, agar plates were prepared from CDM-HI
containing glucose and thiamine, glucose but no thiamine, and neither glucose nor thiamine.
After three days slight colony growth was visible on plates with glucose and thiamine. Minimal
growth was also detected on the other plates on day five. Since this strain is not thiamine
auxotrophic, it can compensate for the lack of thiamine in its surroundings by producing this
vitamine from precursors. This may explain bacterial growth in CDM-HI without thiamine
and also that growth takes longer (colonies appear only after five days). In order to verify
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that the colonies are indeed Haemophilus influenza cells, single colonies were picked and
restreaked on bacitracin chocolate agar. Subsequent tests of these cultures by Gram staining
and microscopy as well as metabolic tests (see Section 6.3.4) confirmed them as H. influenza.
Since Haemophilus influenza growth was proven to occur under these conditions, agar
diffusion tests were performed (see Section 6.3.3.3 for experimental details) using 128mM
or 12.8mM of either TT, compound 14, or thiamine on CDM-HI agar with glucose but
without thiamine. Additionally, cells were also streaked on a plate with CDM-HI with glucose
and with thiamine. After three days, very faint H. influenza growth was observed, however
addition of thiamine or compound did not result in any quantifyable inhibition, even after
incubation for up to 14 days. This could be due to uncertain stabilities of the compounds or
any components in the growth agar.
3.2.2.3 Isolation thiamine derivatives from cell extract and tracing by HILIC/MS
TT activates the thiM riboswitch in a concentration dependent manner. However, it has
been shown that the pyrimidine as well as the pyrophosphate helix of the aptamer domain
need to be brought together by ligand binding to activate the riboswitch (Rentmeister et al.,
2007). Therefore, it is likely that the TT compounds, like PT, are phosphorylated in vivo.
To prove this, the isolation and detection of phosphorylated triazole thiamine from bacterial
cell extracts was attempted using hydrophilic interaction liquid chromatography (HILIC)
followed by mass spectrometry (MS). HILIC allows the separation of polar and hydrophilic
compounds like amino acids, peptides, carbohydrates, plant extracts and various other polar
compounds that usually have little or no retention in reverse phase liquid chromatography
(RPLC) (Grumbach and Iraneta, 2004).
To analyze TT phosphorylation by HILIC/MS, bacterial cultures were grown in the presence
or absence of thiamine or triazolethiamine and harvested after 24 h. After cell lysis, the lysate
was cleared of proteins and nucleic acids by precipitation. The amount of thiamine species
(thiamine, thiamine monophosphate (TMP) and thiamine pyrophosphate) was estimated by
the thiochrome method (see Section 6.3.8 and 6.3.9 for experimental details).
All HILIC and HILIC/MS analysis were performed by Dr. Giorgia Greco in collaboration
with Dr. Thomas Letzel from the Competence Pool Weihenstephan at the Technical University
Munich.
First of all it had to be ensured that different thiamine species can be separated and
detected by this method. Therefore, thiamine (T), TMP and TPP were analyzed separately
(Figure 8.16) and as a mixture (Figure 8.17). To achieve this, standard solutions of thiamine
and its derivatives were analyzed using a ZIC-HILIC column (see Section 6.3.10 for a detailed
listing of the methods 6.19). The ZIC-HILIC stationary phase is attached to porous silica
and is made of sulfobetaine, which has two permanently charged groups (Jandera, 2011).
The separation of analytes is based on polar differences and is achieved by a hydrophilic
partitioning mechanism superimposed on weak electrostatic interactions (Grumbach and
Iraneta, 2004). The retention increases with polarity and hydrophobicity of the analyte.
Hence, increasing the water content in the mobile phase will increase the affinity of the
compound for the mobile phase as well, thus eluting the compound (Grumbach and Iraneta,
2004). Compounds like thiamine and TPP are more soluble in water due to their charges. All
thiamine variants were detected individually, but also successfully separated and detected,
when a compound mixture was used. Moreover, this experiment allowed an estimate on the
expected retention times for thiamine (and variants) to be investigated in cleared cell lysates.
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Sample
number
Culture
volume
500 µM T in
o/n incuba-
tion
added to cell
lysate
added post
isolation
T
detected
TPP
detected
1 8ml - - - - -
2 8ml - 10 µM T - - -
3 8ml - 100 µM T - + -
4 8ml - - 10 µM T + -
5 8ml - - 100 µM T + -
6 8ml - 10 µM TPP - - -
7 8ml - 100 µM TPP - - +
8 8ml - - 10 µM TPP - +
9 8ml - - 100 µM TPP - +
10 8ml + - - - -
11 8ml + 10 µM T - - -
12 8ml + 100 µM T - + -
13 8ml + - 10 µM T + -
14 8ml + - 100 µM T + -
15 8ml + 10 µM TPP - - -
16 8ml + 100 µM TPP - - +
17 8ml + - 10 µM TPP - +
18 8ml + - 100 µM TPP - +
19 32ml - - - n. a. n. a.
20 32ml - 10 µM T - n. a. n. a.
21 32ml - 100 µM T - n. a. n. a.
22 32ml - - 10 µM T n. a. n. a.
23 32ml - - 100 µM T n. a. -
24 32ml - 10 µM TPP - n. a. n. a.
25 32ml - 100 µM TPP - n. a. n. a.
26 32ml - - 10 µM TPP n. a. n. a.
27 32ml - - 100 µM TPP n. a. +
28 32ml + - - n. a. -
29 32ml + 10 µM T - n. a. n. a.
30 32ml + 100 µM T - n. a. n. a.
31 32ml + - 10 µM T n. a. n. a.
32 32ml + - 100 µM T n. a. n. a.
33 32ml + 10 µM TPP - n. a. n. a.
34 32ml + 100 µM TPP - n. a. n. a.
35 32ml + - 10 µM TPP n. a. n. a.
36 32ml + - 100 µM TPP n. a. n. a.
37 80ml - - - n. a. +
38 80ml - 10 µM T - n. a. n. a.
39 80ml - 100 µM T - n. a. n. a.
40 80ml - - 10 µM T n. a. n. a.
41 80ml - - 100 µM T n. a. n. a.
42 80ml - 10 µM TPP - n. a. +
43 80ml - 100 µM TPP - n. a. +
44 80ml - - 10 µM TPP n. a. n. a.
45 80ml - - 100 µM TPP n. a. n. a.
46 80ml + - - n. a. +
47 80ml + 10 µM T - n. a. n. a.
48 80ml + 100 µM T - n. a. n. a.
49 80ml + - 10 µM T n. a. n. a.
50 80ml + - 100 µM T n. a. n. a.
51 80ml + 10 µM TPP - n. a. n. a.
52 80ml + 100 µM TPP - n. a. +
53 80ml + - 10 µM TPP n. a. n. a.
54 80ml + - 100 µM TPP n. a. +
Table 3.8: Cell extracts investigated by HILIC measurements and T or TPP detection
results. n. a.= not applicable, where matrix background was too high for accurate detections.
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Figure 3.19: HILIC of 8 and 32ml cultures. Detection of T and TPP in samples 5, 9 and
10 (8ml culture volume, A) as well as samples 23, 27 and 28 (32ml culture volume, B) using the
UV-detector at 280 nm.
In order to identify optimal conditions for efficient detection of phosphorylated triazole
compounds in cleared cell lysates, culturing and isolation procedures were optimized using
thiamine. Not only different culture volumes, but also incubation of cells in the presence
or absence of 500 µM thiamine were examined (Table 3.8). Additionally, cell lysates from
these samples were supplemented to concentrations of 10 or 100 µM thiamine or TPP at
two different points in the procedure: 1. immediately after cell lysis and 2. after the entire
isolation protocol (Table 3.8 shows the array of samples analyzed).
In all 8ml isolations, background matrix was so little that HILIC separation and MS
detection was possible (Figure 3.19 A). Interestingly, T or TPP were only detected when
spiked with 100 µM after cell lysis, or at least 10 µM after the isolation procedure (Figure
3.19 and Table 3.8). Thus, natural levels of thiamine conversion to TPP by mere addition
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Figure 3.20: HILIC of 32 and 80ml culture extracts. Detection of T and TPP in samples
37, 42, 43 and 46 using the UV-detector at 280 nm.
of thiamine to the culture medium were not detectable at this culture volume and by this
detection method. Moreover, the fact that supplementation to 10 µM T or TPP to the cell
lysate did not result in the detection of either substance later, implies the losses occuring
during lysate clearance and the isolation protocol.
It would be interesting to estimate how much the difference is in T or TPP detected in
sample 2 and 3 (or 6 and 7) as well as sample 2 and 11 or 3 and 12 (Table 3.8). Even
though the comparison of normalized areas under the curve can only be considered a rough
estimate of compound amounts present (personal communication Greco), such an analysis
was undertaken for samples 52 and 54 (Figure 8.19) as well as 37 and 46 . These isolations
are result of 80ml cultures which in general showed higher matrix background that rendered
the detection of thiamine impossible, as its peak is hidden in the matrix peak (Figure 3.20,
Table 3.8 samples 37-54). Sample 37, which results from an incubation in the absence of
thiamine and does not contain any supplementations added during the work-up procedure,
contains 6 fold less TPP than sample 46, which only differs by its incubation in the presence
of 500 µM thiamine over night (Figure 3.20). This indicates that the detection of naturally
synthesized TPP from absorbed T is possible, when higher culture volumes are used for the
isolation of thiamine derivatives (Table 3.8). However, this method detected only half the
amount of TPP in a sample that was spiked with 100 µM TPP after the isolation protocol
(sample 54) in comparison to a sample, to which TPP was added already to the cell lysate
(sample 52, Supplementary Figure 8.19).
Matrix effects for samples 37-54 are very high and likely to interfere with the elution of
TPP, which sometimes results in a double peak (personal communication Greco, Figure 8.20).
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Comparing the double peaks of Figure 8.20 with the standards analyzed earlier, it also seems
plausible that the double peak is due to degradation of added TPP to TMP (Figure 8.17),
however this has to be investigated further.
Since HILIC analysis is very sensitive to pH, buffer conditions and salt concentrations, assay
parameters were further optimized to contain as little additional ions as possible (refer to
final isolation protocol Section 6.3.8 for exact conditions). Additionally, the chromatographic
conditions were changed to be less retentive for ionic compounds, because so far thiamine
and TPP were separated well, however the triazole compounds to be finally analyzed are
Figure 3.21: HILIC of low salt DH5αZ1 cell extracts. Analysis of DH5αZ1 cell with and
without the pRS414 plasmid incubated in the presence and absence of thiamine (A). Estimation
of TPP amounts in sample II by spiking sample IV with 2.5 µM TPP (B).
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non-ionic (Greco, personal communication). Therefore, a YMC-Pack colum was used which
has a diolic stationary phase with which retention depends on compound polarity (see Section
6.3.10 for a detailed listing of the methods 6.19). Accordingly, TPP is the most polar due to
its charge (thiazole ring and pyrophosphate group), T is more polar than TT, because it is
charged and therefore TT is eluted first. These alterations resulted in successful detection of
low amounts of TPP in cells grown in the absence of thiamine (III and IV, refer to Figure
3.21 A) and a strong TPP-signal for cells incubated with thiamine over night (I and II, Figure
3.21 A). This indicates that even low TPP levels can be seen that most likely represent that
portion of the vitamine previously engaged in its natural cofactor functions. Interestingly, no
traces of thiamine were found (Figure 8.18), which could be due to the fact that thiamine is
mostly converted to its phosphorylated forms intracellularly. To further prove that samples
do not contain thiamine, sample B was spiked with different thiamine concentrations and
thiamine could be detected easily at concentrations as low as 1 µM. Moreover, these spiking
experiments allowed to check if thiamine ionization was affected by the matrix, which was
not the case (Greco, personal communication). Moreover, no differences between sample
III & IV and sample I & II were detected (Figure 3.21 A), indicating that the presence of
the pRS414-thiM plasmid does not effect thiamine take-up or conversion to TPP. Assuming
that sample IV and II have the same matrix, and further assuming that sample IV does not
contain any TPP, then about 2.5 µM TPP is present in sample II (Figure 3.21 B).
After this optimization of assay, isolation and separation methods, the detection of in vivo
phosphorylated triazolethiamine (TT) was attempted. Figure 3.22 shows the total ion current
of a TT standard solution, detected in positive (red) and negative (blue) mode. In case of
thiamine the positive mode was much more sensitive, because thiamine is already a positive
ion and does not require addition of H+. Rather than acquiring a H+, TT loses one, so that
the [M-H]− species is more easily detected (Greco, personal communication). No TT was
detected in samples which had been incubated in the presence of 500 µM compound. However,
analysis of DH5αZ1 cells incubated in the presence of 500 µM thiamine revealed TPP to be
present, but no traces of thiamine were found, as observed in previous experiments (Figure
3.19). Taken together the hypothesis of intracellularly phosphorylated TTPP remains to be
proven (Section 4.2.5 and 5.2).
Figure 3.22: Ion chromatogram of triazolethiamine. Traces show TT (21 µM) detected in
positive (red) and negative (blue) mode.
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3.2.3 Investigation of triazole thiamine derivatives containing metal chelating
groups as thiM riboswitch activators
In order to activate the thiM riboswitch, the recognition of two moieties by the aptamer domain
is essential (Section 1.3.2). These are the pyrimidine moiety of TPP, which is recognized
by the pyrimidine sensor helix, and the phosphate moiety recognized by the pyrophosphate
sensor helix together with two Mg2+ ions and their coordinated water molecules (Edwards
and Ferré-D’Amaré, 2006; Rentmeister et al., 2007). The TT compounds investigated in 3.2.2
contain the pyrimidine moieties and are thought to be pyrophosphorylated by the bacteria
to receive the pyrophosphate group. In this section, the screening system introduced in
3.2.2 was used to investigate thiM riboswitch activation by TT compounds with alkyl-chain
extensions capable of chelating up to two divalent metal ions. Therefore, these compounds do
not rely on in vivo phosphorylation, because metal chelating groups are intended to mimic
phosphate moieties. These compounds were divided into four different groups according to
their structural similarity (Figures 3.23-3.26).
The first set of compounds comprise sulfones (16), sulfonamides (17,18), amide-linked
pyruvate, malonate and salicylic acid moieties (19-21), a nitroalkene (22) and one compound
that lacks a triazole ring and only contains a trimethoxybenzylmoiety linked by an amide bond
to the pyrimidine ring that is common to all derivatives (Figure 3.23 A). These structures
were investigated for thiM riboswitch activation in E. coli DH5αZ1 and MG1655 (Figure 3.23
B, C).
Generally, as observed in the previous screening (Section 3.2.2), compounds induce stronger
β-galactosidase repression in MG1655 at 500 µM compared to the thiamine auxotrophic strain.
In DH5αZ1, all compounds except 22 and 20 showed about 50% reduction in reporter gene
expression (Figure 3.23 B). However, in MG1655 the sulfone 16 leads to the strongest decrease
in reporter gene expression (to about 10%), closely followed by 18 (20% reporter gene
expression, Figure 3.23 C). The benzenesulfonamide 17 reveals only about 30% reduction,
possibly due to the bulky benzyl-ring (Figure 3.23 C). As these compounds all contain two
S=O groups, they are most likely able to coordinate one metal ion. Similarly, the C=O
groups in 19-21 can coordinate metal ions, however the pyruvate, malonate and salicylic acid
moieties are the least active in the array of compounds tested. In addition, a relation between
activity and bulkiness of the substitution can be supposed, as illustrated by the difference
in reporter gene expression by 17 and 18 (Figure 3.23 A, C). However, the concentration
dependent influence of these compounds will have to be investigated, so that IC50-values can
be used to relate differences in compound structure to differing thiM riboswitch activation.
Interestingly, only for 17 and 21 β-galactosidase expression is comparable between the two
E. coli strains (Figure 3.23 B, C). Compared to the reporter gene repression by 16, the
nitroalkene 22 shows a strong thiM riboswitch activation in MG1655 cells (Figure 3.23 C).
Since the nitrogroup confers significant electron density, this moiety potentially interacts with
a positively charged, divalent Mg2+ ion. Additionally, the difference in effect of compound 22
between MG1655 and DH5αZ1 is striking, and future experiments will have to reveal what
causes this difference (Section 5.2).
Compound 23 is an exception to this group as it does not contain any ring structure in its
center, but merely a planar amide bond (Figure 3.23 A). The oxygen of the methoxy groups
imparts potential coordinating capability. The lack of a middle heterocyclic ring structure may
not cause severe losses in binding affinity as it has been shown in thi -box riboswitch crystals to
have only long distance electrostatic interactions with the RNA (Edwards and Ferré-D’Amaré,
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Figure 3.23: In vivo screening of compound group I. Chemical formulas of compounds
16 to 23 (A). ThiM riboswitch-dependent reporter gene expression in DH5αZ1 and MG1655 in
the presence of thiamine analogs belonging to the compound group I (B).
2006; Thore et al., 2006). Compound 23 reduces thiM-dependent β-galactosidase expression
to about 50% in DH5αZ1 and to about 30% in MG1655 (Figure 3.23 B, C).
The second group of triazolethiamine derivatives comprises sulfonamide (24) and the
sulfone (25) connected to a benzyl group (Figure 3.24 A). These compounds only scarcely
activate the thiM riboswitch in DH5αZ1 cells, especially the sulfonamide does not induce
much reporter gene repression (Figure 3.24 B). In MG1655 cells, the effects are somewhat
more pronounced, however reporter gene expression is only downregulated to about 50%
(Figure 3.24 C). Compound 17 which is fairly similar in structure, had a similar effect on
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Figure 3.24: In vivo screening of compound group II. Chemical formulas of compounds
24 and 25 (A). ThiM riboswitch-dependent reporter gene expression in DH5αZ1 and MG1655 in
the presence of thiamine analogs belonging to the compound group II (B).
thiM mediated reporter gene expression. Here again, it is conspicuous that compounds
containing the planar benzol ring are not as active in thiM riboswitch activation, even though
it is imaginable that this aromatic ring could tighten compound-riboswitch interaction by
π-π-stacking with RNA nucleobases (Edwards and Ferré-D’Amaré, 2006; Thore et al., 2006).
The third group of triazolethiamine compounds are methotrexat- or folate-like (Figure 3.25
A). The carboxylate-ethyl-esters 26 are probably hydrolyzed by esterases when this compound
is admitted into the cells resulting in 27, which was also tested individually. Both compounds
show significant reporter gene repression to less than 40% in thiamine auxotrophic cells
(Figure 3.25 B). In MG1655 cells, reporter gene expression is reduced to about 25% (Figure
3.25 C). Reporter gene repression of 27 is slightly less prominent, which may be due to the
fact that it is likely to be taken-up less efficiently due to its carboxy-moieties. As the assay is
carried out over a time course of 24 hours in aqueous solutions, the hydrolyzation of esters is
favored. This may explain the merely faint difference in reporter gene expression between
compound 26 and 27. Compounds of this group have enough flexibility to theoretically
interact with two metal ions via the ester or carboxyl groups (personal communication Fraser
Scott). Interestingly, these molecules activate the thiM riboswitch extensively, despite their
relatively large size.
Finally, a fourth group of compounds was investigated, which is characterized by phos-
phonate groups (Figure 3.26 A). The carboxylate-ethyl-ester (28) is more likely to passively
diffuse into the cells than compound 29 bearing the carboxyl-group. Phosphonate moieties
are effective chelating agents and theoretically, should be able to coordinate two Mg2+-ions.
Interestingly, both substances show only slight thiM activation, which reaches even in MG1655
cells only 50%. Maybe these compounds are not well absorbed by bacteria, or possibly the
chelating effect the phosphonate group does not sufficiently mimic characteristics successfully
employed by the naturally occuring pyrophosphate group.
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Figure 3.25: In vivo screening of compound group III. Chemical formulas of compounds
26 and 27 (A). ThiM riboswitch-dependent reporter gene expression in DH5αZ1 and MG1655 in
the presence of thiamine analogs belonging to the compound group III (B).
Figure 3.26: In
vivo screening
of compound
group IV.
Chemical formu-
las of compounds
28 and 29 (A).
ThiM riboswitch-
dependent
reporter gene
expression in
DH5αZ1 and
MG1655 in
the presence of
thiamine analogs
belonging to the
compound group
IV (B).
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In general, several compounds containing metal chelating moieties were identified that
activate the thiM riboswitch in both bacterial strains and lead to a decrease in reporter gene
expression of at least 50%. These include compounds 16, 18, 19, 23 as well as 26-29, which
should be further investigated, i. e. by determining IC50-values from concentration dependent
compound effects on riboswitch mediated gene expression (Section 4.2.6 and Section 5.2).
3.3 Screening set-up for identifying preQ1 riboswitch
modulators
Having employed the in vivo screening approach quite successfully for the identification
of thi-box riboswitches, an analogous set-up was utilized to obtain a screening system for
compounds that affect gene expression by the Staphylococcus aureus preQ1 riboswitch. This
class of riboswitches was first described in 2007 by Roth et al. in Bacillus subtilis (Section
3.3.1) and predicted to be present in at least 24 other bacterial species, among them also
S. aureus (Supplementary material of Roth et al. (2007)). Hence, the aptamer domain or the
entire intergenic region was cloned upstream of the lacZ gene to construct a preQ1-dependent
reporter gene assay, which is eventually to be used to screen a small library of preQ-analogs
provided by Colin Sucklings group at the University of Strathclyde, Glasgow, UK.
3.3.1 PreQ riboswitch
The preQ riboswitch binds the queuosine precursor preQ1 and contains the smallest aptamer
domain known to date. Only 34 nt are necessary to recognize the ligand and discriminate it
from preQ0 with a five fold difference in affinity (Roth et al., 2007). The preQ1 ligand forms
hydrogen bonds that would be eliminated when its methylamine moiety is replaced by the
cyano moiety of preQ0 (compare structures in Figure 3.28). Two different aptamer classes,
differing in structure, have been identified to recognize preQ1 (Roth and Breaker, 2009; Meyer
et al., 2008). The preQ1-I class is more widely distributed as it was identified in firmicutes,
Figure 3.27: PreQ1 riboswitch classes. Secondary structure consensus models of preQ1
riboswitch classes I (A) and II (B). PreQ1-I riboswitch class is taken from Roth et al. in 2007.
Nucleotides in red and black are more than 95% and 80% conserved. Less conserved regions,
which may vary slightly in the number of nucleotides, are represented by circles or heavy lines.
Locations of less conserved, putative stem elements are indicated in gray (Roth et al., 2007).
Conservation details for preQ1-II riboswitch class are shown as inset in (B), which is taken from
Meyer et al. 2008.
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fusobacteria, and proteobacteria (Barrick and Breaker, 2007). It consists of a stem-loop
and a short, adenosine-rich tail sequence. In-line probing analysis of wild-type and mutant
preQ1 riboswitches indicate that the specific preQ1 contacts are made by a canonical Watson-
Crick base pairing interaction with the ligand. The preQ1-II class representatives are more
confined in their distribution to the family of streptococcaceae. PreQ1-II riboswitches adopt
a pseudoknot structure and do not seem to bind their ligand by Watson-Crick interactions.
Both riboswitch classes regulate gene expression either by inhibition of translation initation
or formation of a terminator stem loop structure that leads to premature transcription
termination.
The aptamer domain folds into an H-type pseudoknot conformation where L1 and L3 are
positioned in the major and minor grooves of co-axially stacked stems P2 and P1 (Kang et al.,
2009; Spitale et al., 2009; Klein et al., 2009; Jenkins et al., 2011). PreQ1 is almost completely
encapsulated in the ligand-binding pocket by intercalating between the two helices where
it forms a Watson-Crick base pair with C17. This helps to maintain continuous stacking of
the two stems. Other parts of the molecule are specifically recognized by base and backbone
residues within the aptamer structure (Klein et al., 2009). These interactions are facilitated
by Ca2+ cations (Zhang et al., 2011).
3.3.1.1 PreQ biosynthesis and tRNA hypermodification
Prequeuosine (preQ) is a precursor of queuosine (Q), which is a hypermodified nucleoside
found in most bacteria at the wobble position of GUN anticodons in tRNAs for tyrosine,
asparagine, aspartate and histine (Harada, 1972). This queuosine modification is important
for translational fidelity (Bienz, 1981; Meier, 1985). The biosynthesis of Q starts with
GTP and proceeds through the intermediate preQ0 (7-cyano-7-deazaguanine) and preQ1 (7-
aminomethyl-7-deazaguanine) by a series of reactions involving QueC and QueF (Iwata-Reuyl,
2003). In eubacteria, preQ1 is then transferred to the appropriate tRNAs by a tRNA-guanine
transglycosylase (TGT, Okada et al. (1979)), where it is further modified in situ by QueA to
yield Q (Reuter et al., 1991) or its aminoacylated derivative (Roth et al., 2007; Salazar et al.,
2004; Blaise et al., 2004).
Figure 3.28: Schematic representation of the queuosine biosythesis pathway in bac-
teria. For detailed description refer to main text.
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3.3.2 PreQ riboswitch reporter gene assay
Before initiating the actual screening, the reporter system was constructed. For this, the
already mentioned pRS414 vector was used (Simons et al., 1987), and either the aptamer
domain of the riboswitch or the entire intergenic region (IGR) located upstream of the queEDC
operon was cloned in front of the lacZ reporter.
The secondary structure of the preQ1 riboswitch of Staphylococcus aureus (Figure 3.29 A)
consists of a 70 nt aptamer domain (blue), which forms two hairpin loops and a pseudoknot,
and an expression domain (red) that inhabits a terminator stem (nucleotides 71-113). Upon
preQ1 binding (Figure 3.29 B), the terminator structure is formed. Consequently, the RNA
polymerase halts and eventually falls off, thus downregulating transcription and reporter gene
expression.
Figure 3.29: PreQ1 riboswitch screening set-up. Secondary structure of S. aureus preQ1
riboswitch illustrating the aptamer (blue) and expression platform (red, A). PreQ1 and preQ0
structures are shown in B. β-galactosidase assay of thiamine, guanine and the thiamine analogs
triazolethiamine and pyrithiamine (C). Concentration dependent inhibition of reporter gene
expression of S. aureus preQ1 riboswitch (D). Examples of preQ1 and preQ0 analogs to be
investigated for riboswitch modulation (E).
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For want of prequeuosine, the influence of thiamine, guanine, and pyrithiamine on β-
galactosidase expression was investigated using the aforementioned assay system (Figure 3.29
C). Guanine is known to be recognized by the preQ1 riboswitch at elevated concentrations,
whereas thiamine and PT do not share structural features with prequeuosine and were therefore
used as negative controls. Unexpectedly, the addition of thiamine led to a downregulation of
β-galactosidase expression (Figure 3.29 C). However, examining the metabolic network of
E. coli, this effect could be caused by a cross-talk of the thiamine and guanine biosynthesis
pathways. Pre-queuosine1 is made from GTP, hence increasing the amount of precursors for
GTP synthesis (like AIR or guanine), will lead to the production of more preQ1. This may
be the reason for the effects produced by thiamine, as it is converted via common precursors
(AIR, Figure 3.28 and 1.12) into guanine or preQ1, which could act on the riboswitch-mediated
gene expression.
Guanine shows reporter gene downregulation at concentrations of up to 100 µM (Figure
3.29 B). Even though a similar biosynthetic cross-talk as for thiamine can be inferred for
guanine leading to an increase in preQ1 concentration, it is also possible that guanine itself
causes the effective downregulation of β-galactosidase expression by binding to the riboswitch.
Chemical features that distinguish preQ1 from guanine, the aminomethyl group and carbon
atom substitution at the 7 position, are molecular recognition determinants (Figure 3.29
B, Roth et al. (2007)). For B. subtilis preQ1, a Kd of about 20 nM was demonstrated by
equilibrium dialysis (Roth et al., 2007) and is thereby only about 25-fold greater than for
guanine (Roth et al., 2007). In this respect, 100 µM may seem quite high for demonstrating
first effects, however it has to be pointed out, that guanine which is only barely soluble in
aqueous solutions, was not used in these assays as a dilution in organic solvents such as
DMSO. Hence, it is possible that the active concentration lies below the ones stated here.
Using 0.25 µM of the thiamine analog PT revealed a decrease of reporter gene expression
to about 80% (Figure 3.29 C). DH5αZ1 cells used for this experiment have been proven
to be PT-insensitive before (Section 3.2.2.1). This resistance against PT is possibly due
to the tenA gene, which codes for a thiaminase. This enzyme may accept PT as substrate
and detoxify it directly by hydrolysis, hence contributing HMP to the salvage pathway for
thiamine biosynthesis (Sudarsan et al., 2005). This in turn frees precursors for guanine and
GTP biosynthesis, whose elevated concentrations may influence the reporter gene expression
indirectly.
Finally, pre-queuosine1 was tested and revealed reporter gene repression in a concentration
dependent manner (Figure 3.29 D). This dose-response curve was fitted to obtain an IC50-value
of 0.56 µM. The preQ1 was provided as trifluoroacetic acid (TFA) salt making it highly soluble
in water. This assay system is now to be used for the in vivo screening of preQ analogs
(Figure 3.29 E).
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4 Discussion
In this study, riboswitches were investigated for their potential as new antibacterial targets.
Two riboswitch representatives were used for the identification of new riboswitch modulating
entities, namely the thiM riboswitch of E. coli and the glmS ribozyme of S. aureus. Riboswitch-
targeting compounds were sought through screening in silico predicted, and rationally designed
artifical compounds as well as classes of naturally occuring prospective riboswitch activators.
These attempts led to the identification of carba-sugars as novel activators of the glmS
ribozyme, which were thoroughly characterized in vitro and were found to induce bacterial
growth inhibition at a minimal inhibitory concentration of 625 µM. Furthermore, the natural
nitrosourea analog of glucosamine, Streptozotocin, was identified as glmS ribozyme activator at
millimolar concentrations in vitro and the investigation of aminoglycosides revealed Neomycin,
Tobramycin, Paromomycin and Sisomycin as the most potent inhibitors of glmS ribozyme
cleavage among the aminosugars tested. Triazolethiamine and its derivatives were identified
as novel thiM riboswitch activators in vivo. They mimic the natural ligand TPP with
their aminopyrimidine moiety and by either containing metal chelating groups imitating the
pyrophosphate group or by being phosphorylated intracellulary by bacterial enzymes. The in
vivo screening system for riboswitch modulators can be easily adapted to other riboswitch
classes as shown for the preQ1 riboswitch.
4.1 The glmS riboswitch of S. aureus Mu50
For the screening of potential natural as well as artifical ribowitch activators, the glmS
ribozyme from S. aureus strain Mu50 was used, due to its clinical relevance for drug targeting.
The predicted RNA sequence from Barrick et al. showed enzymatic activity dependent on the
presence of GlcN6P and Mg2+-ions in vitro (Section 3.1.1). The high structural conservation
and wide phylogenetic distribution, which hypothesize glmS ribozymes in at least 463 Gram-
positive and a few Gram-negative organisms (McCown et al., 2011), make an in vivo relevance
of this ribozyme, as shown for B. subtilis, very likely (Collins et al., 2007). So far, there is only
one other publication where the glmS ribozyme from S. aureus was used for a HTS set-up
(S. aureus subsp. aureus Rosenbach, ATCC 35556, a methicillin-sensitive strain, Blount et al.
(2006)). However, this study also focused on in vitro assays, presenting no in vivo proof of
ribozyme activity. Nevertheless, definite proof of glmS ribozyme dependent GLMS expression
in S. aureus remains to be given. Therefore, a reporter gene fusion would have to be designed,
as has been done previously (Winkler et al., 2004; Collins et al., 2007) to prove in vivo use of
this ribozyme-related regulatory mechanism.
It was suggested that the glmS mRNA might persist for extended periods of time in the
cell without undergoing significant ribozyme cleavage, and then respond rapidly to rising
concentrations of GlcN6P (Winkler et al., 2004). The in vitro characterization of the S. aureus
glmS ribozyme revealed that it responds instantaneously to the addition of GlcN6P (Figure
3.8). This indicates that the RNA serves as a rapid switch that can form its active structure
without the need for a forceful denaturation and annealing step (Lünse et al., 2011).
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In B. subtilis, cobalt was shown to be able to substitute for magnesium and support RNA
cleavage (Winkler et al., 2004). However, this was not the case for S. aureus glmS ribozyme. It
is known that the specificity of a metal-ion binding pocket can result from a variety of factors,
including the hardness of an ion, the identity of the coordinating ligands, the ionic radius, the
preferred coordination geometry of the ion, and the metal’s hydration number (Feig, 1999).
Comparing these characteristics of divalent cobalt and magnesium ions demonstrates that they
are quite similar (e. g. oxidation state: 2+, hydration number: 6, ionic radius 0.75 vs. 0.72,
etc., see Feig et al page 290f for extended list of metal ions and their properties). So why are
cobalt ions not capable of replacing magnesium in the S. aureus ribozyme? One explanation
could be given by the observation that larger RNAs tend to be more specific for certain
metals than smaller ribozyme species. This is probably due to the more complicated overall
fold, which creates greater opportunities for specific interactions and more tertiary contacts
that must be maintained by these ions (Feig, 1999). Therefore, it should be investigated
whether the elongated P1 stem of the staphylococcal glmS ribozyme (50 nt longer than that
of B. subtilis) causes an increased specificity for magnesium ion interactions. Hence, this
disparity in primary sequence and secondary structure may also account for the difference in
optimal Mg2+ ion concentration needed for the cleavage reaction (Table 3.1).
4.2 Artificial riboswitch activators
In order to identify compounds that efficently target riboswitches and modulate their activity
different routes can be followed. One of the approaches applied here includes the design of
small libraries of chemically synthesized riboswitch ligand analogs. These were screened for
riboswitch modulation either by an in vitro metabolite-induced self-cleavage assay in the case
of the glmS ribozme or by an in vivo reporter gene assay for the thiM riboswitch. Additionally,
a virtual screening method was employed for the identification of compounds mimicking
GlcN6P in its 3D structure. Taken together these methods enabled the discovery of potent
riboswitch activators, i. e. carba-sugars for glmS ribozyme activation and triazolethiamine as
thi -box riboswitch activator.
4.2.1 Compounds mimicking the 3D-shape of GlcN6P
Screening a small library of compounds predicted by an in silico screening for chemical entities
that mimic the three dimensional shape of glucosamine-6-phosphate (Section 3.1.3.1), led to
the identification of a variety of compounds that were capable of either slightly inducing glmS
ribozyme cleavage or of inhibiting its cleavage by GlcN6P.
In the initial screening for glmS ribozyme activators, performed at a final compound
concentration of 2mM, five compounds were identified which slightly activate the ribozyme
(compounds D4, D7, E5, E9, and F5). Except E9, all of them were benzyl compounds with
at least one amine moiety (anilines). The necessity of an amino-group for ribozyme cleavage
has been known (Winkler et al., 2004) and now seems to be affirmed by the hit compound
structures. However, the observed cleavages could also be due to an unspecific effect of RNA
strand scissions that can be caused by anilines at abasic sites. Abasic sites are known to
be spontaneously generated in RNA (Kazuya Nishikawa, 1982; Kochetkov and Budovskii,
1972) and could be present in the in vitro transcribed and purified RNA. An aniline-catalyzed
strand cleavage proceeds via β-elimination to yield 3’ fragments bearing 5’-phosphorylated
termini (Figure 4.1). Cleavage is initiated by immonium ion formation, which renders the 2’-H
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base-labile and the 3’-phosphate unit prone to β-elimination. The intermediate enol strongly
prefers the keto tautomeric form which renders a δ-elimination, that could in principle be
initiated via vinylogous deprotonation of 4’-H, slow (Küpfer and Leumann, 2007). Hence,
amines like aniline can greatly accelerate strand cleavage near neutral pH in abasic RNA,
whose spontaneous generation is slower than in DNA, but still observed (Kochetkov and
Budovskii, 1972). This may also explain why compound D4 increases glmS cleavage above
percentages observed in the mere presence of GlcN6P (Figure 3.5).
Therefore, effects caused by these compounds should be further investigated, e. g. by
cleavage-assay-independent experiments such as thermophoresis or isothermal titration calorime-
try (ITC), where direct binding of the compounds could be monitored. Moreover, the analysis
of cleaved glmS ribozyme on a high resolution sequencing gel should enable the detection
of differences between the 2’,3’ cyclic phosphate and the 5’ OH that is formed by a normal
GlcN6P-mediated glmS cleavage reaction and the 5’ phosphorylated terminus generated by
the aniline-mediated scission.
Figure 4.1: Intermediates in the aniline mediated strand scission at RNA abasic
sites at slightly acidic pH.
In the second screening approach with more stringent assay determinants (500 µM compound
in 0.5% DMSO), several hits were identified that increased cleavage more than five fold over
background cleavage. Especially compound C11 and D3 should be further investigated,
preferably in a concentration dependent manner, as they induce cleavage to about 35% at
concentrations of 500 µM.
Interestingly, the strongest activators from the first screening, compounds D7 and E5, were
not confirmed under these screening conditions. They are close to the hit definition cut-off,
but so are about 20 other compounds that were previously not able to activate glmS cleavage
(Figure 3.4). The decrease in DMSO concentration under these assay conditions can have
two effects that each may explain this differential outcome. On the one hand, decrease in
DMSO concentration can change assay performance. Even though previous tests showed
that DMSO concentrations up to 2% did not have strong effects on glmS activation, cleavage
was slightly pronounced in the presence of GlcN6P or GlcN with DMSO (Figure 8.3 E). The
altered assay perfomance may be explained by the loss of RNA conformation structure due
to the presence of DMSO (Gillchriest and Nelson, 1969). On the other hand, the decrease
in DMSO concentration can influence compound solubility. Therefore, hits identified in the
2mM, 2% DMSO screening may not be as soluble as under the conditions in the 500 µM,
0.5% DMSO screening. These two facts could individually or as a combination lead to the
identification of different hits in the described screenings for glmS ribozyme activators.
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In comparison to the natural activator GlcN6P all compounds identified by this in silico
screening have much worse activities. Cleavage of compounds tested either at 2mM or 500 µM
never approached that of the 200 µM GlcN6P, or even GlcN tested. Only compounds C11
and D3 showed at 500 µM in 0.5% DMSO a glmS activation close to 35%. This activation
is more prominent than that conferred by the natural compound Streptozotocin (20% at
2mM), but not nearly as promising as that of the synthetic CGlcN6P (80% at 200 µM). In
contrast, the comparison of ribozyme inhibition by Reymond compounds and aminoglycosides
demonstrates that here the natural compounds accomplish lower IC50-values (e. g. 28.7 µM
for Neomycin vs. 488 µM compound D2), hence more efficiently inhibit cleavage reactions.
However, hits with low nanomolar potency are only rarely identified by virtual screening
methods (Eckert, 2007).
Persistant blocking of glmS ribozyme action may also enable interference with GlmS
regulation with detrimental outcome for glmS riboswitch containing bacteria. Hence, Reymond
compounds were also investigated for their potential of interfering with proper ribozyme
cleavage initiated by GlcN6P (Section 3.1.3.1 Figures 3.5). It remains to be proven whether
these compounds specifically inhibit glmS ribozyme cleavage by competing with GlcN6P for
its binding site or if more unspecific effects, like intercalation or binding to common RNA
motifs (Thomas and Hergenrother, 2008), are the reason for these observations.
Virtual screenings are bound to identify lead structures instead of ready-to-use drugs, as
they are usually used by industry or academia to support HTS-approaches (Schneider, 2010).
Therefore, it is not surprising, that the virtual screening method used by Reymond did not
lead to the identification of low micromolar glmS ribozyme activators. However, compounds
were discovered which are capable of inhibiting ribozyme cleavage in the high micromolar
range. These compounds can now be used as lead structures for refinded investigations.
4.2.2 Carba-sugars activate the glmS riboswitch of S. aureus and B. subtilis
in vitro
The importance of GlcN6P functional groups for glmS ribozyme binding and activation
has been investigated in several studies (Winkler et al., 2004; Lim et al., 2006; Klein and
Ferré-D’Amaré, 2006; Cochrane et al., 2007). The phosphate group was shown to be critical
for binding, as well as the closed ring conformation of the sugar with the first hydroxy-group in
the α position (Lim et al., 2006). Crystal structures of the glmS ribozyme and GlcN6P show
that the ring oxygen and the phosphate group are required for stabilization of the interaction
of the glmS-riboswitch with GlcN6P rather than being involved in the catalysis reaction
(Klein and Ferré-D’Amaré, 2006; Cochrane et al., 2007). Destabilization of these interactions
as reflected by the carba-analog of GlcN6P is well tolerated, and is likely to account for the
slight discrepancy in EC50- and kobs-values. However, more pronounced modifications, like as
in compound 3, lead to a significant loss of affinity and thus activity.
Moreover, crystallographic data underline that methylations at the anomeric C-atom
hydroxyl (compounds 5-7) render these molecules inactive, probably due to steric clashes
and/or abolishment of hydrogen-bond interactions (Ferré-D’Amaré, 2010). Even though the
4-hydroxy group is critical for binding, the 3-hydroxy group might have only a modest impact
on binding or otherwise might influence reactivity by means of an inductive effect on the
2-amine group (Lim et al., 2006). Indeed, compound 2, which contains all functional groups
minimally required for riboswitch recognition, is able to slightly induce ribozyme activation
at elevated concentrations (Figure 8.3 D).
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The observed rate constant for B. subtilis glmS riboswitch measured here is comparable
to rate constants for this ribozyme in its cis-form observed by others (Winkler et al., 2004;
Brooks and Hampel, 2009). However, the about ten fold slower rate of the S. aureus variant
is remarkable. Brooks et al. found that in vitro folding of the glmS ribozyme into a native,
catalytically active form is slow and rate-limiting. They determined the individual reaction
rates specific to either Mg2+ dependent folding or ligand binding and catalysis (Brooks and
Hampel, 2009). As described in Brooks et al., the glmS ribozyme was heated to 70 °C for
2min and then allowed to cool to room temperature for 5min which is concurrent to methods
employed in the study at hand. However, their protocol proceeded by allowing prefolding
in the presence of 15mM Mg2+ for 90min. Therefore, it is possible that the comparatively
small observed rate constants are due to incomplete or unproper RNA folding. In future
reactions prolonged prefolding incubations in the presence of appropriate divalent ions may
be beneficial for assay performance. Considering the structural differences in S. aureus and
B. subtilis as the former is known to comprise an extended P1 stem loop making its structure
even more complex, glmS ribozyme mutants lacking this extended stem should be tested for
their ribozyme speed after different folding procedures. Possibly this extension complicates
folding in S. aureus compared to B. subtilis.
Furthermore, the comparatively small observed rate constants could be due to the lack of
accessory proteins under in vitro conditions, that S. aureus needs for folding. Alternatively,
it is possible that the P1 loop actually interacts with other important cofactors in vivo, i. e.
another metabolite, ion or protein, which assists in more speedy cleavage.
In vitro results showed a slight decrease in cleavage activity of the natural ligand compared
to its carba-analog. This may also be caused by the influences of RNA folding processes
mentioned above, or by the increased EC50 values of an imperfect interaction partner which
does not make as many specific contacts to the RNA (Section 3.1.4). In this regard, future
work will attempt to restore the hydrogen bond which is lost in the carba-sugar compared
to the natural ligand, i. e. by the addition of an aryl-residue at the carba-position (Section
5.1.4).
In summary, the spectrum and tolerance of GlcN6P modifications have now been addressed
by biochemical ribozyme activity assays as well as crystallizations. The following interactions
and characteristics are known to support ribozyme activation and should be kept in mind
when designing or optimizing novel glmS ribozyme activating molecules (Section 5.1.4):
• a closed ring conformation (Lim et al., 2006; Lünse et al., 2011) with C-1 in the
α-anomeric form
• the ring oxygen hydrogen bonds with a glmS nucleobase (Ferré-D’Amaré, 2010), loss of
this group leads to a 2 fold reduction in EC50-value (Lünse et al., 2011)
• C-6 position should contain a phosphate group, as loss of this moiety results in reduction
in affinity (50 fold difference in EC50-value, Winkler et al. (2004); Lim et al. (2006))
• presence of the amino-group at C-2 is essential for ribozyme activation (Winkler et al.,
2004)
• C-3 and C-4 hydroxy groups interact with the RNA via hydrogen bonds (Lim et al.,
2006; Klein and Ferré-D’Amaré, 2006).
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4.2.3 Carba-GlcN inhibits growth of S. aureus Mu50
The minimal inhibitory concentration of CGlcN (625 µM or 133 µg/ml) may seem quite high
in comparison to other antibiotics in use (e. g. MIC for vancomycin in Mu50 is ≥ 2.5 µM
or ≥ 8 µg/ml). However, it is in the same range as MICs reported for other riboswitch-
targeting compounds (Figure 1.5). For instance, L-4-oxalysine has a MIC of 4-140 µg/ml in
B. subtilis, or the purine analogs reported by Blount et al. displayed MICs in the mg range
(0.6-5mg/ml, S. aureus MSSA). This indicates that targeting riboswitches needs elevated
compound concentrations (Blount et al., 2007). Future experiments will have to reveal whether
these elevated concentrations are caused in part by off-target effects (Section 5.1.3).
Mu50 cell count decreased with CGlcN concentrations increasing from 40 µM. However, it
is yet unclear whether this is a result of bactericidal or bacteriostatic effects. Bacteriostatic
antibiotics are those, which inhibit bacterial growth and cell division, but do not kill them.
The killing effect of vancomycin, a bactericidal antibiotic, is evident from growth curve data,
as bacterial growth only slightly elevates and then remains at the same absorption value
(Figure 3.9 B). Chloramphenicol is a bacteriostatic and as VISA strains are known to be
susceptible to chloramphenicol treatment under laboratory conditions, growth curves in the
presence of this antibiotic in comparison to CGlcN should be performed. It is very likely
that chloramphenicol curves look similar to growth curves obtained in the presence of CGlcN,
where bacterial cell count increases to a certain level at which it remains. It is still under
debate and investigation which of the effects, bactericidal or bacteriostatic, would be generally
more beneficial in a clinical setting (Pankey and Sabath, 2004). Nevertheless, it is desirable
to define their influence on carba-sugar activity, as each mechanism brings about its own
advantages and contraindications. Bacteriostatic antibiotics for example, rely on the help of
the immune system for clearance of the bacteria, whereas bactericidal antibiotics can cause
immunogenic side effects by the quick release of bacterial toxins or antigens into the body.
Conclusive data on bacteriocidal versus bacteriostatic effect cannot be drawn from mere
growth curve analysis. Due to the fact that only bactericidal antibiotics that also have bacte-
riolytic characteristics, meaning the ability of inducing bacterial cell rupture and lysis, would
lead to decreasing or constantly low OD600 values, like observed for vancomycin. Therefore,
growth curves in the presence of CGlcN, should be accompanied by a test for cell viability
(such as the determination of colony forming units or minimal bactericidal concentrations
(MBCs)).
There were several reasons for investigating synergistic effects of subinhibitory concentrations
of vancomycin in combination with CGlcN on the VISA Mu50 strain. Vancomycin is an
inhibitor of cell wall synthesis in S. aureus and other Gram-positive organisms. It binds
to the C-terminal D-Ala-D-Ala residue of the peptidoglycan precursor and forms a stable,
noncovalent complex, which prevents the use of the precursor for cell wall synthesis (Pootoolal
et al., 2002). Therefore, trapping of vancomycin molecules in the cell wall peptidoglycan is
believed to be one vancomycin resistance mechanism. The thicker the cell wall, the more
vancomycin molecules would be trapped within the cell wall, thus allowing a decreased number
of vancomycin molecules to reach the cytoplasmic membrane where its real functional targets
are present (Breukink et al., 1999).
There are several Mu50 characteristics that are, at least in part, accounted responsible for
this thickened cell wall. Mu50 shows increased GlmS activities compared to those reported
for other control strains (Cui et al., 2000), which would secure the supply of UDP-GlcNAc
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needed for enhanced peptidoglycan biosynthesis. Moreover, it was found that the uptake of
GlcNAc is enhanced in Mu50 (Cui et al., 2003). More than 95% of the absorbed GlcNAc is
incorporated into the cell wall via UDP-GlcNAc, the central precursor metabolite of cell-wall
peptidoglycan synthesis (Bearne, 1996; Ghosh et al., 1960; Wong et al., 1974).
The decreased bacterial growth in the presence of CGlcN and subinhibitory concentrations
of vancomycin may present evidence for the interference of CGlcN with vancomycin resistance
mechanisms. Increased GlcNAc import, and especially the increased peptidoglycan synthesis
via elevated GlmS activities are likely to be counteracted by CGlcN action. After the observed
tendencies have been confirmed, detailed future experiments will have to closely examine the
influence of CGlcN on single vancomycin resistance factors (Section 5.1.5).
Carba-sugars were not only shown to be potent activators of the glmS ribozyme in vitro,
but also abolished bacterial growth of a vancomycin intermediate resistant S. aureus strain at
concentrations of 625 µM. This may mark the discovery of a new class of riboswitch modulating
compounds that target glmS ribozymes. It will be interesting to further investigate the sole
and combinatorial effects of CGlcN.
4.2.4 thi -box compound screening
Using a reporter gene-based assay system, a small library of triazolethiamine (TT) and
derivatives was screened for thiM riboswitch activation in bacteria. TT was discovered as
one of the most potent activators among the substances tested, and revealed IC50-values in
the low micromolar range for downregulation of β-galactosidase. Additionally, TT induced a
decrease in bacterial growth with increasing concentrations (Sections 3.2.1, 3.2.2 and 3.2.2.2).
There have been other attempts to identify chemical scaffolds that act as thi -box riboswitch
activators. In 2010, a fragment-based screening approach was published (Chen et al., 2010),
that introduced low molecular weight compounds capable of competing with thiamine for
binding to the aptamer domain of the thiM riboswitch. However, these compounds showed
only affinities in the high micromolar to low millimolar range. Therefore, there was still
potential for describing new modulators for this riboswitch class in addition to the already
known thi-box riboswitch activator pyrithiamine.
The fragment-based screening approach presented by Chen et al. theoretically allows the
discovery of structurally and chemically diverse ligands whose optimization can eventually
lead to high affinity binders (Chen et al., 2010, 2012). However, results of the thiM-reporter
gene assay indicate that compounds acting on riboswitches have to be carefully investigated
in vivo while sole in vitro data may not be sufficient to predict compound behaviour. The
differences in activation observed for the two tested bacterial strains suggests that an array
of distinct strains with altering characteristics should always be investigated to confirm and
underline observed in vivo effects.
The screening system introduced in this work is unique in that it allows the search for thiM
riboswitch modulating compounds in vivo. Therefore, compounds that lead to downregulation
of reporter gene expression are instantly known to be absorbed and metabolized by the
bacteria in a way that is not detrimental to riboswitch activation. However, compound concen-
trations used in the growth medium do not reflect actual effective intracellular concentrations.
Therefore, supporting in vitro assays will remain to be necessary for the characterization
of riboswitch activators found by an in vivo screening. Additionally, it can be difficult to
appraise which and how many metabolic conversions occurred to activate, or even deactivate,
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promising compounds. However, elucidating these enzymatic reactions will oftentimes not only
clarify compound mode of action, but may also reveal new, unresolved metabolic pathways
and networks. Furthermore, this screening system is easily adaptable to other riboswitches
controlling translation initiation, could be adjusted to transcription termination riboswitches
and can be optimized for high-throughput screening by downscaling (see (Müller, 2011)).
4.2.5 Triazolethiamine compounds activate the TPP riboswitch
Thi -box riboswitches are interesting and attractive target structures for developing antibacte-
rial compounds (Sudarsan et al., 2005; Blount and Breaker, 2006). Therefore, the thiM-reporter
gene assay was used to screen a library of triazolethiamine and derivatives for riboswitch
activation in vivo. Replacing the thiazole heterocycle of thiamine with 1,2,3 triazole appears
to be a valuable strategy to generate thiamine analogs that interact with thi -box riboswitches
and, thus, induce repression of gene expression in vivo, because this middle ring shares only
long distance electrostatic interactions with the aptamer domain (Edwards and Ferré-D’Amaré,
2006).
Chen et al. showed that triazolethiamine pyrophosphate interacts with the thiM riboswitch
in vitro with a similar affinity, as does thiamine pyrophosphate (Chen et al., 2012). Compli-
menting their in vitro studies, is the in vivo demonstration of triazolethiamine (TT) effects
on repressing thiM-mediated reporter gene expression reported here. The advancement into
the targeted organism, is a critical step that has to be taken, as drastic differences between
in vitro and in vivo effects were observed. In vitro translation assays performed by Chen
et al. indicated that TT and TTPP were able to induce conformational changes within the
thiM riboswitch expression domain, however only to about 90 and 65%, respectively (Chen
et al., 2012). However, monitoring of reporter gene expression after overnight incubation in
the presence of TT in vivo, indicated stronger repression to about 20%. This alludes to an
enhancement of gene regulation intracellularly that goes beyond mere binding and subsequent
secondary structure changes followed in vitro. Maybe, yet unknown accessory cofactors, that
are absent from the in vitro translation assay, support this signal amplification in bacteria.
Apart from that, it was observed that compound effects can differ drastically between
bacterial strains. IC50-values for TT compounds were found to vary 2-4 fold between DH5αZ1
and MG1655 cells, which is likely to be caused by the differences in genetic background
between both strains. Half maximal inhibitory concentrations for TT-compounds were not as
pronounced in MG1655 cells, which are thiamine prototroph, meaning capable of synthesizing
thiamine from its precursors. Moreover, MG1655 cells bear a mutation in the pyrE gene, which
codes for orotate phosphoribosyltransferase. This enzyme is responsible for the formation of
orotidine 5’-monophosphate (OMP) from orotate and phosphoribosyl pyrophosphate (PRPP).
As a result, levels of PRPP possibly increase, because it is not used for the synthesis of OMP
anymore. This in turn may lead to enhanced purine and thiamine biosynthesis (Jensen, 1993)
and also an increase in intracellular thiamine concentration that is usually between 0.25 µM
and 4.5 µM (Schyns et al., 2005; Miranda-Ríos, 2007). Hence, the diminished compound effect
could arise from the permanent intracellular presence of thiamine and its phosphorylated forms.
These molecules are likely to compete with the compounds for binding to the riboswitch and
especially for conversion of TT to TTPP by intracellular enzymes. In contrast, in DH5αZ1
cells available thiamine amounts can be controlled by addition of this vitamine to the culture
medium, because these cells are thiamine auxotrophic. Therefore, it is likely that the amount
of available thiamine or TPP for competition with compounds in riboswitch binding and
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activation is less than in MG1655 cells.
Nevertheless, the differences in IC50-values could not only arise from competing thiamine
species, but also from differential TT-compound take-up or metabolism, which is certainly
similar between these E. coli strains, but still distinct due to their discriminative genetic
backround (Table 7.5). Influences by differing genetic backgrounds will have to be investigated
in a continuative study (Section 5.2).
Additionally, there is another phenomenon that distinguishes reporter gene assay outcome
between both strains. In E. coli cells, absolute β-galactosidase expression for compounds
11-15 is usually more pronounced than in DH5αZ1. This may be due to another promi-
nent difference in the genetic background of these strains, namely their natural copy of the
lacZ gene. In DH5αZ1 cells this gene is inactivated (Simons et al., 1987; Hanahan, 1985),
whereas in MG1655 E. coli cells it is still present and active (Blattner et al., 1997). A simple
point mutation at amino acid position 202 changing aspartic acid to phenylalanine (D →
F) obliterates all binding and catalysis of the endogenous β-galactosidase (Xu et al., 2004).
Furthermore, DH5αZ1 cells bear a thi−1 mutation, which renders them dependent on thiamine
supplementation (Table 7.5). This genetic alteration is a deletion of a single nucleotide in the
sequence of thiG leading to a frameshift and thereby an inability of autonomously synthesizing
thiamine precursors (Kay, 1972). Although thiG itself has not been directly assigned to
thiamine phosphorylation in vivo (Jurgenson et al., 2009), its mutation may lead to imbalances
in the thiamine biosynthesis cascade that account for the lack of activity of some compounds
in this strain, i. e. compound 13.
HILIC has been found to allow enrichment and the targeted analysis of post-translational
modifications (PTMs) such as glycosylation (Hägglund et al., 2004), N-acetylation (Boersema
et al., 2007) and phosphorylation (McNulty and Annan, 2008) in proteomics applications
(Boersema et al., 2008). HILIC measurements of triazolethiamine-treated cell lysates are
intended to illuminate compound fate in vivo and prove phosphorylation of TT to TTPP in
E. coli. Even though the isolation procedure could be significantly optimized to reliably detect
TPP in E. coli cell lysates, matrix backgrounds were too high and amounts of phosphorylated
triazolethiamine to low to detect any TTPP (Section 6.3.10). Future directions involve the
spiking of untreated cell lysate with chemically synthesized TTPP. This would allow to further
optimize HILIC parameters and to note TTPP retention times. Moreover, cells could be
engineered to overexpress separate proteins of the TPP biosynthesis pathway, so that, if
TTPP is also generated by these enzymes, its levels would increase and be more readily
detected (Section 5.2).
The influence of compounds 11-14 on bacterial growth was evaluated. The distinct ef-
ficiencies in gene repression and inhibition of bacterial growth point at possible secondary
effects of the metabolite-analogs. These side effects may be due to interactions with enzymes
involved in TPP metabolic pathways. The contradictory effects observed for compound 13,
being ineffective in regulation of thi -box controlled gene expression, but inhibiting bacterial
growth, may point in this direction. Indeed, it has been shown that triazole-derivatives of
TPP inhibit enzymes involved in the biosynthesis of TPP (Erixon et al., 2007; Chen et al.,
2010; Kay, 1972). However, thi-box riboswitches have been shown to bind their ligand in
an extended conformation (Serganov et al., 2006), which contrasts the V-conformation in
which TPP is known to be bound in enzymes (Muller et al., 1993). This may enable a precise
refinement of compound characteristics, so that only the thiM riboswitch is bound.
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Investigation of compound effects on Haemophilus influenza growth should be further
optimized, maybe by preparing the chemical defined medium and the agar plates afresh for
every experiment and avoid any storage at 4 °C. Additionally, other strains containing thi -box
riboswitches that control essential genes should be investigated in growth assays, e. g. Brucella
melitensis (Blount and Breaker, 2006).
4.2.6 Triazolethiamine compounds with metal-chelating groups activate the
TPP riboswitch in vivo
Crystallographic and biochemical studies of the TPP riboswitch bound to TPP analogs reveal
that the riboswitch is less sensitive to variations at the pyrophosphate end of the molecule
than within the aminopyrimidine moiety (Edwards and Ferré-D’Amaré, 2006; Sudarsan et al.,
2005). This suggests that the pyrimidine acceptor loop (J2/3) is somewhat preorganized
and consequently unable to adapt to alterations in the composition of the aminopyrimidine
moiety, whereas the pyrophosphate acceptor loop is more disordered and flexible (Rentmeister
et al., 2007; Montange and Batey, 2008; Edwards and Ferré-D’Amaré, 2006). This is why
triazole compounds were synthesized that should function directly without further enzymatic
modification. These compounds contain groups capable of chelating at least one divalent
metal ion, and thereby possibly mimic a phosphate or pyrophosphate group.
Compounds 16-19 which can coordinate a metal ion via their sulfonyl or pyruvate-like
diketone groups, showed less successful reporter gene repression with larger substituents. This
indicated a tendency towards less tolerance of the riboswitch toward more bulky substituents
(e. g. compound 17).
The benzyl, phenyl, or aryl fluoride rings added to several compounds (17, 21, 24, 25)
were intended to form additional RNA interactions, possibly through stacking. However, it
appears that the linker distances used were not optimal to allow such an interaction, since all
compounds containing such a moiety showed only modest thiM riboswitch activation.
Sulfone and sulfonamide compounds have long been known for their antibacterial action
(Domagk, 1940). Therefore, similar sulfur containing compounds, such as 16-18, should be
tested for antibacterial effects unrelated to thiM riboswitch activation, i. e. in bacterial strains
that do not use thi -box riboswitches for gene regulation.
The methotrexate-like and folate-like compounds 26 and 27 belong to those molecules
investigated here, which are theoretically capable of chelating two divalent ions. This would
make their metal-complexing characteristics very much like TPP and in fact these compounds
revealed quite strong influences on reporter gene expression in both strains. Surprisingly, the
difference between the ester and carboxylic acid form of the otherwise identical compound is
not significant. It would be expected that compounds whose charged carboxylic acid groups
are “masked” via esterification, would enter the cell more easily. Yet, it has to be kept in
mind, that for the reporter gene assay the cells are incubated in the presence of compound
for 24 hours in aqueous solution. In this milieu it is very likely that esterifications are already
hydrolyzed before 26 can be taken-up. Maybe shorter incubation times will enable the
investigation of differential effects of 26 and 27 as actual ester or carboxylic acid. The same
considerations can be applied to the phosphonate-compounds 28 and 29 and their carbon
acid moiety. Surprisingly, the otherwise observed tendency of larger substituents leading to
a general decrease in thiM activation, does not prove true for 26 and 27. In vitro binding
studies will have to reveal the influence of the kind of metal chelating moiety on riboswitch
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binding. The phosphonates 28 and 29 are very soluble in water, which can be very beneficial,
especially when compared to compounds with non-polar moieties (17, 24, 25), that are
less easily dissolved. However, these compounds show only slight effects on thiM riboswitch
activation despite their ability to theoretically coordinate two metal ions and no differences
can be observed between the carboxylic acid and ester form.
Compound 23, which represents an exception from the triazoles tested, revealed intriguing
effects on thiM riboswitch activation in DH5αZ1 and MG1655 cells- an effect previously only
so drastically observed for TT itself. In 23, the pyrimidine ring is linked via a peptide bond
to a trimethoxybenzyl moiety (Figure 4.2). As the central thiazole ring of TPP is known
to only form long distance interactions with the binding pocket, it is not surprising that
the triazole ring can be omitted. Additionally, another structual feature of compound 23
raised curiosity: taking together the pyrimidine ring and the trimethoxybenzyl moiety, this
compound looks very similar to trimethoprim (Figure 4.2). Trimethoprim is known to have
antibacterial features and to date they are accounted to the inhibition of proteins within
the bacterial tetrahydrofolate biosynthesis pathway. However, these results indicate that
trimethoprim may be able to interact with thi -box riboswitches. Haemophilus influenza and
E. coli are known to be especially susceptible to trimethoprim treatment. It is intriguing that
at least for the former, essential genes are regulated by thi -box riboswitches and in the latter
at least three of these riboswitches control a total of 11 genes (Blount and Breaker, 2006).
Therefore, the effect of trimethoprim on thiM riboswitch activation should be investigated
using the β-galactosidase reporter gene assay.
Figure 4.2: Chemical formulas for compound 23 and trimethoprim.
Moreover, it would be worthwhile to further investigate the influence of the absent triazole
ring in compound 23 on reporter gene modulation. The synthesis of a trimethoxybenzyl
containing triazole thiamine derivative would allow such an evaluation.
Future experiments, such as thermophoresis, will have to reveal, how tightly these metal
chelating triazolethiamine derivatives (16-29) bind to the riboswitch in vitro (Section 5.2).
However, mere in vitro data is not sufficient to interpret compound effects on riboswitches, as
not only binding to the aptamer domain, but also the induction of rather global structural
changes within the expression domain are necessary to confer gene regulatory function.
Therefore, the β-galactosidase assay should be used to determine IC50-values for the most
active compounds, e. g. 16, 18, 22, 23, 25 and 26. Furthermore, the mutated thiM variant
should be used to investigate specificity of compound effects, as has been done for TT
derivatives lacking any metal chelating groups.
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4.3 Natural riboswitch activators
If riboswitches are indeed valuable antibacterial targets, microorganisms will have evolved
substances that address these RNA elements. Roseoflavin, an FMN analog produced by
S. davawensis, is a prominent example of a natural riboswitch activator (Lee et al., 2009).
Therefore, apart from the methods of ribowitch modulator identification by investigating
“artificial” chemical entities, there are numerous routes conceivable in order to find “ natural”
riboswitch modulators. Examples include the screening of natural product libraries, like the
one at the Max-Planck-Institute for Molecular Physiology in Dortmund, using similar or even
identical assay systems as employed for searching through small molecule libraries. Addition-
ally, assaying crude extracts or culture supernatants for substances causing a riboswitch-related
phenotype may present a route of investigation.
Here, already known RNA targeting molecules, aminoglycosides, were explored for their
effect on glmS ribozyme cleavage. As observed for other ribozymes, aminoglycosides also
inhibit glmS ribozyme cleavage reactions. Furthermore, Streptozotocin, which shares high
structural similarity to the natural glmS ribozyme cofactor GlcN6P, was found to activate
the glmS ribozyme.
Finally, when exploring the mode of action of novel or known natural products, riboswitches
should be considered as targets.
4.3.1 Aminoglycosides as glmS ribozyme inhibitors
Aminoglycosides were tested for their ability to modulate glmS ribozyme activation for several
reasons. Apart from some structural analogy, aminoglycosides are known to bind to and
interact with RNA. Their primary mode of action for conferring antibiotic activity is supposed
to be their interaction with the A-site of the ribosome (Green and Noller, 1997; Pape et al.,
1999). However, in the 1990s they have been shown to be potent inhibitors of ribozymes.
Group I intron self-splicing (von Ahsen et al., 1991), self-cleavage of the hammerhead (Stage
et al., 1995) and human hepatitis delta virus (HDV) ribozymes (Rogers et al., 1996; Chia
et al., 1997), the magnesium-induced self-cleavage reaction of the hairpin ribozyme (Earnshaw
and Gait, 1998) and the tRNA processing activity of RNase P RNA (Mikkelsen et al.,
1999) are all inhibited by the same aminoglycosides, most prominently by Neomycin B and
Tobramycin (Schroeder et al., 2000). Binding of aminoglycosides to nonribosomal RNAs is
now acknowledged to possibly contribute to their potential therapeutic applications but also
to the side effects that are observed for this class of compounds (Walter et al., 1999).
Here, Neomycin B was also identified as the most potent inhibitor of glmS ribozyme
cleavage. Literature suggests that this effect is not caused by a specific competition of the
aminoglycoside with GlcN6P on its binding site, but the rather unspecific binding interactions
that aminoglycosides are known to form with structured RNA (Famulok and Hüttenhofer,
1996; Tor, 2003). This is supported by the finding that a group I intron inhibited by Neomycin
B was shown to bind more than one antibiotic molecule (von Ahsen and Noller, 1993) and
multiple binding sites for aminoglycosides on RNA molecules are likely to coexist (Hendrix
et al., 1997; Michael K, 1999). There have been attempts to modify aminoglycosides to make
them more specific for a certain target (Blount and Tor, 2006). These strategies could also
be used to improve aminoglycoside-glmS ribozyme binding. Future experiments, such as
thermophoresis may allow to investigate glmS ribozyme-Neomycin B interactions and establish
whether binding occurs in a 1:1 ratio or how the change of certain moieties (Neomycin vs.
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Tobramycin, Kanamycin A vs. Kanamycin B) affects binding constants.
Changing an amino group in Kanamycin B to a hydroxy group in Kanamycin A practically
abolishes inhibitory activity in the self-splicing (von Ahsen et al., 1991) and Rev-RRE assays
(Zapp et al., 1993) and a similar trend was observed for Neomycin B versus Paromomycin in
these studies. Analogous to these reports are the observations for glmS ribozyme cleavage
inhibition that takes place in the presence of Kanamycin B, but is not detectable, when
Kanamycin A is used. In the same way, Paromomycin is not as potent as Neomycin B in
hindering glmS ribozyme cleavage.
Hence, the mere change of an amino group can have great effects on aminoglycoside
activity. This accentuates the fact that electrostatic interactions are a major contributor to
aminoglycoside-RNA affinity. Therefore, altering the basicity of the amino groups by the
removal of their neighboring hydroxy group affects the overall charge of the modified analogs
and their RNA binding capability (Wang, 1997). Thus, the appropriately deoxygenated
aminoglycoside derivatives possess a higher overall positive charge at a given pH value relative
to their parent natural product. Hence, the hydroxy groups also influence RNA affinity.
Kanamycin B, for example, is twenty-fold less active than Tobramycin (its 3’-deoxy derivative)
in inhibiting self-splicing of group I introns, and the trend holds also for other RNA targets
(Tor, 2003) including the glmS ribozyme as investigated here. Generally however, it remains
difficult to estimate the influence of additional or lacking amino- or hydroxyl groups, as in
some cases already slight structural differences cause a prominent effect on glmS ribozyme
cleavage inhibition, for example for Neomycin and Paromomycin, whereas in other cases, e. g.
Tobramycin and Kanamycin B, small structual variations did not have such a great effect.
In addition, there are several reports in which aminoglycosides enhance RNA cleavage. Ex-
amples include Neomycin B which hydrolyses the phosphate ester bonds in a di-ribonucleoside
monophosphate (ApA) (Tor et al., 1998) and the tRNAPhe which was found to be susceptible
to aminoglycoside-mediated cleavage (Kirk and Tor, 1999; Belousoff et al., 2009). This is
due to the remarkable ability of aminoglycosides to flexibly remodel themselves to fit into
multiple RNA folds. This makes them to promiscous RNA binders (Tor, 2003), as they often
occupy several binding sites on the RNA molecules and rigidify the RNA by these interactions.
Even though direct interactions of the aminoglycoside in RNA cleavage reactions cannot
be excluded, this aminoglycoside-mediated increase in rigidity is also held responsible for
contributing to aminoglycoside-mediated RNA hydrolysis (Tor, 2003). These observations
prompted the investigation of glmS ribozyme activation by aminoglycosides, however without
identifying any amino-cyclitiols capable of inducing specific RNA scission.
RNA aptamers binding to aminoglycosides with high affinity (in the nanomolar range) have
also been selected by in vitro methods (Wallis et al., 1995; Famulok and Hüttenhofer, 1996).
Interestingly, all aptamers have a similar architectural fold but little sequence homology.
In order to investigate, which structures are recognized by the aminoglycosides, truncated
versions of the glmS ribozyme, comprising interesting structural architectures, could be tested
in vitro for aminoglycoside binding.
4.3.2 Streptozotocin as glmS ribozyme activator
The nitrosourea glycoside Streptozotocin has been investigated for its potential activation of
the glmS ribozyme. Even though ribozyme specific cleavage was induced at high millimolar
concentrations in vitro, the question remains whether these effects are relevant in vivo.
Streptozotocin is taken-up by PTS transporters which phosphorylate it at its C-6 position.
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This may lead to a significant increase in ribozyme activation potential, which will have to be
evaluated in vitro by the testing of a synthesized phosphorylated Streptozotocin variant for
glmS ribozyme cleavage.
Additional evidence for the potential ability of Streptozotocin binding to the glmS riboswitch
can be conferred from data presented by Lim et al. In their study, compound 9 is almost
as active as GlcN6P and only bears an additional methylation at the amino group. This
indicates that there is some tolerance at this group in ribozyme activation (Lim et al., 2006).
Definite proof of Streptozotocin influence on glmS ribozyme activation in vivo, however,
can only be obtained by the concerted investigation of ribozyme-reporter gene fusions and
quantitative real-time PCR of the glmS mRNA (Section 5.1.6). These experiments will allow
the quantification of glmS mRNA levels under Streptozotocin influence compared to untreated
cells. If this compound acts on the glmS ribozyme, mRNA levels are expected to drop.
Finally, it has to be ruled out that cleavage intensities observed are only due to a contami-
nation of Streptozotocin with GlcN, that is still present in the purified product at about 2%.
Detailed investigations indicate that the ribozyme cleavage observed cannot be accounted to
the mere presence of up to 2% GlcN (Schüller, 2012).
The minimal inhibitory concentration data obtained for Streptozotocin in different media
suggests that richer medium decreases Streptozotocin uptake. This indicates that decreasing
concentrations of amino-sugars in the medium will lead to enforced Streptozotocin take-up,
which is conferred by PTS mediated transport. Furthermore, it was surprising to find that
the vancomycin-resistant Mu50 strain has lower MICs than the sensitive SG511 strain, which
is known to be very susceptible to cell wall targeting antibiotics. This observation for Mu50
cells can be due to different scenarios. As this VISA strain is known to have increased GlmS-
mediated production of cell wall precursors, lower MICs may stem from more pronounced
effects of Streptozotocin on GlmS protein repression via the glmS ribozyme action proposed
here. Alternatively, merely the enhanced take-up of GlcNAc (Cui et al., 2003) results in
increased incorporation of Streptozotocin.
Lastly the synthesis of a Streptozotocin analog that is not capable of alkylating DNA is
needed to understand how much of the observed antibacterial effect is due to the prospective
action on the riboswitch or due to the mere DNA alkylating character of this nitrosourea
compound.
4.4 The promise of riboswitches as antibacterial drug targets
RNA is known to be a suitable drug target (Section 3.1.7.1) and many antibacterial drugs
address rRNA structures (Schroeder et al., 2000). However, these interactions are often found
to be due to rather fortuitous and not due to natural actions of the RNA, which can cause a lack
of selectivity (Hermann and Tor, 2005). Riboswitches however, evolved to bind low molecular
weight ligands in a defined binding pocket with high affinity and specificity (Blount and
Breaker, 2006). As such, this should allow the design of highly selective riboswitch-targeting
compounds that do not bind to other cellular targets (Blount and Breaker, 2006). Because of
the characteristic recognition of ligands, the screening of small molecule libraries containing
ligand analogs proved to be a very successful strategy for the identification of riboswitch
modulators (Sections 3.1.3.2, 3.2.2 and 3.2.3). Carba-sugars as well as triazolethiamine and
its derivatives descend from those screening approaches.
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As many different riboswitch classes have been described that bind a variety of metabolites,
this would allow targeting of different metabolic pathways in bacteria. Therefore, exist-
ing analog libraries for a broad spectrum of metabolites, usually previously employed for
the identification protein inhibitors, are oftentimes readily available for the application in
riboswitch-modulator screenings (i. e. the TT compound library, or the adenine analog library
used for the screening by Alexander Müller, Müller (2011)).
Many genes regulated by riboswitches are often essential and therefore important for survival
or virulence (Zhang et al., 2004). Especially compounds targeting these essential genes should
have lethal effects, provided that the mimic cannot functionally replace the natural metabolite
(Blount and Breaker, 2006). This underlines the prospect of the glmS ribozyme being a
valid target for the identification of antibacterial substances, as Donald et al. proved the
glmS gene to be essential in S. aureus by chemical genomics, based on 245 Staphylococcus
aureus antisense RNA strains (Donald et al., 2009). This corroborates the observed ability of
CGlcN to effectively interfere with bacterial growth of S. aureus Mu50 (Section 3.1.5). In
addition to this, riboswitches sometimes regulate a collection of genes, which in themselves
may not be essential, but the interference with proper expression of this assembly may have
detrimental effects on bacterial growth (Blount and Breaker, 2006; Mandal et al., 2003). The
decreased growth of E. coli in the presence of TT is a good example of this phenomenon. In
these bacteria, eleven TPP-metabolism-related genes are controled by three riboswitches and
possibly the collective attack of regulatory components within this metabolic pathway by TT
causes the observed loss in viability (Section 3.2.2.2).
Depending on their phylogenetic distribution, riboswitches could be used as broad spectrum
antibiotic targets (e. g. thi -box riboswitches, which are the most widely distributed riboswitch
class), or the only sparsly distributed ribsowitches are targets for selective drugs, e. g. glmS
ribozymes are mostly found in Gram-positive organisms and only few examples are predicted to
exist in Gram-negatives (McCown et al., 2011). This implies completely different, prospective
application patterns for TT compounds or carba-sugars as antibacterials.
Furthermore, an array of riboswitch targeting compounds, that display either long known
antibacterial effects, or are newly rationally designed or found as natural products, proves
these RNA elements to be addressable structures. Several riboswitch-activating compounds,
like guanine analogs (Kim et al., 2009; Gilbert et al., 2006) and others, were identified by
rational design according to available 3D structures and biochemical data. A similar approach
was used in designing the GlcN6P-analog library screened here (Section 3.1.3.2 A). However,
the virtual screening described in Section 3.1.3.1 takes the use of 3D information for the
identification of riboswitch targeting compounds one step further. Subsequent in vitro analysis
of the appointed potential 57 glmS ribozyme modulators suggests activities in the micromolar
range regarding their ability to inhibit ribozyme cleavage (Section 3.1.3.1). Hence, with
increased availablility of riboswitch-ligand crystals more artificial riboswitch activators can be
designed for yet untargeted riboswitch classes either by hand or with computer-aided methods.
In combination with the applicability of riboswitch activity tests for high-throughput screening
approaches (Mayer and Famulok, 2006; Blount et al., 2006), the concerted use of rational/in
silico methods and brute force attempts pave the way for the successful identification of
riboswitch modulators from comparatively large, but ligand-optimized libraries.
The fact that antibacterial compounds with previously unidentified mode of action affect
riboswitches, supports the arguement for these RNA structures as suitable antibacterial
targets. Most prominent examples of such compounds with previously unidentified MoA
include pyrithiamine (PT) which was found to target thi -box riboswitches (Woolley and White,
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1943) and L-aminoethylcysteine (AEC) and DL-4-oxalysine (Shiota et al., 1958; McCord,
1957) which act on lysine riboswitches (Figure 1.5). Future investigations will show, if the
natural GlcN analog Streptozotocin owes part of its antibacterial effect to the action on the
glmS ribozyme rather than only causing cell death by DNA methylation (Section 3.1.7.2).
Similarly, effects of compound 23 on thiM riboswitch activation encurage the investigation of
the long used antibiotic trimethoprim for side effects on thi -box riboswitches.
Ultimate proof of riboswitches being valid antibacterial targets is presented by organisms
which produce vindicative substances acting on riboswitches. Roseoflavin, a riboflavin analog,
is synthesized by Streptomyces davawensis and inhibits the growth of several Gram-positive
bacteria by repression riboflavin biosynthesis through activation of the FMN riboswitch.
Furthermore, Streptozotocin may turn out to be a second example of such a natural defense
mechanism, in this case employed by Streptomyces achromogenes (Section 3.1.7.2).
In summary, riboswitches make great targets for antibacterial research for all the above
mentioned reasons. However, there are some important challenges that need to be met. It
will be crucial to identify those riboswitches that can repress the expression of a relevant gene
below a level that is required for survival (Blount and Breaker, 2006). And even when gene
expression is completely abolished, bacterial salvage pathways may allow compensation of the
lack of important metabolites, as seen for PT, which is detoxified by some bacteria via TenA
activity. Moreover, it is crucial to choose riboswitch targets that regulate the biosynthesis
of metabolites that cannot be readily available from mammalian host tissue (Blount and
Breaker, 2006). The Streptozotocin growth curves presented here underline the importance
of this fact, as it was observed that already in bacterial cell culture richer growth media
led to increased MICs. This suggests that Streptozotocin uptake is diminished when other
sugar species compete for absoption by PTS transporters. Of course, in human tissue other
sugar species are also going to be present. In addition, even though riboswitches have not
been identified in humans or any other higher eukaryotic organism yet, it is important to
consider toxic effects that could arise from riboswitch targeting compounds that mimic ligands
also present in humans, e. g. we may not have a TPP riboswitch, but TPP is also used by
our enzymes as cofactor. Therefore, riboswitch targeting compounds need to be optimized
to exclusively and specifically address their target and not human proteins, which may be
possible considering the fact that riboswitches recognize their ligand differently than proteins
(Blount and Breaker, 2006). TPP for example is bound by proteins in a V-conformation,
however by the TPP riboswitch in an extended conformation. Nevertheless, TT identified as
thiM riboswitch activator here is already known as pyruvate decarboxylase (PDC) inhibitor
in Zymomonas mobilis (Erixon et al., 2007), depending on protein homologies this may also
be true for the human PDC. Also, a CGlcN analog, 2-acetamido-1,2,5-trideoxy-1,5-imino-D
glucitol has been shown to inhibit a human enzyme, namely N-acetyl-β-hexosaminidase (Ho
et al., 2010). These two examples indicate, how challenging it can be to identify compounds
that target only riboswitches.
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In this study, mainly the glmS ribozyme of S. aureus and the thiM riboswitch of E. coli were
addressed as new antibacterial targets. For both riboswitch classes, activators were sought
through a variety of different means, such as evaluation of compounds predicted by a virtual
screening, screening of rationally designed metabolite analog libraries as well as investigation
of natural products. Compound screenings were undertaken either by in vitro or direct in
vivo approaches. Through these efforts, carba-sugars were discovered as novel glmS ribozyme
activators, that cofactor cleavage of the glmS ribozyme in S. aureus almost as efficiently as
the natural metabolite GlcN6P. Moreover, CGlcN revealed reduced bacterial growth of a
VISA strain with a MIC of 625 µM. In addition to carba-sugars, triazolethiamine (TT) was
discovered as another class of riboswitch targeting compounds. TT is likely to be taken-up
by the bacteria and phosphorylated in vivo. The newly formed TTPP acts on the thiM
riboswitch, as shown by a reporter gene assay as well as underlined by in vitro ITC interaction
measurements by Chen et al. (Chen et al., 2012). Taken together these findings pose exciting
new questions to be solved and open up new research possibilities.
5.1 The glmS ribozyme of S. aureus Mu50
It was sought to identify modulators of the glmS ribozyme of the vancomycin intermediate
resistant Staphylococcus aureus strain Mu50. Natural and chemical compound collections
and candidates were investigated for their influence on ribozyme cleavage using a metabolite-
induced self-cleavage assay. However, initially, the glmS ribozyme had to be amplified from
genomic DNA and enzymatic activity verified, since it had only been in silico predicted to exist
in S. aureus (Barrick et al., 2004). This characterization revealed some discrepancies between
the S. aureus and the B. subtilis glmS ribozyme. The B. subtilis glmS ribozyme not only
accepts Co2+ as divalent ion for the cleavage reaction and needs lower Mg2+ concentrations
for efficient RNA scission, it also cleaves 10× faster than its S. aureus homolog (Winkler et al.,
2004; Lünse et al., 2011).
Hence, future investigations should try to illuminate the reason for these differences.
Considering the ribozyme secondary structure, one distinction is obvious: the P1 stem of the
S. aureus is 50 nucleotides longer than the one in B. subtilis. Therfore, it is imaginable that
differences in observed rate constants might originate from distinct functions of this structural
feature. Ribozyme variants should be designed to investigate this. For example, parts of the
P1 stem of the S. aureus glmS should be deleted or transferred onto the B. subtilis P1 stem.
These modified constructs could be used in cleavage assays to define changes in observed
rate constants. Additionally, cleavage deficient mutants could be used for thermophoresis
measurements to evaluate changes in affinity for the ribozyme’s cofactor, or chemical and
enzymatic probing studies may be employed to define important secondary structural motifs
necessary for glmS ribozyme activity. Finally, these variants should also be tested for their
metal ion requirements and the influences metal ion variations have on cleavage.
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Taken together these investigations may provide conclusive explanations for differences in
ribozyme cleavage speeds and metal preferences.
5.1.1 Refinement of in silico prediction of compounds mimicking the 3D
shape of GlcN6P
The in silico screening by the Reymond group identified 57 compounds with high similarity
in their 3D shape to GlcN6P, which were subsequently tested for glmS ribozyme activation or
inhibition. All compounds tested revealed activities in the high micromolar to millimolar range,
which is often the case for compounds identified via virtual screenings (Eckert, 2007). However,
these compounds may serve as starting point for lead optimizations to yield substances that
have affinities in the low micromolar to nanomolar range (Tudor I. Oprea and Leeson, 2001).
Therefore, hit structures identified in this initial screening could be used to refine database
searches by looking for compounds that are structurally similar to them. Perhaps, the new
structures show identical or even enhanced effects in ribozyme activation.
Furthermore, it has been shown that in ligand based virtual screenings combinations of 2D
and 3D approaches predominantly identify hits with affinities in the low micromolar range (< 1
µM, Ripphausen et al. (2010)). Therefore, the combination of the already applied 3D method
with 2D approaches, and possibly machine learning methods, may allow the identification of
stronger binders (Ripphausen et al., 2010).
Additionally, other computational methods should be considered. Given that there are
several crystal structures of the glmS ribozyme available, computer-assisted de novo design
of bioactive compounds with drug-like properties could be tried. De novo design is the
creation of bioactive compounds by incremental construction of a ligand model within a
model of the receptor, the structure of which is known from X-ray or NMR data (Schneider,
2010; Schneider and Fechner, 2005). Thereby, novel molecular structures are produced from
scratch with desired pharmacological properties (Schneider and Fechner, 2005). Together with
rational refinements, i. e. ensuring the presence of an amino-group or equivalent for ribozyme
activation, this may lead to interesting chemical structures, that are not necessarily GlcN6P
analogs. This may in turn solve specificity concerns arising with respect to drug applications
in humans, that do not have riboswitches but GlcN6P catabolizing enzymes.
Finally, it may also be expedient to search more data bases for possible hit structures and
possibly expand the searches towards natural products that are available.
5.1.2 Detailed investigation of hit compounds screened from current
Reymond prediction
The hit structures identified as glmS ribozyme activators (C1, C11, D1, D3, D4, D7, E5,
E9, F2, F5) or inhibitors (B7, C3, C8, C9, D2, D6, D9, E6, E8, F6, F7, F8) should be
investigated for concentration dependent modulation of ribozyme activity, if this has not been
done already. For most promising hits cleavage rate constants should also be determined to
allow comparison with GlcN6P and CGlcN6P. Furthermore, the already created glmS cleavage
mutant (Figure 8.3 B) should be used, to descry binding and affinity of these compounds, for
example by thermophoresis measurements. For this, the uncleavable glmS riboswitch mutant
is GMPS transcribed and fluorescein labelled at its 5’ end and subsequently used to determine
dissociation constants (Section 5.1.7).
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5.1.3 Define the mode of action of carba-sugars
Carba-sugars have been discovered as glmS ribozyme activators by screening a small, rationally
designed GlcN6P analog library (Section 3.1.3.2 and 3.1.4). Furthermore, CGlcN was shown
to inhibit bacterial growth with increasing concentrations. Of course, although in vitro data
suggests that this is due to direct action on the glmS ribozyme, this has to be proven in
vivo. For this, the total RNA content of S. aureus will be isolated from cells incubated in
the presence and absence of CGlcN. After reverse transcription of the RNA to cDNA using
random hexamer primers it is subjected to quantitative real-time PCR amplifications. This
will define the relative amounts of glmS RNA originally present in untreated vs. treated
cells. This experiment should allow to conclude whether CGlcN confers at least part of its
detrimental effects due to constitutive activation of the glmS ribozyme and hence enforced
degradation of the glmS mRNA by RNases. However, since CGlcN is an analog of GlcN and
GlcN6P it is also possible that some of its effect is derived from interference with naturally
occuring protein actions. Therefore, in a broader study, enzymes which convert GlcN, GlcN6P
or close derivatives thereof should be investigated in vitro for their ability to recognize and
potentially be inhibited by carba-sugars.
Another important question that will have to be addressed is how carba-sugars enter
the bacterial cell. For CGlcN6P, it is very unlikely that passive diffusion through the cell
membrane is taking place. In addition, it is questionable whether there are transporters that
would transmit this charged molecule through the bacterial barriers. Therefore, masking of
the phosphate group may allow passive diffusion of CGlcN6P (McGuigan et al., 2008).
For the unphosphorylated CGlcN however, it is very likely that this cyclitiol is taken-up via
endogenous sugar transporters. The phosphoenolpyruvate:sugar phosphotransferase system
(PTS) allows bacteria to specifically transport sugars across the cell membrane and phosphory-
late them in the process. PTS are multi-protein transporters that are composed of two general
energy coupling proteins, Enzyme I (EI) and a histidine-containing phosphoprotein (HPr) and
several sugar-specific Enzymes II (EII). In S. aureus ptsG codes for EII recognizing glucose,
glcA for an EII for glucoseamine and ptaA for N-acetyl-glucoseamine-EII module. Hence,
constructing genomic deletion mutants of each of these PTS transporters or combinations
thereof, would allow the investigation of CGlcN take-up. If staphylococci really absorb this
compound via active transportation using one or a mixture of these PTS, minimal inhibitory
concentrations are expected to rise in according mutant strains. Moreover, strains which
contain a mutation in two, possibly all three PTS transporters would allow to estimate
how much CGlcN or even CGlcN6P could passively diffuse into the cell. The construction
of genomic deletion mutants is already described for staphylococci (McNamara, 2008) and
directed mutagenesis by allelic replacement is now the most commonly used technique to alter
the S. aureus genome. It involves the design of an appropriate insert for a deletion plasmid
that contains a fusion of the 5’ and 3’ ends of the gene to be deleted. The plasmid can be
amplified in E. coli and then brought into RN4220. This S. aureus strain can accept plasmid
DNA isolated from E. coli as it is restriction endonuclease deficient. Finally, plasmids isolated
from this strain can be tranferred into S. aureus Mu50 cells (Arnaud et al., 2004).
If CGlcN really is to be taken-up via PTS transporters it would imply that the compound
will be phosphorylated to yield CGlcN6P, which was proven to be even more effective in glmS
ribozyme activation in vitro. This bioactivation phenomenon of the prodrug CGlcN by PTS
to the drug CGlcN6P should also be further investigated by isolating the phosphorylated
cyclitiol variant from bacterial cell lysate. Methods like HILIC (introduced and discussed
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in Sections 3.2.2.3 and 6.3.10) and metabolome analysis may be suitable for this. The
latter enables the identification and quantification of primary metabolites in bacterial cells,
which may provide insight into the fate of CGlcN. The characterization of the intracellular
metabolism has been vastly investigated by Lalk and coworkers, who have established suitable
methods for the investigation of the intracellular Staphylococcus aureus metabolome (Meyer
et al., 2010). Established methods include HPLC-MS (high pressure liquid chromatography-
mass spectrometry), GC-MS (gas chromatography-mass spectrometry) and NMR approaches
(Meyer et al., 2010).
Since carba-sugars or other riboswitch-targeting compounds could be useful as new an-
tibacterial drugs, it should be assessed early on whether these metabolite analogs have any
adverse effects in in vivo models. The primary objectives of early in vivo preclinical toxicity
testing of drug candidates is to characterize potential adverse effects, and to provide initial
estimates of safety margins to determine if a compound is likely to be safe for use in humans,
or whether to eliminate such molecules from further development (Fielden and Kolaja, 2008).
Since there have been no riboswitches identified in higher eukaryotes yet, compounds aiming
at these structures should not have any effect. But riboswitch modulators known to date are
all metabolite analogs with relatively high similarity to the natural riboswitch ligand, ligands
that are present in eukaryotes: TPP, adenine, guanine, FMN, GlcN6P. Therefore, it has to be
investigated whether these analogs disturb processes in the host. Therefore, some preliminary
testing could be performed by assaying riboswitch targeting compounds for toxic effect on
human cell culture cells.
Another specificity test of riboswitch-modulator-mediated effects is the investigation of
bacterial species that do not regulate their genes via the explored riboswitch. Therefore,
carba-sugars should be tested on other Gram-positive organisms, which do not contain the
glmS riboswitch. If bacterial growth is impeded here as well, this observation may provide
a first hint at some off-target phenomena. Gram-positive organisms that do not control
GlcN6P metabolism via the glmS ribozyme are Streptococcus pneumoniae and Mycobacterium
tuberculosis (Blount and Breaker, 2006).
Gram-negative strains only seldomly carry the glmS ribozyme. Hence, pathogenic strains like
Yersinia pestis, Vibrio cholera, Helicobacter pylori, Haemophilus influenza, Escherichia coli,
Francisella tularensis, Acinetobacter baumannii, Brucella melitensis or Salmonella enterica
could be used for these assays (Blount and Breaker, 2006). Gram-negative organisms may
already pose another complication to specificity testing, as it may be possible that the
compound is hindered in getting to its actual target by another barrier - the outer membrane.
Apart from investigating off-target effects on bacteria that do not contain the glmS ribozyme,
it will also be of utmost interest to define the spectrum of organisms affected by carba-sugar
action. There are several other pathogenic bacteria which are predicted to carry the glmS
riboswitch, e. g. Listeria monocytogenes, Enterococcus fecalis or Bacillus anthracis (Blount
and Breaker, 2006). Therefore, it would be interesting to subject these and other organisms
to minimal inhibitory concentration (MIC) measurements, assess changes in growth curves, or
determine minimal bactericidal concentrations (MBC) to define carba-sugar mediated effects
on bacterial survival.
5.1.4 Second generation carba-sugars
Even though CGlcN6P binds to and activates the glmS ribozyme almost as efficiently as its
natural metabolite GlcN6P, there is still room for improvement. The exchange of the ring
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oxygen in the carba-compounds for a CH2-group abolishes one hydrogen bond interaction
between ligand and RNA according to crystal structures (Figure 5.1 A, Klein and Ferré-
D’Amaré (2006)). Therefore, the synthesis of second generation of carba-sugars which reach
better affinites, e. g. by restoring this hydrogen bond, is indicated.
One strategy for creating high affinity glmS ribozyme binders by rational design involves
the modification of R to simple methyl, ethyl or propyl extensions, an aryl moiety or other
heterocycles like imidazole (Figure 5.1 B). Depending on the linker length, the aryl-ring may
possibly get involved in stacking interactions with the nucleobase G65 (Figure 1.7). Moreover,
the placement of an alkine or acylester via a linker at R would allow to modify the carba-sugar
at this position with a variety of azide-compounds by “click-chemistry”, or carbonic acid
fragments by a transesterification reaction (Figure 5.1 C and D).
5.1.5 Combination of vancomycin and CGlcN
Vancomycin is often combined with other antibiotics like gentamicin and rifampin, for the
treatment of serious methicillin-resistant S. aureus infections (Deresinski, 2009). These
combinations are desirable to overcome some shortcomings of this glycopeptide antibiotic,
like poor tissue and intracellular penetration, lack of activity against organisms growing in
biofilm, slow bactericidal effect, lack of interference with toxin production and lack of activity
against some S. aureus isolates, including hVISA and VISA strains (Deresinski, 2007a,b).
Even though the role of CGlcN in aiding to overcome the first four deficits is unclear, it may
present a novel means of rendering vancomycin-resistant staphylococcal strains susceptable
again for this glycopeptide antibiotic. If CGlcN, which hampers GlmS-enzyme fidelity indi-
rectly by targeting the glmS ribozyme, is used in combination with vancomycin it may convert
vancomycin resistant strains back to being more vancomycin susceptable by antagonizing
some of the resistant phenotype characteristics. Likewise, increased uptake of GlcNAc in
Mu50 would aid CGlcN action, because it is likely that this carba-sugar is also taken-up by
this PTS transporter.
Therefore, investigations as performed in Section 3.1.6 should be intensified and underlined
by additional experiments, e. g. electron micrograph imaging which would allow an evaluation
of changes in cell wall thickness upon treatment with CGlcN (Howden et al., 2010).
5.1.6 Synthesis and investigation of phosphorylated Streptozotocin in vitro
As Streptozotocin is known to be taken-up via PTS transporters, it is also evident that it will
be phosphorylated in vivo (Lengeler, 1980). Hence, its active form is the C-6 phosphorylated
variant inside bacteria.
In the in vitro studies of Streptozotocin-induced glmS ribozyme self-cleavage revealed
induction of RNA scission at millimolar concentrations. It has been discussed previously
(Section 3.1.7.2 and 4.3.2) that the lack of the phosphate group at C-6 of Streptozotocin very
likely causes a significant decrease in EC50-values (Table 3.2) for glmS ribozyme cleavage.
This suggests that the phosphorylated variant of Streptozotocin may be even more potent in
activating the glmS ribozyme in vitro. Therefore, phosphorylated Streptozotocin should be
synthesized.
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Figure 5.1: Second generation carba-sugars. Crystal structure of glmS ribozyme with
GlcN6P. The inset zoomes in on the metabolite binding site of the glmS aptamer domain with
GlcN6P bound and illustrates the hydrogen bond interaction the oxygen forms normally with
adjacent nucleobases (A, Figure by Prof. Dr.Günter Mayer). Modifications of protected CGlcN6P
at R for ethyl, methyl, propyl, aryl, or imidazole moieties (n=1-7, B). The insertion of an alkine
linker allows modification of CGlcN6P with a library of azides via “click-chemistry” (C). The
insertion of an acetylester linker allows modification of CGlcN6P with a library of carbonic acid
molecules via a transesterification reaction (D).
94
5.2 The thiM riboswitch of E. coli
5.1.7 Determination of binding constants of streptozotocin and CGlcN to
glmS RNA via thermophoresis
Microscale thermophoresis is a novel technique that allows the determination of different
interaction parameters, such as dissociation constants or binding kinetics based on the
movement of molecules along a temperature gradient (Wienken et al., 2010; Duhr and Braun,
2006). To be able to monitor the movement of molecules, they have to be fluorescently
labelled, or intrinsic fluorescence, such as tryptophan fluorescence in proteins, can be used. In
the case of the glmS ribozyme, the RNA can be generated with a guanosine monophosphate
thioate at its 5’ end that will allow coupling to fluorescein (Section 6.4.1.1 and 6.4.1.3). For
this, the cleavage deficient glmS mutant should be used to facilitate the mere investigation of
affinities and no enzymatic activities, which already has been sufficiently analyzed using the
metabolite-induced self-cleavage assay.
Once this assay has been tested for its validity with molecules known to interact with
the ribozyme (like GlcN6P, Glc6P, GlcN etc., Klein and Ferré-D’Amaré (2006); Klein et al.
(2007a)), it can be employed to investigate CGlcN, Streptozotocin, aminoglycosides and
Reymond compounds for their interactions with this RNA. This may shed more light on
structure activity relationships, or allow the identification of moieties tolerated in cofactor
binding, but that are, in comparison with the metabolite-induced self-cleavage assay, not
capable of ribozyme activation.
5.2 The thiM riboswitch of E. coli
Triazolethiamine (TT) and some of its derivatives were discovered as thi-box riboswitch
activators in vivo. This section will briefly summarize how TT and its derivatives should
be further characterized regarding their binding to thi-box riboswitches , their influence on
bacterial metabolism or viability.
Even though affinity of TTPP has been determined via equilibrium dialysis and ITC (Chen
et al., 2012), analogous information needs to be obtained for compounds that mimic TPP
through metal chelating moieties. Aforementioned microscale thermophoresis measurements
are in analogy also suitable to measure interactions between triazolethiamine compounds and
the thiM riboswitch. In addition to the wild-type thiM RNA construct, the aptamer domain
mutant used in Section 3.2.2, and other riboswitch classes distinct from TPP riboswitches
should be used to exclude unspecific small molecule-RNA interactions.
Moreover, concentration dependent effects of metal chelating compounds 16 to 29 on thiM
riboswitch activation should be tested using the reporter gene assay. These compounds enable
thiM riboswitch activation independent from in vivo phosphorylation.
Together, these data will highlight structure activity relationships (SARs) and facilitate the
design of triazolethiamine analogs with improved properties with respect to RNA binding and
thiM riboswitch activation. Of course, these investigations can always be extended towards
TPP riboswitches from other model organisms or clinically relevant pathogens.
The attempts of proving triazolethiamine phosphorylation in vivo using HILIC should
be continued. Even though amounts of TTPP generated in vivo are not detectable against
background, it may be possible to improve this signal-to-noise ratio by feeding TT to
bacterial cells engineered to have increased thiamine metabolism. This could be achieved
by a concommitant overexpression of proteins that are very likely using TT as substrate for
phosphorylation, such as ThiK (Figure 1.12).
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Possibly, also stable isotope labelling of TT-compounds may allow tracing and MS detection.
The impact of triazolethiamine compounds on β-galactosidase repression has been shown to
be dependent on the bacterial strain used. Because TT and its non-metal-chelating derivatives
need to be phosphorylated by bacterial enzymes before they can bind to and activate the thiM
riboswitch, the genetic background of the bacterial strain can have a significant influence on
thiM-mediated reporter gene expression.
These differences in genetic background should be addressed in future studies to learn
not only about TT-compound metabolism, but also to illuminate the fates of other thi-box
riboswitch activators, such as PT or oxythiamine. Therefore, MG1655 mutants should be
constructed that contain the same thiG point mutation that renders DH5αZ1 cells thiamine
auxotrophic (thi−1, (Kay, 1972)). If this deletion causes MG1655-thi−1 cells to behave like
DH5αZ1 cells in response to PT or TT compounds in their β-galactosidase repression, genes
within the thiCEFGH cluster should be more closely investigated, since thiG itself has not
directly been assigned to thiamine phosphorylation in vivo yet. The separate expression of
these and other proteins involved in thiamine biosynthesis may enable an in vitro reconstitution
of this metabolic pathway. This could be used to investigate compound alterations catalyzed
by Thi-proteins in an extracellular context as an extension of what may happen in vivo.
Apart from this, MG1655 cells bear a mutation in the pyrE gene, which codes for orotate
phosphoribosyltransferase responsible for metabolizing phosphoribosyl-pyrophosphate (PRPP)
into orotidine-5-phosphate. As a result, levels of PRPP possibly increase, which may lead to
enhanced purine and thiamine biosynthesis and, thus, probably higher levels of enzymes that
phosphorylate thiamine and consequently the compounds described in Section 3.2.2 (Jensen,
1993). Therefore, a similar mutation may be brought into DH5αZ1 cells for comparison with
MG1655 performance in the reporter gene assay.
Finally, a genetic variant of MG1655 cells in which the natural lacZ gene is deleted should
be studied. Even though the presence of endogenous levels of β-galactosidase do not abolish
TT-compound effects, maybe the enzyme is responsible for having faster ONPG-conversions
in comparison to DH5αZ1 cells. This strain can be obtained from the Coli Genetic Stock
Center (CGSC) at Yale University, USA.
Additionally, the use of fragments identified by Cressina et al. in 2011 for crystallization
in complex with the thiM riboswitch revealed interesting abilities of the aptamer domain to
interact with small molecules deficient in a pyrophosphate (-like) moiety. A nucleobase was
observed to flip into the binding pocket allowing enhanced interaction with groups of the
ligand otherwise not engaged (personal communication Katie Deigan). Therefore, the thiM
riboswitch should be crystallized in the presence of TT and its metal-chelating derivatives.
It would be interesting to investigate whether similar mechanisms are employed in their
recognition. Especially compound 14, whose in vivo phosphorylation is enigmatic, could bind
and activate the thiM riboswitch through a similar interaction.
5.2.1 Investigation of antibacterial effects on H. influenza and other bacterial
species
Haemophilus influenza, which is known to control essential genes via thi-box riboswitches,
has been used to monitor antibacterial effects of TT compounds. However, since this strain
is fairly difficult to cultivate under minimal conditions, other bacterial species should be
considered for the investigation of antibacterial effects.
The decrease in bacterial growth in E. coli indicates that even when compounds interfere
96
5.3 Identification of modulating compounds for other riboswitch classes
with thiM riboswitches that do not control essential genes, a phenotypic effect can be observed.
Therefore, growth curves, agar diffusion tests or minimal inhibitory concentration tests may
be performed for other bacterial species, like Staphylococcus aureus for example that do not
regulate essential genes via thi -box riboswitches.
Another interesting organism for the investigation of antibacterial effects is Mycobacterium
tuberculosis due to its thiamine prototrophy. As these cells refrain from thiamine take-up and
depend entirely on their own thiamine biosynthesis (Du et al., 2011). Inhibiting this metabolic
pathway may have detrimental effects on the bacterium. The thiamine biosynthetic genes
thiC, thiD, thiS, thiF, iscS, thiG, thiO and thiL are essential for M. tuberculosis (Sassetti et al.,
2003). Of them thiO and thiL are under riboswitch control. Therefore, if TT compounds
are able to passively diffuse into the cells or enter them via thiamine carrier independent
mechanisms, they may have effects on this recalcitrant bacterium.
Additionally, the filarial endobacteriumWolbachia was found to contain a thi -box riboswitch,
which controls the expression of a putative membrane protein (personal communication
Alexander Müller). Therefore, the impact of TT compounds on Wolbachia growth should be
assayed.
5.3 Identification of modulating compounds for other
riboswitch classes
The variety of screening approaches discussed earlier in this work for the glmS ribozyme as
well as for the preQ1 and thi -box riboswitches (Sections 3.1.1, 3.2.1 and 3.3.2) can easily be
transferred to other riboswitch classes or to the same riboswitch class from different organisms.
A reporter gene assay in analogy to the preQ1- or the thiM system has been employed already
to screen for adenine riboswitch modulators (refer to Alexander Müller’s thesis for details,
Müller (2011)). Additionally, the preQ1 screening system can be used for the screening of
prequeuosine analogs (Section 3.3.2).
So far, only five different classes of riboswitches are addressed by artifical ligands, including
lysine, FMN, TPP and purine riboswitches as well as the glmS ribozyme (Figure 1.5).
Therefore, there is a variety of undrugged riboswitches left (see Section on riboswitch classes,
1.1.1) to be addressed. Screening of small, rationally designed libraries has proven to be a very
promising approach for riboswitch modulator identification. However, future experiments and
evaluations will have to reveal, if metabolite analogs survive the tough assessment of off-target
effects in toxicology and in vivo testing, as they are, as of now, very likely, to interact with
proteins also.
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This chapter describes the standard methods used for all experiments whose data is referred
to in the results or which are discussed throughout this work. The main experimental areas
include working with nucleic acids (Section 6.1 and Section 6.2) and working with bacteria
(Section 6.3). Techniques employed in these two fields are often prerequisites of methods used
for the interaction analysis (Section 6.4).
6.1 Working with nucleic acids
Investigating RNA elements like riboswitches demands the use of a fairly broad spectrum of
methods dealing with nucleic acids. In the following sections protocols for the amplification
of DNA, the in vitro generation of RNA, the labelling, enrichment, purification, modification
and analysis of nucleic acids are given.
6.1.1 Preparation of DEPC water
In order to prepare RNase free water diethylopyrocarbonate (DEPC) was added to ddH2O in
a ratio of 1:500 (v/v). After vigorous mixing, the solution was incubated over night at room
temperature (RT) in a fume hood. Then, the solution was autoclaved at 121 °C for 60min for
sterilization and to destroy unreacted DEPC (Wiener et al., 1972).
6.1.2 Agarose gel electrophoresis
Agarose gels were used to check the yield of PCR reactions or integrity of RNA. These
gels have a wide range of separation, but a relatively low resolving capacity. Varying the
concentration of agarose, nucleic acid fragments from about 20 to 50,000 bp can be separated.
2.5% (w/v) gels have been used to separate up to ∼1000 nt long PCR products from shorter
primers. 1% (w/v) gels were used to separate longer sequences, e. g. plasmids.
The agarose powder was suspended in 0.5× TBE, melted and kept at 65 °C. 0.5× TBE was
used as gel running buffer as well. Agarose solution (40ml) was mixed with 4 µl ethidium
bromide and poured into the gel cast. Before loading, samples were mixed 1:1 with 2× gel
loading buffer (7.1). The gel was run at 140V for 15-25min. The bands were visualized in a
UV transilluminator (BioRad) and evaluated by comparison with the DNA or RNA ladder
(7.6).
6.1.3 Polymerase chain reaction
PCR was used to exponentially amplify defined DNA sequences by in vitro enzymatic
replication. When the dsDNA template is heated to 94 °C it is separated into single strands
that do not reanneal when rapidly cooled to 60 °C. The primers added are complementary
to the 3’ and 5’ ends of the DNA template and are now able to bind to their target sites.
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This allows the DNA polymerase to start the amplification at 72 °C. Since Kary Mullis
introduced the use of a thermostable DNA polymerase to this concept, several PCR cycles
can be performed in a row without having to add new enzyme after each heating to 94 °C
(Saiki et al., 1988). Here two different thermostable polymerases where used whose specific
characteristics were of advantage.
6.1.3.1 Taq PCR
To amplify DNA templates larger than 600 nt a Taq PCR was performed. The Taq polymerase
derives from the thermophilic bacterium Thermus aquaticus (Chien et al., 1976), which
survives high temperatures during the PCR reaction. Even though it can replicate a 1000 bp
strand in less than 10 s at 72 °C it has no 3’-5’ exonuclease activity. Due to this lack of
proof-reading a single base substitution error of about 1 in 9000 nt has been measured by
(Tindall and Kunkel, 1988).
Reagent Amount Stock Resultant
Taq PCR buffer (Promega) with MgCl2 10 µl 10× 1×
5’ Primer 1 µl 100 µM 1µM
3’ Primer 1 µl 100 µM 1µM
dNTP Mix 0.8 µl 25mM 0.2mM
DNA template 1 µl 1-10 nM
Taq DNA Polymerase 0.5 µl 5U/µl
water 85.7 µl
total volume 100 µl
Table 6.1: Pipetting scheme for Taq polymerase chain reaction
Standard PCR conditions
Denaturing 94 °C 60 s
Annealing 60 °C 60 s
Extension 72 °C 90 s
Heated Lid 110 °C
Table 6.2: Standard reaction conditions for PCR
6.1.3.2 Pfu PCR
DNA sequences below 1000 nt were amplified using Pfu PCR (homemade). The Pfu DNA
polymerase, isolated from Pyrococcus furiosus, comprises a 3’-5’ exonuclease and thus proof-
reading activity. Although not as fast as the Taq, only 1 in 1.6 × 106 mismatches occur
(Lundberg et al., 1991). This makes the Pfu DNA polymerase a desirable tool for exact
DNA amplification. For this PCR same standard conditions were used as for Taq PCR
reactions. Whenever exact amplification of DNA sequences longer than 1000 nt was necessary,
a commercially available Pfu polymerase was used (7.3).
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Reagent Amount Stock Resultant
Pfu PCR buffer 10 µl 10× 1×
MgCl2 8 µl 25mM 2mM
5’Primer 1 µl 100 µM 1µM
3’Primer 1 µl 100 µM 1µM
dNTP Mix 0.8 µl 25mM 0.2mM
DNA template 1 µl 1-10 nM
Pfu DNA polymerase 1 µl 2.5mM
water 77.2 µl
total volume 100 µl
Table 6.3: Pipetting scheme for Pfu polymerase chain reaction
6.1.3.3 Site-directed mutagenesis
Site-directed mutagenesis, first described by Hutchison et al. (1978), was performed to obtain
e. g. the glmS ribozyme cleavage mutant or the thiM riboswitch mutant variant. The
mutagenic primers (7.10) were 30-32 nt in length centering the changed nucleotide(s).
Both mutagenic primers must contain the desired mutation and anneal to the same sequence
on opposite strands of the plasmid. Primers should be 25 to 45 bp in length and contain
app. 10 to 15 bp of the correct sequence up- and downstream of the mutation. The melting
temperature Tm should be over or equal to 78 °C and can be calculated according to formula
Tm = 81.5 + (0.41(%GC))− 675
N −%mismatch (6.1)
or formula
Tm = 81.5 + 0.41(%GC)− 675
N
, (6.2)
where N is the primer length in basepairs, % GC and % mismatch are integers.
The GC-content should be over 40% and primers should start with a G or C nucleobase.
It is important to keep the primer concentration in excess. Stratagene suggests varying the
amount of template while keeping the concentration of the primer constantly in excess.
Reagent Stock Volume [µl] Resultant
reaction buffer 10 × 5 1×
Vector x 80 ng
5’ Primer 1.25 12.5 pmol
3’ Primer 1.25 12.5 pmol
dNTP mix (provided) 1
Quik sol. Reagent 1.5
water ad 50 µl
Table 6.4: Pipetting scheme for site-directed mutagenesis using a QuikChange Lightning Kit
from Stratagene.
80 ng of vector containing the insert to be mutated, 12.5 pmol of primer (see 7.10 for
designed primers) and other components were mixed as indicated in Table 6.4. After mixing,
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1 µl of QuikChange Lightning Enzyme was added. For the negative control the reaction mix
was also prepared as shown above, only primer volumes were substituted by water. The
PCR reaction was run under the parameters stated in Table 6.5. 5min were chosen to secure
complete elongation, although elongation time for the plasmid was calculated to be shorter.
Cycles Temperature Time
Initial Denaturation 1 95 °C 2min
Denaturation 2-18 95 °C 20 s
Annealing 60 °C 10 s
Elongation 68 °C 30 s/kb of plasmid
Final Elongation 68 °C 5min
Table 6.5: PCR parameters of site-directed mutagenesis.
The PCR samples were purified using the Nucleospin Extract II kit (Macherey Nagel,
6.1.4.2). Provided instructions were followed, except for the elution step, where 2× 15 µl water
were used. Hereafter, a DpnI digest was performed by addition of 2 µl enzyme (provided with
Stratagene kit) to each sample and incubation at 37 °C for 30min. The Dpn I endonuclease is
specific for methylated and hemimethylated DNA and is used to digest the parental DNA
template and thus to select the mutation-containing DNA. Another Nucleospin purification
protocol was followed, including changes mentioned above, before the whole eluate was used
for a transformation into 100 µl XL10 GOLD cells (6.3.1.2). All of the transformation mix
was plated on an agar plate containing the appropriate antibiotic.
This site-directed mutagenesis protocol should be performed for vector without any muta-
genic primers, to check for DpnI enzyme function by estimating the background of unmutated
plasmids still present after transformation into XL10 GOLD cells.
6.1.3.4 Quantitative real-time PCR
Quantitative real-time PCR (qPCR) is a method to quantitatively evaluate the amount of
target DNA molecules and to either define an absolute number of copies or to get a relative
estimate compared to a standard condition. In this study, the qPCR ΔΔCT method was used
(Livak and Schmittgen, 2001), which enabled an estimate of relative mRNA levels compared
to control conditions.
For this a mastermix according to Table 6.6 is assembled in a PCR-template free envi-
ronment. Primers and all solutions used for the mastermix were opened before cDNA vial
was, to avoid any DNA contamination. Once the mastermix was prepared, the enzyme was
added last and the mix was put in the PCR stripes (19 µl per well). Then 1 µl sample was
added and every row was sealed with a lid-stripe immediately afterwards. Before actual
PCR reaction, the stripes were shortly centrifuged to collect reaction in the bottom of the well.
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Reagent Amount Stock Resultant
Rox 0.5 µl 1:10
PCR buffer 2 µl 10× 1×
MgCl2 1.6 µl 25mM 2mM
SYBR green 0.2 µl 100× 1×
5’ primer 1 µl 10 µM 0.5 µM
3’ primer 1 µl 10 µM 0.5 µM
dNTPs 0.025 µl 100mM 125 µM
Taq Genaxxon 0.4 µl 5U 1.25U
ddH2O ad 19 µl
Table 6.6: Pipetting scheme for qPCR.
Cycles Temperature Time
Initial Denaturation 1 95 °C 30 s
Denaturation 2-40 95 °C 10 s
Annealing 55 °C 10 s
Elongation 72 °C 30 s
Melting curve 95 °C to 25 °C
Table 6.7: qPCR parameters.
Samples were usually run in triplicates and at least three non template controls (NTC)
were also included into the assay. After the PCR reaction samples were run on an agarose gel
to evaluate them for unspecific amplifications such as primer dimers.
6.1.4 DNA and RNA purification
After enzymatic reactions nucleic acids had to be purified to separate them from proteins or
to desalt before further enzymatic treatment. There were two options for purification, namely
phenol-chloroform extraction followed by precipitation (6.1.4.1) and the use of a commercially
available kit (6.1.4.2).
6.1.4.1 Phenol-chloroform extraction and precipitation of nucleic acids
Phenol-chloroform extraction is used to isolate DNA or RNA from proteins. To one volume of
sample one volume of phenol was added, vortexed well and centrifuged at maximum speed for
3min. The aqueous phase was transferred into a new microcentrifuge tube and two volumes of
chloroform were added, followed by vortexing and centrifuging (see above). Again the upper
phase was separated, 1/10 volume 3M NaOAc, 1 µl glycogen and three volumes of EtOH
abs. were added, gently mixed and incubated at -80 °C for 30min. Now the samples were
centrifuged at maximum speed (Eppendorf tabletop centrifuge 5417C, 20817 rcf) for 20-30min
at 4 °C. Afterwards, the supernatant was removed, the pellet was washed with 100 µl 70%
EtOH, centrifuged for 5min and air-dried after the supernatant had been removed. The RNA
or DNA was taken up in (DEPC) water (1/10 of the starting volume) and kept at -20 °C until
use.
103
6 Methods
6.1.4.2 Nucleospin columns
The NucleoSpin Extract II kit from Macherey-Nagel was used for purifications of DNA
after PCR or restriction digests, DNA extractions from agarose gels, as well as desalting or
elimination of shorter DNA fragments (i. e. primer dimers).
The procedures stated in the manufacturers manual were closely followed, except for elution
steps. Here, elution was done with 2× 20 µl of either elution buffer NE or ddH2O/DEPC
H2O.
6.1.5 In vitro transcription
The transcription of DNA into RNA can be accomplished in vitro by designing the template
to contain a T7 promotor at its 5’ end (usually introduced by PCR). The first 2-3 nucleotides
to be transcribed should be guanines, because the T7 RNA polymerase affinity for this purine
is higher compared to that of other nucleotides. This puts a more efficient transcription into
favor.
To prevent inhibitory effects of accumulating pyrophosphate, which is released when a
nucleoside triphosphate is incorporated into the growing chain, inorganic pyrophosphatase
(IPP) is added. It catalyzes the hydrolysis of inorganic pyrophosphate to form orthophos-
phate. Transcription of dsDNA containing a T7 RNA polymerase promoter was performed
at standard conditions (Table 6.8). The reaction was incubated at 37 °C over night. To
body-label RNA, 1 µl α 32P-GTP was added.
Reagent Amount Stock Resultant
Tris pH 7.9 20 µl 200mM 40mM
MgCl2 25 µl 100mM 25mM
DTT 5µl 100mM 5mM
NTP Mix 10 µl 25mM 2.5mM
α 32P-GTP 1µl 10 µCi/µl 10 µCi
RNasin 1.24 µl 40U/µl 0.5U/µl
Inorganic pyrophosphatase 0.2 µl 2U/µl 0.02U/µl
dsDNA template 10 µl 150-300 pmol 1.5-3 µl
T7 RNA polymerase 5 µl 50U/µl 0.5Uµl
water 22.56 µl
total volume 100 µl
Table 6.8: Pipetting scheme for in vitro transcription.
6.1.6 Polyacrylamide gel electrophoresis
Polyacrylamide gel electrophoresis was used to separate DNA or RNA samples either for
preparative or analytical purposes (Chrambach and Rodbard, 1971). Glass plates were washed
with soap and water, rinsed with deionized water, thereafter with 80% ethanol, dried with
paper towels. Spacers and combs are washed and dried like glass plates. Those glass plates
without pocket are put on a pipet-tip-box under the hood. Since three spacers are needed
per gel, one on each side, one on the bottom, they were aligned to glass plate edges. The
glass plate with pocket was put on top of this assembly and spacers and glass plates are
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adjusted, so that everything was level and so that there was no room between spacers. To
fix this construction, clamps were used (one at the bottom, two on each side). Now the
PA gel solution was prepared by mixing solution C, D and B (see 7.1) in appropriate ratios
in an Erlenmeyer flask to obtain wanted thickness and number of gels (refer to 6.9). APS
(10%) and TEMED were added in stated amounts. Erlenmeyer flask was swirled once to mix
components and gel was quickly poured into prepared glass chamber, the comb was added
last. Finally the gel solidified dependent on PA percentage for 15-30min (polymerization
control was used as guide). After polymerization comb and bottom spacer were removed and
wells were rinsed with water. Gel was placed into the running chamber and buffer tanks were
filled with 1× TBE buffer. Gel was pre-run for 30min. Before samples were loaded (70 µl for
thick gels, 15 µl for thin gels), pockets were rinsed again with buffer.
Amount in ml
Gel Percentage Solution 100 70 50 30
4% C 16 11.2 8 4.8
D 74 51.8 37 22.2
B 10 7 5 3
5% C 20 14 10 6
D 70 49 35 21
B 10 7 5 3
6% C 24 16.8 12 7.2
D 66 46.2 33 19.8
B 10 7 5 3
8% C 32 22.4 16 9.6
D 58 40.6 29 17.4
B 10 7 5 3
10% C 40 28 20 12
D 50 35 25 15
B 10 7 5 3
12% C 48 33.6 24 14.4
D 42 29.4 21 12.6
B 10 7 5 3
15% C 60 42 30 18
D 30 21 15 9
B 10 7 5 3
17% C 68 47.6 34 20.4
D 22 15.4 11 6.6
B 10 7 5 3
20% C 80 56 40 24
D 10 7 5 3
B 10 7 5 3
APS 10% 0.8 0.56 0.4 0.24
TEMED 0.04 0.028 0.02 0.012
Table 6.9: PA-gel recipe Shown are the ratios of solutions B, C and D for gels ranging from
4-20%. 30ml are enough for one thin gel, 50ml for one thick gel.
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Gel Percentage Position bromophenol Position xylenecyanol
5 35 nt 130 nt
6 26 nt 106 nt
8 19 nt 70-80 nt
10 12 nt 50 nt
20 8 nt 28 nt
Table 6.10: Migration of DNA fragments with dyes in denaturing polyacrylamide
gels.
6.1.7 RNA work-up
After in vitro transcription the samples (100 µl) were treated with 0.5 µl of DNaseI (5U/µl) for
10-20min at 37°C and purified by polyacrylamide gel electrophoresis. For this, samples were
mixed with 2× sucrose loading buffer and 50 µl were loaded in each pocket of a thick PA-gel
of needed percentage. The gel was pre-run for 15-30min. The gel was run at a constant power
of 20W and approximately 360V. Once the RNA to be separated was in the middle of the
gel (for orientation xylenecyanol and bromphenol blue, see Table 6.10, were used), the glass
plates were removed and gel is wrapped in saran wrap. Placing the gel on a fluor-coated silica
plate allowed UV shadowing at 254 nm. The right sized bands were cut out with a sterile
scalpel blade, crushed with a 1ml plastic tip, suspended in 500 µl 0.3M NaOAc (pH 5.4) and
incubated at 65 °C for 90min under vigorous shaking. Afterwards gel suspension was passed
through a 5ml syringe packed with silanized glass wool followed by 2-5 washings with 100 µl
0.3M NaOAc solution. For short oligos or small amounts of RNA 1 µl of glycogen was added
to make even small pellets visible. The RNA was precipitated with three volumes of EtOH
abs., incubated for 20min at -80 °C and centrifuged at 4 °C for 30min. The supernatant was
taken off and a washing with 100 µl 70% EtOH was performed. After another spin for 5 min
at RT and removal of the supernatant the pellets were air-dried and redissolved in DEPC
water (usually 10 µl).
6.1.8 Concentration measurements
There were two devices used to determine nucleic acid concentration (dsDNA, ssDNA,
RNA). Either the concentration of nucleic acid solutions was determined using a UV-
spectrophotometer which measured the absorption at a wavelength of 260 nm (Abs 260) in a
quartz cuvette (path length 1 cm). The concentration c was calculated using the Lambert-
Beer law
c = Abs260 · d · ε , (6.3)
where d is the dilution factor and ε the absorption coefficient (depending on the nucleic acids
to be measured: dsDNA= 50µg/ml, ssDNA= 30µg/ml, ssRNA= 40µg/ml).
Or nucleic acid concentration was measured using the NanoQuant infinite 200 (Tecan).
Here, 2 µl of samples were applied to previously blanked spots and measured using the correct
parameters (ssDNA/dsDNA/RNA) on the NanoQuant plate (up to 16 samples).
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6.1.9 5’ Phosphorylation
Phosphorylation as needed for 5’ end labelling of glmS ribozyme was performed by using the
T4 polynucleotide kinase (PNK, (Berkner and Folk, 1977) and (van de Sande et al., 1973)).
This enzyme originating from the T4 bacteriophage, catalyzes the transfer of the γ-phosphate
of ATP to the 5’ end of DNA or RNA. Synthetically synthesized oligonucleotides (e. g. needed
for chemical probing analysis) which do not contain a phosphate at their 5’ end, were used
without any further treatment, whereas digested plasmid fragments or in vitro transcribed
RNA had to be dephosphorylated using calf intestine alkaline phosphatase (CIAP, 6.1.10).
The reaction mixture as shown in Table 6.11 was prepared on ice, before an incubation at
37 °C for 30-60min took place. The product was desalted and excess γ-ATP removed by
passing through a G25 column (6.1.11.1).
Reagent Amount Stock Resultant
T4 PNK buffer 2 µl 10× 1×
CIAP DNA/RNA 45 pmol/ 3 µl 0.5 µM
P-ATP 2µl 20 µCi 10 µCi/µl
T4 PNK (NEB) 2 µl 10U/µl 20U
RNasin 0.3 µl 40U/µl 12U
water (DEPC) 9.7 µl
total volume 20 µl
Table 6.11: Pipetting scheme for 5’ phosphorylation.
6.1.10 5’ Dephosphorylation
Calf intestinal alkaline phosphatase (CIAP, Fosset et al. (1974); Chappelet-Tordo et al. (1974))
catalyzes the hydrolysis of 5’ phosphate groups from DNA, RNA, and ribo- and deoxyri-
bonucleoside triphosphates. This enzyme is used to prevent recircularization and religation
of linearized cloning vector DNA by removing phosphate groups from both 5’-termini and
may also be used for the dephosphorylation of 5’ phosphorylated ends of DNA or RNA for
subsequent labeling with γ 32P-ATP and T4 polynucleotide kinase (Section 6.1.9). CIAP is
active on 5’ overhangs, 5’ recessed and blunt ends.
Reagent Stock Amount Resultant
CIAP buffer 10× 5 µl 1×
BSA 10× 5 µl 1×
RNA/DNA template 1.5 µM/75 pmol
CIAP 20U/µl 0.85 µl 17U
RNasin 40U/µl 0.5 µl 20U
DEPC water ad 50 µl
Total volume 50 µl
Table 6.12: Pipetting scheme for 5’ dephosphorylation.
All components stated in Table 6.12 were mixed and the enzymes RNasin and CIAP were
added last. The first incubation took place at 37 °C for 15min, after which 0.5 µl of CIAP
(20U/µl stock) were added, followed by the second incubation step of 15min at 55 °C, after
which 0.5 µl 0.5M EDTA were added. Hereafter, the enzyme was inactivated by incubation
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at 75 °C for 10min. The subsequent addition of 150 µl DEPC water was followed by a
phenol-chloroform extraction and sodiumacetate precipitation (Section 6.1.4.1). The pellet
was dissolved in 5 µl DEPC water of which 3 µl were used for subsequent phosphorylation
reactions and the remaining 2 µl were run on an agarose gel to check for integrity.
6.1.11 Gel filtration
Gel filtration separates molecules according to their size as they pass through a gel filtration
medium packed in a column. This method was used to separate nucleic acids from unincor-
porated nucleotides, to desalt or rebuffer samples. Since the molecules do not bind to the
filtration medium, the buffer conditions do not affect resolution. Therefore, a convenient
buffer for following experiments or one suitable to the preservation of sensitive molecules can
be used for elution. The gel filtration medium is a porous matrix of spherical particles that
are inert as well as chemically and physically stable. As the buffer passes through the column,
molecules that are larger than the pores of the matrix are unable to diffuse into the pores
and pass through the column. Smaller molecules diffuse into the pores and are delayed in
their passage down the column (Healthcare, 2008). There were two different gel filtration
devices used (see Sections 6.1.11.1 and 6.1.11.2).
6.1.11.1 G25 columns
According to the GE booklet (Healthcare, 2008), the MicroSpin G25 columns, which contain
a Sephadex resin, are designed for the rapid purification of DNA for applications, including
desalting, buffer exchange, and removal of unincorporated nucleotides from end-labelled
oligonucleotides. They can be used for any DNA greater than 10 bases in length. For
all applications the instructions provided by the manufacturer were followed. Radioactive
phosphorylation reactions were usually passed through the column after it had been washed
with 100 µl DEPC water.
6.1.11.2 NAP-10 columns
NAP-10 columns follow the same principle as G25 columns (Sephadex resin), but require only
gravity to run and no microcentrifuge steps. They were used to purify GMPS transcribed RNA
samples from excess GMPS-nucleotide before being used for biotin- or fluorescein-labelling
(Sections 6.4.1.1). After cap and bottom of NAP-10 colum were removed, columns were
washed with 15ml DEPC water. After a maximum of 1ml sample was applied to the dry
column, elution followed adding 1.5ml DEPC water. Drops were collected in approximately
200 µl aliquots for sodiumacetate precipitation.
6.2 RNA analysis
6.2.1 Secondary RNA structure analysis
The function of RNA molecules in vitro and in vivo often depends on their secondary and
tertiary structure, as well as on the information encoded in their Watson-Crick base-pairing
potential. Therefore, chemical probing can be used to elucidate the secondary structure of
the ribozymes and riboswitches bound to their ligand or in their apo-state.
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6.2.1.1 Chemical Probing
In chemical probing, those positions in the RNA structure that are single stranded are sensitive
to chemical modifications. Three different chemicals, all attacking different nucleobases, were
used.
Dimethylsulfate (DMS) alkylates the Watson-Crick positions of adenosines (N1) and
cytidines (N3) not involved in base pairing or tertiary-structure hydrogen bonding. Therefore,
four reaction tubes containing the reaction mixture (Table 6.13) with HEPES (0.5M stock
pH 7.8, final concentration 50mM) as probing buffer were prepared. Just prior to use, the
DMS was diluted (1 µl of 10.56M DMS stock in 16.6 µl of 100% ethanol to result in 600mM).
Further dilution to 300, 150 and 75mM occurred. 1 µl of the different DMS dilutions was
added to each tube. The final reaction concentrations were then 60, 30, 15 and 7.5mM
(Rentmeister et al., 2008; Ziehler, 2000).
Kethoxal alkylates the N1 and 2-NH2 Watson-Crick positions of guanosines not involved in
base-pairing or tertiary structure hydrogen bonding. The procedure and probing buffer for the
four reaction tubes was the same as for DMS, except prior to use a 4.27M stock of kethoxal
was diluted (1 µl of 4.27M kethoxal stock in 20.35 µl DEPC water results in 200mM). Further
dilution to 100, 50 and 25mM was performed and 1 µl of each added to a tube. The final
reaction concentrations were thus 20, 10, 5 and 2.3mM (Rentmeister et al., 2008; Ziehler, 2000).
Reagent Amount Resultant
RNA 1µl 0.9 µg/ 20 pmol/ 2 µM
probing buffer 1 µl 1×
100mM MgCl2 0.5 µl 5mM
1M KCl 0.5 µl 0.5M
DEPC water ad 9 µl
Table 6.13: Pipetting scheme for chemical probing reactions.
CMCT (1-Cyclohexyl-3-(2-morpholinoethyl)carbodiimide metho-p-toluenesulfonate) alky-
lates the N3 Watson-Crick position of uridines which are not involved in base pairing or
tertiary structure hydrogen bonding. Different reagents are mixed according to Table 6.13.
As probing buffer potassiumborate (0.5M stock; 50mM final) was used. Prior to use, CMCT
was heated to 37 °C and vortexed well to ensure complete solubilization of reagent. 0.5M
CMCT is immediately diluted to 250mM and 125mM. Final concentrations in the probing
reactions were 50, 25 and 12.5mM (Rentmeister et al., 2008; Ziehler, 2000).
To achieve final concentrations stated above, 1 µl of the chemical was added to the prepared
mix (Table 6.13). One tube, where DEPC water was added instead of the chemical, was
used as negative control. The reactions were incubated at RT for 20min and stopped by
addition of 2 µl of 3M NaOAc and 30 µl ethanol abs. Upon precipitation at -80 °C (20min),
samples were centrifuged at 20817 g, 4 °C for 30min. The air-dried pellet was redissolved in
40 µl RNase-free water. For the primer extension that followed, 4 µl were used.
6.2.1.2 Reverse Transcription for chemical probing
Reverse transcription was performed after the reaction of different alkylating reagents with the
RNA as mentioned in Section 6.2.1.1. The reverse transcriptase will stop upon encountering
alkylated Watson-Crick determinants, thus revealing which nucleotides in the RNA sequence
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are paired and which are single stranded. Strong secondary structure, such as hairpin loops
within the RNA, can cause the enzyme to pause, creating a prematurely terminated product.
Therefore, it is essential to perform a reaction on an unmodified RNA as negative control.
Reagent Amount Resultant
5× first strand buffer 4 µl 1×
0.1M DTT 2µl 0.01M
Chemically modified RNA 4µl
5’ Kinased RT Primer 1 µl
25mM dNTP mix 0.4 µl
DEPC water 7.6 µl
total volume 19 µl
Table 6.14: Pipetting scheme for reverse transcription using Superscript II enzyme.
The reverse transcription was carried out using the Superscript II enzyme (Invitrogen).
Different components of the reaction were mixed as indicated in Table 6.14, incubated for
10min at 65 °C followed by a cool down to 0 °C for 1min. Upon addition of 1 µl of Superscript
II enzyme, a 50min elongation step at 42 °C and an inactivation at 70 °C for 15min occurred.
RNase H (1 µl) was used to digest the RNA strand of the DNA-RNA duplex in 20min at
37 °C. These reactions were followed by sodium acetate precipitation using 2 µl and 66 µl
ethanol abs. (cool for 15min at -80 °C). Supernatant was removed and the dry pellet was
resuspended in 30 µl 1× sucrose loading buffer.
The location of primer-extension terminations is determined by comparison to didesoxynu-
cleotide sequencing reactions using the same primer and template as the RNA being examined
(Ziehler, 2000).
6.2.1.3 Sequencing ladder
A sequencing reaction of a DNA template of RNA used for the chemical probing should be
carried out in order to serve as standard. The 5’ end labelled 3’ primer already prepared
for the reverse transcription is used here as well. 5 pmol (in 5 µl) of the PCR product were
treated with 1 µl exonuclease I (10U/µl) and 1 µl shrimp alkaline phosphatase (SAP, 2U/µl),
supplied with the Sequenase Version 2.0 PCR product sequencing kit, USB.
The exonuclease I removes residual single-stranded primers and any other single-stranded
DNA produced by PCR, whereas the SAP removes the remaining dNTPs from the PCR
mixture. After an incubation at 37 °C for 15min both enzymes were inactivated at 80 °C
(15min).
Then the 5’ end labelled primer (5-10 pmol) was annealed to the pre-treated DNA (6 µl) and
the volume adjusted with water to 10 µl. This was incubated at 100 °C for 2-3min, quickly
placed on ice afterwards and kept there until needed for the next step.
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Reagent Amount
Termination mix (ddA, ddC, ...) 2.5 µl
Sequenase 10× buffer 0.6 µl
Annealed DNA mixture 2.0 µl
DTT 0.1M 0.2 µl
Sequenase 0.7 µl
total volume 6.0 µl
Table 6.15: Pipetting scheme for termination reactions of the sequenase sequencing.
Finally, the termination reactions (four tubes, one for each didesoxynucleotide) were
prepared as shown in Table 6.15 and incubated for 10min at 37 °C. The reaction was stopped
by addition of 1 µl 3M NaOAc, 30 µl EtOH abs. and the DNA was precipitated (-80 °C, 15min,
centrifuged 30min at 20817 g). Once supernatant was taken off, the pellet was resuspended
in 6 µl 1× sucrose loading buffer. The samples were heated to 75 °C for 2min immediately
before loading and 2-3 µl were applied to the gel in the order GATCGTAC.
6.2.1.4 Sequencing Gels
Sequencing gels were run in chemical probing experiments or for separation of nucleic acids
with only a small difference in the number of nucleotides.
To prepare a sequencing gel, glass plates were thoroughly washed with a sponge and soap
to remove gel pieces. Then plates were rinsed with deionized water and finally with 80%
ethanol. Each washing step was followed by careful drying. Glass plates were silanized with
5% dimethylsilylchloride in dichloromethane. The gel chamber was assembled by putting
spacers along the long sides of that glass plate attached to the buffer chamber, the other
silanized glass plate was put on top, clamps were clipped to the sides of the glass plate
sandwich and aligned with the glass-plate-spacer assembly at the bottom. When the bottom
clamp had been tightened, the comb was sled into the upper space between the plates and
secured by small clamps. 100ml of an e. g. 8% urea PA-gel were prepared in an Erlenmeyer
flask (6.1.6), APS and TEMED are added and the mixture is drawn into a 60ml syringe
with a short flexible tube ending in a tip. All air bubbles were removed and the syringe was
used to slowly pump gel between the glass plates. Gel polymerized for at least 1 h or over
night, bottom clamp was removed and gel placed in buffer chamber. Before sample loading,
the sequencing gel is pre-run at 1800V for 1 h. 1× TBE was used as running buffer. 3 µl
the sample, sequencing ladder or 1× sucrose loading buffer were loaded. The sequencing gel
was run at increasing voltages (1800-2200V, changed about every 45min) until the sample
was nicely separated (about 3-4 h). After the run, the gel was disassembled by removing the
buffer and the side clamps and it was placed on pipet-tip-boxes - the buffer chamber facing
up. Thereafter, the glass plates were carefully separated from each other, the upper glass
plate slowly and carefully removed, the gel wet with ddH2O using a spraying device. A thin
Whatman paper was slightly and homogeneously wet with ddH2O, thoroughly placed onto
gel. Then the wet paper with gel sticking to it was bent, thereby slowly removing the gel
from the lower glass plate. Bubbles close to the edge were removed and the gel was covered
with saran wrap and a phosphorimager screen followed by incubation at -80 °C over night.
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6.2.2 mRNA isolation from Gram-positive bacteria
For isolation of complete bacterial RNA, 5ml precultures were incubated to an OD600 of about
1.0. Then, 2 volumes of prewarmed (37 °C) RNA protect Bacteria reagent are pipetted into a
15ml falcon tube (10ml) and one volume (5ml) of bacteria suspension are added, followed by
immediate vortexting for 5 s. After incubation at RT for 5min, the sample was centrifuged for
10min at 5.000 g. The supernatant was decanted and residual liquid was removed by gently
dabbing the inverted tube once onto a paper towel (the remaining supernatant did not exceed
about 80 µl per 100 µl Hepes in the lysis step). At this point pellets can be stored at -20 °C
for up to 2 weeks or at -80 °C for up to 4 weeks. For subsequent RNA purification pellets are
thawed at room temperature.
For the actual RNA isolation the PrestoSpin R Bug-Kit (Molzym) was used. The pellet
was thawed at RT, resuspended in 500 µl Hepes-EDTA (Hepes 10mM, EDTA 1mM, pH8)
and 32 µl Lysostaphin (5mg/ml, Sigma-Aldrich) were added. This mixture was incubated for
2 h at 37 °C in a waterbath.
The RNA preparation was performed according to the manual provided with the PrestoSpin
kit, starting at step 3 with the addition of 250 µl buffer CH and immediate vortexing for
5 s. When necessary, the suspension was stirred with the pipet tip for homogenization and
stood until visible lysis had occurred (at least 5min). Once the suspension became clear and
viscous, hence complete lysis had taken place, 200 µl of buffer AB were added. After vortexing
for 5 s, the solution was transferred to a spin column by pipetting, and centrifuged for 30 s
at 12.100 g. The flow through was discarded and 400 µl of buffer DB2 were added into the
spin column. After centrifugation for 30 s, flow through was discarded and this washing step
with DB2 repeated. For DNA degradation, buffer DB2-DNase I mix (preparation: 4 µl=40U
DNase I were mixed with 110 µl DB2 in a sterile, RNase-free tube, vortexed and placed on
ice until use) was added to the sample and incubated at RT for 20min with closed tube
lid. Subsequently, 400 µl of buffer WB were added to the spin column, which was thereafter
centrifuged at 12.100 g for 30 s and the flow through was discarded. Finally, the column was
washed with 400 µl 70% ethanol by centrifugation at 12.100 g for 3min. Here, it is strictly
avoided to contaminate the column with ethanol. Now, the column was carefully transferred
into a new 1.5ml reaction tube and 80 µl DEPC H2O preheated to 70 °C were used to elute the
RNA by placing the liquid in the center of the column, closing the lid and incubating for 1min.
Subsequent centrifugation at 12.100 g for 1min eluted RNA solution, whose concentration
was then determined as described under Section 6.1.8.
Finally, before total RNA can be used for reverse transcription it had to be purified and
concentrated. This was done with the help of the RNeasy Min Elute Clean-up Kit by Qiagen.
The sample volumes were adjusted to 100 µl by addition of DEPC H2O. Then, 350 µl buffer
RLT were added and the solutions mixed well. Thereupon, 250 µl of 96-100% ethanol were
added to the diluted RNA and mixed by pipetting. Without centrifugation, the sample
(700 µl) was transferred to an RNeasy Min Elute spin column that had been placed in a 2ml
collection tube. After the lid was closed gently, centrifugation followed at 8.000 g for 15 s.
The flow through was discarded and the spin column put into a new 2ml collection tube.
After addition of 500 µl buffer RPE, centrifugation for 15 s at 8.000 g washed the spin column
membrane. Flow through was discarded again and 500 µl of 80% ethanol were added to the
column. Centrifugation with the lid closed for 2min at 8. 000 g washed the spin column
membrane. Again, the flow through was discarded, however this time it was assured that
no ethanol was carried over. For this, the column was placed in yet another 2ml tube and
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centrifuged with an open lid for 5min at full speed. Thereafter, the collection tube was
discarded and the column was placed into a 1.5ml tube for final elution. For this, 14 µl RNase
free water, preheated to 70 °C, was added directly to the center of the membrane, the lid
was closed gently and the sample was centrifuged at full speed for 1min to elute RNA (dead
volume of the spin column is 2 µl, therefore resulting in 12 µl final volume).
This protocol was followed by RNA concentration measurement (concentrations were
between 800-1500 ng/µl).
6.2.3 Reverse transcription for quantitative real-time PCR
Before reverse transcription for quantitative real-time PCR took place, RNA integrity was
checked by running it on an agarose gel of appropriate percentage. If no RNase degradation
took place, two distinct bands (around 1500 nt and 2900 nt) were observed representing
bacterial rRNA.
Reagent Resultant Amount Stock
step 1
RNA 3µg x
Random hexamer primers 0.3 µg 1.5 µl 0.2 µg/µl
DEPC H2O ad 12 µl
step 2
Reaction buffer 1× 4 µl 5×
dNTPs 1 µl 10mM
RNasin 1 µl
DEPC H2O 1.75 µl
step 3
BioScript 0.5 µl 200U/µl
Table 6.16: Pipetting scheme of RT for qPCR.
For reverse transcription, RNA and primers were mixed according to Table 6.16 step 1 and
incubated for 5min at 70 °C followed by cooling to RT/4 °C. Then, components as stated in
step 2 (Table 6.16) were added, followed by an incubation for 10min at 25 °C. Finally, the
BioScript reverse transcriptase was added (step 3, Table 6.16) and the mixture incubated
for 30min at 60 °C, another 0.5 µl BioScript were added followed by another incubation for
30min at 60 °C. The reaction was stopped by adding 2.5 µl EDTA (0.5mM pH 8) and 5 µl
NaOH (1M), incubation for 15min at 65 °C. Finally, the mixture was neutralized by adding
12.5 µl Tris (pH 7.5, 1M).
Reverse transcription protocol was followed by purification of cDNA using the Fermentas
PCR purification kit according to the manufacturer’s protocol. For cDNA elution, 40 µl
elution buffer were used.
6.2.4 Metabolite induced self-cleavage assay
The metabolite-induced self-cleavage assay (as described in (Winkler et al., 2004; Lünse et al.,
2011)) was used not only to investigate different glmS ribozyme characteristics, such as kobs
and EC50 values, but also to screen for glmS riboswitch modulators. This makes this assay
an integral part of the glmS ribozyme research presented in this work.
113
6 Methods
6.2.4.1 RNA preparation for metabolite-induced self-cleavage assay
To investigate the glmS ribozyme by the metabolite-induced self-cleavage assay, radioactively
labeled glmS RNA had to be prepared. For this, a T7 RNAP transcription from the
PCR template was performed according to Section 6.1.5. However, whenever working with
glmS RNA, Tris buffer has to be avoided. Therefore, Hepes buffer was used for all glmS
ribozyme containing reactions. In vitro tanscription was followed by PA-gel purification
(Section 6.1.6 and Section 6.1.7). RNA was dissolved in 10 µl DEPC H2O and used for the
5’ dephosphorylation and phosphorylation with γ 32P-ATP (Sections 6.1.10 and 6.1.9). The
phosphorylation reaction is purified by employing a G25 column. Subsequent PAGE and
RNA work-up led to RNA pellets that were dissolved in 10-20 µl DEPC H2O.
Before actual experiments were performed, a cleavage assay test was done to control glmS
ribozyme cleavage in the presence of 200 µM GlcN6P or GlcN and 10mM MgCl2. Moreover,
these tests were used as an estimate on how much the stock RNA can be diluted for further
experiments (usually 1:10-1:20)
For the cleavage assay test a thin 17% PA-gel is poured (according to Section 6.1.6).
Then 1.5ml tubes are prepared by appropriate labelling. For every experiment a positive
control (addition of 200 µM GlcN or GlcN6P), an RNase control (no addition of MgCl2) and a
negative control (no addition of metabolite) was performed. Reaction contained components
according to Table 6.17. The cleavage buffer, MgCl2, DEPC water and metabolite were mixed
in prepared 1.5ml tube. The final reaction volume was 10 µl.
GlmS RNA has to be prefolded before its use in the cleavage assay. For this, the RNA
was heated to 90 °C for 1min. It has to be assured that the RNA solution does not contain
divalent ions like Mg2+ as they would cause disintegration of RNA, when heating. After a
short spin, the RNA was allowed to adjust to room temperature by incubation at 23 °C for
5min so that RNA can fold into its active conformation.
Now the radioactively labeled glmS RNA was added to the cleavage reaction mix thereby
initating it. Therefore, incubation at 37 °C for 30min was started immediately.
Reagent Stock Volume Resultant
Cleavage buffer 10× 1 µl 1×
MgCl2 100mM 1µl 10mM
RNA 0.5 µl
Metabolite 1mM 2µl 200 µl
DEPC H2O ad 10 µl
Table 6.17: Pipetting scheme for metabolite-induced self-cleavage assay.
The cleavage reaction was stopped by the addition of 2× sucrose-loading buffer (5 µl)
and a short spin to collect the entire sample in vial bottom for proper mixing. In the
mean time, a PA-gel was pre-run, then samples were loaded and run at 450-600V for 2-3 h.
Subsequently, the gel chamber was disassembled, the gel wrapped in saran wrap and exposed
to a phosphorimager screen over night at -80 °C. The screen was read and band intensities
evaluated using AIDA software.
Thereupon, RNA stocks were diluted as stated above and used for either endpoint determi-
nations (Section 6.2.4.2) or kinetics (Section 6.2.4.3) depending on the scientific hypothesis
under investigation.
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6.2.4.2 Endpoint determinations
Endpoint determinations of the metabolite-induced self-cleavage assay were used to monitor
concentration dependent effects of compounds or metabolites on glmS cleavage, as well as for
the screenings of Reymond compounds, the GlcN6P analog library and the natural activators,
namely aminoglycosides and Streptozotocin. These measurements were stopped after a certain
time interval had passed, usually 30 minutes, by addition of 5 µl 2× sucrose PAGE loading
buffer. Subsequently, the samples were loaded on a pre-run, analytical PA-gel (17%) until
full length glmS ribozyme band and cleavage fragment were well separated (usually 2-3 h, at
400-600V).
Reymond screenings were performed with stated compound and DMSO concentrations. For
example, for the screening in the presence of 2mM compound in 2% DMSO, compound stocks
(usually 100mM in 100% DMSO) were diluted to 10mM in 10% DMSO with DEPC water.
Finally, 2 µl of this screening stock solution were used per reaction. Assay buffer contained a
final concentration of 50mM Hepes, pH 7.5, 200mM KCl and 10mM MgCl2, 200 µM GlcN
or GlcN6P in controls or 2mM compound in 2% DMSO in a final reaction volume of 10 µl.
The cleavage reaction took place at 37 °C for 30min until it was stopped by addition of 2×
sucrose PAGE loading buffer.
EC50 value determinations increasing concentrations of activator (i. e. GlcN6P, CGlcN6P,
GlcN6S etc.) were assayed. To evaluate half maximal glmS cleavage, the ratio of glmS
cleaved was plotted against the logarithm of metabolite concentration used in the cleavage
reaction, leading to a sigmoidal dose-response curve (Figure 8.1). This curve was fitted using
the equation Y = (Bottom) + (Top−Bottom)/1 + 10LogEC50−X , which yielded EC50 values
shown in Table 3.2. R2 values were referred to as indicators for goodness of fit.
IC50 values were calculated from dose-response curves of tested cleavage inhibitor and fitted
using the equation Y = (Bottom) + (Top − Bottom)/1 + 10LogIC50−X . For this, varying
concentrations of potential inhibitors were tested in competition with constant GlcN6P
concentration (usually 200 µM).
6.2.4.3 Kinetics
For kinetic measurements samples were withdrawn from a larger stock at different time
intervals (0, 1, 3, 5, 7, 10, 15, 30, 60 minutes). The 10 µl taken were put in prepared
microcentrifuge tubes that already contain 5 µl 2× sucrose-loading buffer to immediately
stop the reaction. These kinetic measurements were mainly used for the determination of
kobs values which were obtained by fitting the curve of cleavage rate/time to the equation
Y = YMAX ∗(1−e−K−X). This equation describes the pseudo-first order association kinetics
of the interaction between a substrate and an enzyme. Y is in this case enzyme activity. X is
time. Y starts out equal to zero and increases to a maximum plateau (at equilibrium) equal
to YMAX. When X equals 0.6932/K, Y equals 0.5*YMAX (Turner, 1997).
6.3 Working with bacteria
Bacteria are not only the key player in antibacterial research for evaluating drug effects on
bacterial growth (Section 6.3.6) and viability (Section 6.3.5), but they are also important
laboratory tools for the amplification (Section 6.3.12) and manipulation of DNA (Sections
6.3.15, 6.3.15.2). The following sections provide insight into laboratory techniques used
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for handling and investigating bacteria such as Staphylococcus aureus, Escherichia coli and
Haemophilus influenza.
6.3.1 Cultivation of Escherichia coli
Initial inoculations of E. coli bacteria from frozen glyci cultures as well as E. coli used for the
amplification of DNA plasmids were cultivated in LB-medium (7.1) at 37 °C under vigorous
shaking (130–150 rpm). For experiments in which the influence of thiamine analogs on
bacterial growth or on β-galactosidase expression was tested, minimal medium was used (7.1).
Several E. coli strains were used in this study. XL10 Gold were utilized for standard plasmid
transformations. For β-galactosidase assays two different strains were chosen: The laboratory
K12 strain MG1655 that has only few mutations in its genome (Table 7.5, Blattner et al.
(1997)), and DH5αZ1, carrying, in addition to DH5α inherent genomic alterations (Table 7.5),
at its attB locus two copies of Lac and Tet repressor encoding genes driven by the constitutive
promoters Placiq and PN25, integrated according to Lutz and Bujard (1997); Diederich L
(1992).
6.3.1.1 LB media and plates
For about twenty 10 cm dishes 7.5 g agarose and 10 g LB media were mixed and deionized
water was added to 500ml. This was autoclaved for 15min at 121 °C. Hereafter, the LB agar
had to cool until handwarm before the appropriate antibiotic (stock: Ampicillin 100mg/ml,
Kanamycin 50mg/ml) was added 1:1000. After proper mixing, LB agar plates were poured
and solidified under sterile conditions. Plates were kept at 4 °C.
6.3.1.2 Transformation of XL10 GOLD
XL10 GOLD ultracompetent cells were gently thawed on ice. For each reaction 45 µl of cells
were aliquoted into a pre-chilled 2ml tube and 2 µl β-mercaptoethanol were added. Cells
were kept on ice constantly. After a gentle swirl, the entire ligation reaction (up to 20 µl) was
added and the cells were incubated for 30 min on ice after gentle mixing. In the meantime
SOC medium was pre-warmed to 37 °C. Cells were heat-shocked at 42 °C (in a waterbath) for
30 s, followed by a short incubation on ice for 2min. Then 500 µl SOC medium were added
and the cells were incubated at 37 °C for 1 h shaking at 225-250 rpm. This incubation time
varies depending on the antibiotic resistance that needs to be produced by the cell. Prior
to plating, cell suspension was centrifuged at 1000 rpm for 3min and the supernatant was
decanted. Cells were resuspended in remaining medium and spread on an LB-agar plate
containing the appropriate antibiotic using a Drigalski applicator followed by incubation at
37 °C over night.
6.3.2 Cultivation of Staphylococcus aureus strains
The Gram-positive S. aureus grows optimally at temperatures between 35 and 37 °C. From
a mixed population of bacteria, selective or differential media, such as mannitol salt agar
or Baird-Parker-Agar are used (McNamara, 2008). For routine cultivation however, Brain
Heart Infusion (BHI), Tryptic Soy, Columbia, Mueller-Hinton or Penassay broth can be used.
Chemically defined media, as published by Charles and Rawal (1976); Laue and Macdonald
(1968); Wu and Bergdoll (1971) can be used to cultivate Staphylococci under controled growth
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conditions. For freezing of bacteria at -80 °C the media should contain 30% v/v glycerol (low
passage organisms should always be chosen).
6.3.2.1 Mueller-Hinton (MH), 0.5×MH and chemically defined medium (CDM)
In this study, S. aureus was mainly cultivated either in chemically defined medium (for
components and preparation refer to 7.4) or in Mueller-Hinton (MH) or 0.5×MH broth.
Mueller-Hinton media was developed for the cultivation of pathogenic neisseriae and other
fastidious microorganisms. It consists of 2 g/l beef infusion, 1.5 g/l corn starch, 17.5 g/l acid
casein peptone (H) (pH of 7.4). Mueller-Hinton Broth was used because it is a rich medium
however without any monosaccharides such as glucose readily available. Furthermore, MH
agar can be used to carry out sensitivity testing of a great number of antimicrobial agents.
The chemically defined medium (CDM) was used as a 2× solution and did not contain any
sugar equivalent, however higher aminoacid concentrations. Aminoacids are used by bacteria
to synthesize glucose. This medium supports S. aureus growth, however, because glucose
has to be synthesized from aminoacids, bacterial growth is slower compared to rich medium
such as BHI or MH. Components for this medium were weighed and dissolved in appropriate
solutions according to Table 7.4. The different groups were mixed by adding the groups to
group V. Sterile water was added to about 400ml and the pH was set to 7.0 using HCl. Once
all components are mixed the medium is sterilized by filtration.
6.3.3 Cultivation of Haemophilus influenza and parainfluenza
Haemophilus influenza is a Gram-negative, non-acid fast, nonmotile, nonsporeforming bac-
terium whose shape ranges from cocobacilli to filamentous rods. This bacterium is a facultative
anaerobic and requires factor X (hemin) and factor V (NAD). Both Haemophilus strains
were grown in humid atmosphere with added 5-10% of CO2 and temperatures ranging from
33-37 °C. H. influenza is usually grown on plates that contain either so-called Haemophilus-test
agar (HT), chocolate agar (boiled blood agar) or blood agar with a hemolytic strain as nurse.
6.3.3.1 Chocolate agar, bacitracin chocolate agar, blood agar with nurse, Haemophilus
test agar
Chocolate agar is a non-selective, enriched growth medium consisting of 10% fresh sheep
blood that was slowly heated to 80 °C. Lysed red blood cells provide the essential growth
factors NAD and hemin for Haemophilus influenzae. Chocolate agar alone is non-selective,
however with the addition of bacitracin the medium becomes selective, most critically, for the
genus Haemophilus.
Blood agar contains mammalian blood (usually sheep or horse), typically at a concentration
of 5–10% and in addition meat extract, tryptone, sodium chloride, and agar. Blood agar is
usually used to isolate fastidious organisms and detect hemolytic activity. However, these
plates were used here to observe H. infl. growth in the hemolytic zone of a S. aureus. Hemolysis
frees factor V and X as nutrients for the Haemophilus.
Extensive studies performed by Jorgensen and colleagues led to the development of
Haemophilus Test Medium (HTM, Jorgensen et al. (1987, 1990)). This medium is Mueller
Hinton agar or broth supplemented with X factor, V factor and yeast extract (beef extract
2 g/l, yeast extract 5 g/l, acid hydrolysate of casein 17.5 g/l, hematin 15mg/l, starch 1.5 g/l,
nicotinamide adenine dinucleotide 15mg/l, agar 17 g/l).
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6.3.3.2 Chemically defined medium for H. influenza for growth in liquid culture or on
agar plates
Chemically defined medium for Haemophilus influenza (CDM-HI) was prepared according to
the protocol stated for 2× CDM for S. aureus with the following alterations: in the preparation
of CDM-HI not only glucose was omitted, but also the vitamin thiamine was not added.
Appropriate glucose and thiamine sterile stock solutions were prepared to be added separately
after the medium was prepared and steril-filtered. Additionally, an NAD and heme solution
(also sterile) were prepared and added to the normal CDM medium preparation protocol.
For this, heme was dissolved in sterile water/2N NaOH mix (1:1) to a final concentration
of 7.5mg/ml. This solution was used to supplement the sterile 2×CDM-HI to a final heme
concentration of 30mg/l. Moreover, 15mg NAD were dissolved in 6ml water/NaOH mix (1:1,
sterile) and added to the medium.
Furthermore, the medium was used as 1× whenever it was used for growth assays in liquid
culture, however, when agar plates were prepared the 2× stock solution was mixed 1:1 with
agarose (which was dissolved in sterile water also to a 2× concentration, i. e. 2%). This
resulted in a 1% 1× CDM-HI agarose, that was poured into 3 cm dishes for growth tests on
agar.
6.3.3.3 Agar diffusion test
Triazolethiamine compounds were investigated for their effect on H. influenza growth by
so-called agar diffusion tests. Here, a cell suspension was made by collecting several colonies
from a chocolate agar plate and inoculating a NaCl solution with them. This suspension was
vortexed until all cell lumps were dissolved. Subsequently OD600 was measured and cells with
an OD of 0.7 were streaked on the appropriate agar plate (e. g. HI-CDM). Holes were punched
in the center of the agar plate using the front of a sterile blue pipet tip. The holes were filled
with the appropriate compound dilution (i. e. 128mM or 12.8mM of TT compounds). Cells
were incubated at 37 °C for several days until colonies were visible. Normally, the size of the
zone of inhibition is used as a measure of the compound’s effectiveness. However, with faint
Haemophilus growth this was not possible.
6.3.4 H. influenza tests
In order to determine whether colonies grown on HI-CDM medium were H. influenza, different
tests as suggested by the “Manual of clinical microbiology” (Kilian, 2001) were performed.
6.3.4.1 Gram-staining
For the Gram-staining (Gram, 1884; Gephart and Phillips., 1981), bacteria were streaked
onto a cover slip which was prepared with a drop of NaCl solution. Cover slips were air-dried
for about 10min, and then drawn through a bunsen burner flame 3 times to fix cells on the
cover slip. Now, crystal violet solution (see below for solution preparation) was added for
2min, followed by washing step with Lugol solution for 1min. Cover slip was washed using
acetone decolorizer (acetone, 50ml, ethanol (95%), 50ml) and rinsed under ddH2O. This
procedure was followed by the counterstaining with Safranin (Stock solution: 2.5 g Safranin
O, 100ml 95% ethanol; Working solution: 10ml stock solution, 90ml ddH2O). Cover slip was
dried in filter paper.
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Subsequent microscopy was performed using a Laica DMLB with an N-plan 10×/0.25 or
100×/1.25 lens.
Crystal violet staining reagent is prepared as solution A which contains 2 g Crystal violet
(certified 90% dye content) in 20ml ethanol, 95% (v/v), and solution B which contains 0.8 g
ammonium oxalate in 80ml ddH2O. Solutions A and B were mixed to obtain crystal violet
staining reagent, which was stored for 24 h and filtered through paper prior to use.
6.3.4.2 Catalase and oxidase test
The majority of H. influenza are oxidase and catalase positive (Kilian, 2001). For catalase
test, a colony was streaked on a cover slip and H2O2 was added dropwise. If bubbles were
observed, the catalase test was declared positive.
The oxidase test uses disks impregnated with a reagent such as N,N,N’,N’-tetramethyl-
p-phenylenediamine (TMPD) or N,N-dimethyl-p-phenylenediamine (DMPD), which is also
a redox indicator. The reagent becomes a dark-blue to maroon color when oxidized, and
colorless when reduced. Oxidase-positive bacteria possess cytochrome c oxidase or indophenol
oxidase which result in a color change to pink, through maroon and into black, within 10–30
seconds.
6.3.4.3 Fermentation tests
H. influenza use only glucose for fermentation (Kilian, 2001). To prove this, vials (2ml)
containing the appropriate medium (supplemented with factor V and X) with according sugar
(glucose, sucrose, mannose, lactose and xylose) and bromokresol purple as indicator were
inoculated with Haemophilus influenza. Upon fermentation of the sugar the indicator will
turn yellow.
However, even for the positive control, no change in color could be observed. Probably the
liquid cultivation medium is not sufficient for proper growth of this fastidious bacterial strain.
6.3.5 Determination of minimal inhibitory concentrations
For minimal inhibitory concentration determinations 5ml precultures were incubated over
night under appropriate conditions from a picked colony. In the morning this preculture was
used to inoculate a new culture, i. e. to an OD600 of 0.2, and grown till an optical density of 1
(approximately 1×10−9 cells per ml) was reached. This bacterial suspension was then diluted
1:10.000 to approximately 1×10−5 cells per ml, e. g. by adding 50 µl bacterial suspension to
5ml medium and then using this to further dilute 20 µl in 20ml.
A sterile 96-well plate (clear, round-bottom, clear lid) was used to prepare compound
concentrations to be tested. Total volume of 200 µl or, to save precious compounds, a total
volume of 100 µl was used. However, row A and H as well as column 1 and 12 were not used
for data point collection, but rather filled with 200 µl medium, as were all other wells not
used for the experiment.
For a final total volume of 100 µl, 50 µl of growth medium were put in each well. A stock
solution of the compound to be tested was prepared, that is 4 fold concentrated, e. g. if the
highest concentration in the assay was supposed to be 600 µM, the stock solution was 2.4mM.
Then a dilution row was made in the well plate by adding 50 µl of the compound stock to
first well. After mixing by pipetting, 50 µl are transferred from the first to the second well.
This was carried on to the lowest compound concentration to be tested. From this last well,
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50 µl are taken and discarded. Finally, 50 µl of bacterial suspension (prepared as described
above) were added to each well. Mixing occurred by pipetting.
A medium contamination control as well as a compound contamination control were also
pipetted and evaluated.
The plate is mixed for 10min on a shaking plate and then transferred to a 37 °C incubator.
After 24 h, or 48 h if no growth is visible after first time interval, the plate was read and all
wells were marked where no obvious bacterial growth was seen. The minimal concentration
for which no growth was observed is noted as MIC.
6.3.6 Measurement of growth curves in a Tecan plate reader
Bacterial growth in the presence of compounds was monitored in a sterile 96-well plate (clear
round-bottom) with a clear lid. For this, either a total volume of 200 µl or, to save precious
compounds, a total volume of 100 µl was used. However, row A and H as well as column 1
and 12 were not used for data point collection, but rather filled with 200 µl medium, as were
all other wells not used for the experiment.
For a final total volume of 100 µl, 50 µl of growth medium are put in each well. A stock
solution of the compound to be tested is prepared, that is 4 fold concentrated, e. g. if the
highest concentration in the assay is supposed to be 600 µM, the stock solution was 2.4mM.
Then a dilution row is made in the well plate by adding 50 µl of the compound stock to first
well. After mixing by pipetting, 50 µl are transferred from the first to the second well. This is
carried on to the lowest compound concentration to be tested. From this last well, 50 µl are
taken and discarded. Finally, 50 µl of bacterial suspension were added to each well. Mixing
occurred by pipetting.
A medium contamination control as well as a compound contamination control were also
pipetted and evaluated.
The bacteria are prepared for this assay by picking a colony from an approprate culture
plate and incubating a 5ml preculture over night under optimal growth conditions. Next day,
OD600 was determined and cells were diluted in a new 5ml preculture to an OD600 of 0.1.
Now, cells were incubated till an OD600 of 0.2, which was then added to the prepared 96-well
plate, leading to a final OD of 0.1 in each well.
Even though an OD600 of 0.1 is quite high, it is necessary to enable immediate Tecan
measurements. Tecan plate reader Sunrise was used for these growth curve recordings, usually
measuring OD600 every 15min for 24 h under vigorous shaking every 2min for 1min.
6.3.7 β-galactosidase assay
On day one, 5ml precultures of E. coli cells (either DH5αZ1 or MG1655) containing the
reporter gene plasmid pRS414.2 thiM were prepared in LB medium. These cultures were
incubated over night at 37 °C and 155 rpm.
The following day, 8ml precultures of E. coli [pRS414.2 thiM] were prepared in minimal
medium with and without 20 µM thiamine and with increasing AHT concentrations (if pNYL
MCS11 N25 aptamer plasmids were used as well) according to Table 6.18. These cultures
were inoculated with the LB culture (OD600= 0.5) 1:500 and incubated for 24 h at 37 °C,
150 rpm.
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Reagent Stock Volume
M9 Medium 5× 1600 µl
MgSO4 1M 40 µl
Glucose 20% 80 µl
Casamino Acids 20 µg/µl 75 µl
Ampicillin 100mg/ml 8 µl
depending on reporter construct and other plasmids add:
Kanamycin 50mg/ml 8 µl
Thiamine 20mM 8µl
AHT 2mg/ml 0.4-3.2 µl depending on assay
ddH2O ad 8ml
Table 6.18: Pipetting scheme for β-galactosidase assay.
After the incubation time had passed (day three), the OD600 was measured by mixing the
cell suspension well and transferring 195 µl of it into a 96-well plate (flat bottom, F profil,
Roth) and subsequent measurement in the Tecan NanoQuant reader. The rest of the cell
suspension was centrifuged at 5000 g for 3min, the supernatant was discarded and cells were
washed twice with 800 µl ice cold 1× PBS. Washed cells were transferred into a 1.5ml reaction
tube before the last washing step, centrifuged at 5000 g for 3min, the supernatant discarded.
The cell pellet was resuspended in 200 µl lysis buffer (promega, a 5× buffer diluted to 1×
before addition) and incubated for 15min at RT. During the incubation time, reaction tubes
(1.5ml) were prepared for each sample in duplicate and 75 µl of 2× assay buffer added. After
the incubation time, cells were pelleted by centrifugation at 5000 g for 3min and 75 µl cell
lysate were added to the 2× assay buffer. Then tubes were incubated in a thermomixer of
appropriate size at 37 °C until conversion to a yellow colored suspension was obvious. The
incubation time was noted and 250 µl 1M Na2CO3 solution was added to stop the reaction.
Finally, absorbance was measured at 420 nm in the Tecan NanoQuant plate reader.
The same assay conditions were used for preQ1 riboswitch reporter gene assays, here
however thiamine was exchanged for appropriate preQ1 concentrations. When DH5αZ1 cells
were used that contained the thiM reporter gene plasmid as well as AHT-dependent hairpin
expressing plasmid pNYL MCS11, kanamycin and also appropriate AHT concentrations had
to be added to the medium (see Table 6.18).
This assay set-up was also down-scaled for the screening of TT-compounds by using only
4ml as final volume.
6.3.8 Thiamine, TMP and TPP extraction for HILIC
Sample preparation for HILIC starts with the same procedure as setting up a β-galactosidase
assay (final volume of 8ml, refer to Section 6.3.7). After the 24 h incubation step, OD600 is
measured in a 96-well plate. Then suspension was centrifuged at 5000 g for 15min, supernatant
was discarded and the cell pellet resuspended in 200 µl ddH2O and transferred into a 1.5ml
tube. Sample was centrifuged for 1min at 21.000 g and supernatant taken-off. Again 200 µl
H2O were added and cells incubated for 15min at RT. Hereafter, samples were snap frozen
in liquid nitrogen, thawed and sonicated for 20 s. This freeze-thaw cycle was repeated once
before OD600 of the sample was determined to calculate lysis efficiency (percent lysis =
(1-(A600 sonicated/A600 suspension))*100). Usually lysis efficiencies between 60 and 70%
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were reached.
Now, samples were centrifuged for 20min at 20.000 g, transferred into a new 1.5ml tube
and 600 µl acetonitrile were added for protein and nucleic acid precipitation. The sample was
incubated at -80 °C for 20min, centrifuged at 4 °C for 30min at 20.000 g. The supernatant
was again transferred into a new tube and acetonitrile was evaporated in the speed vac for
approximately 2 h to a remaining volume of 150-200 µM. In order to eliminate phospholipids
from the extraction, a phenol chloroform extraction was performed according to Section
6.1.4.1. This was followed by estimation of thiamine and thiamine derivatives in the sample
by using the thiochrome method.
Samples are immediately snap frozen and stored at -20 °C before they were sent for HILIC
analysis on dry ice.
6.3.9 Thiochrome assay
The thiochrome assay was first proposed by Jansen in 1936 (Fujiwara and Matsui, 1953)
and is a method based on the oxidation of thiamine by potassium ferricyanide in an alkaline
medium, extraction of the thiochrome formed by isobutanol and estimation of the intensity
of the violet-blue fluorescence in ultraviolet light (Hennessy and Cerecedo, 1939). Other
phosphoric esters of thiamine (TMP and TPP) behave similarly in the thiochrome assay
and cocarboxylase activity can be determined to distinguish the different species (Haugen,
1961; Bhagvat and Devi, 1946). Triazolethiamine and derivatives cannot be converted to a
thiochrome-like compound, pyrithiamine however can be converted to “pyrichrome” (Airth
and Foerster, 1962).
In order to estimate the amounts of thiamine species successfully isolated from bacteria,
the thiochrome method was used. For this, a 2× concentrated thiamine standard solution was
prepared ranging from 1mM to 25 µM (final concentration; testing eight concentrations: 1000,
750, 500, 250, 100, 75, 50, 25 µl and also no thiamine). A black 96-well plate (flat bottom,
Greiner) was used for these measurements. The wells were pepared by adding the 100 µl of
the thiamine concentration row and samples to be measured. Each standard or sample was
measured as triplicate. Then 100 µl of 2× thiochrome reagent (2mM K3Fe(CN)6 and 2M
NaOH, always prepared freshly) are quickly added by using a multi-pipet.
Samples were measured immediately using the VarioSkan (Thermo). The program consisted
of a 1-minute shaking followed by a kinetic measurement for 30min every 30 s at ex375/em450.
Standard row was plotted (logarithm of thiamine concentration against RFU) and the
equation for the linear slope was used to calculate sample thiamine concentrations.
6.3.10 HILIC
HILIC measurements were performed by Dr.Giorgia Greco from the technical University
Munich. For samples shown in Table 3.8 and Figures 3.19, 3.20 and 3.21 analysis parameters
according to method 1 (see Table 6.19) were used. For the analysis of the triazole, method
2 was established (Table 6.19). In both methods UV-detection was done at 220, 254 and
280 nm and MS-detection was performed in scan mode ranging from 100-3200 m/z, positive
and negative polarity.
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Method I
Column ZIC-HILIC from Merck Sequant, Umea,
Sweden (150x2.1, 3.5 µm, 200Å)
Eluent A acetonitrile (ACN) 100%
Eluent B NH4OAc 10mM/ACN 90/10 v/v
Flow 0.4ml/min
Gradient (time [min]/% B) 0/30
7/30
20/45
21/30
Method II
Column YMC-pack diol (150x2.1, 5 µm)
Eluent A acetonitrile (ACN) 100%
Eluent B NH4OAc 10mM/ACN 90/10 v/v
Flow 0.4ml/min
Gradient (time [min]/% B) 0/15
5/15
15/50
16/15
20/15
Table 6.19: Methods used for HILIC preparation of cell extracts.
6.3.11 Glycerol stocks
To store transformed cells for prolonged periods at -80 °C, glycerol stocks were made by adding
500 µl of cell culture to 500 µl of sterile glycerin medium (Section 7.1). Glycerinstocks were
prepared in 2ml cryo-vials.
6.3.12 Plasmid preparation from E. coli
For plasmid preparation in different scales, the appropriate plamid prep kit (Macherey Nagel,
7.6) was used. Instructions were followed as stated in the manufacturers protocol, except
that either deionized water was used for elution or, when very large DNA plasmids were
prepared elution proceeded by incubation with 25 µl provided elution buffer and incubation for
three minutes before centrifugation. This procedure was repeated to obtain 50 µl of prepared
plasmid for further experimentation such as sequencing (Section 6.3.14) or cloning (Section
6.3.15).
6.3.13 Isolation of genomic DNA from S. aureus Mu50
The isolation of S. aureus genomic DNA was performed using the PrestoSpin D Bug kit from
Molzym. At day 1, a 5ml culture of MH broth was inoculated with a colony of S. aureus
Mu50 and incubated at 37 °C over night under vigorous shaking. The following day, the
stationary culture was centrifuged (1-4ml liquid culture) in a microcentrifuge at 13.000 rpm
for 2min. After the supernatant was removed completely, the cell pellet was resuspended in
50 µl buffer RS including 5 µl Lysostaphin (10mg/ml stock), which attacks the pentapeptide
chain interconnecting the disaccharide. Lysozyme is inefficient against S. aureus, because
123
6 Methods
these bacteria have acetylated muramic acids which are not recognized for cleavage by this
enzyme anymore. This suspension was mixed until homogeneous and incubated for at least
30min at 37 °C until the solution is viscous. Then 250 µl of buffer CH were added and the
solution immediately vortexed for 5 s. If necessary this suspension was also stirred with the
pipet tip for homogenization. Now, samples were incubated for at least 5 min or until visible
lysis. This was followed by the addition of 200 µl buffer AB, thorough vortexing for 5 s and
transfer of the supernatant to a spin column (provided with the kit). The solution occasionally
became turbid as a result of protein precipitation. The loaded column was centrifuged at
13.000 rpm for 30 s, nucleic acids bind to the matrix and flow through was discarded. For
RNA degradation, 200 µl buffer including RNase A was pipetted into the spin column, which
was then incubated for 5-10min with a closed lid. Then 400 µl buffer WB were added to the
spin column and centrifuged at 13.000 rpm for 30 s. Once the flow through was discarded,
the column was washed with 400 µl of 70% ethanol by centrifugation at 13.000 rpm for 3min.
Again the flow through was discarded and the column was transferred to a 1.5ml tube. For
elution, 80 µl of preheated (70 °C) ddH2O were pipetted in the center of the column. After
incubation for 1min with closed lid, centrifugation for 1min at 13.000 rpm took place. The
eluate was used again for the same procedure. Finally, the concentration of DNA samples
was determined as stated above (Section 6.1.8).
6.3.14 Sequencing
For sequencing, samples were sent to the GATC biotech AG. Appropriate primers were
either chosen from the freely available ones listed on the GATC-website or designed and then
synthesized by GATC. A list of designed primers that are now available at GATC can be
found in Table 7.8.
6.3.15 Cloning
6.3.15.1 Restriction digests
For restriction digests fast digest enzymes by Fermentas were used and a mastermix was
prepared according to Table 6.20.
Reagent Amount Resultant
Digest Buffer 2 µl 1×
DNA x 200 ng
Digest Enzyme 1 µl
ddH2O ad 30 µl
Table 6.20: Pipetting scheme for restriction digests.
Incubation of digest reaction took place at 37 °C for 20min and the digested product was
purified using the NucleoSpin kit (Section 6.1.4.2). Concentrations were measured and part
of the sample was run on an agarose gel to check for correct product length.
6.3.15.2 Ligation of DNA fragments
To ligate DNA, two restricted fragments were mixed to a final amount of 150 ng (in equimolar
concentration) together with 2 µl DNA ligase and 2× ligation buffer (to yield a final 1×) in a
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total volume of 50 µl. The sample was incubated for 5min at room temperature and was then
ready for transformation.
6.4 Interaction analysis
6.4.1 Microscale thermophoresis
Microscale thermophoresis (MST) is a new method that enables the quantitative analysis of
molecular interactions in solution at the microliter scale. This method was used to determine
interactions between compounds or metabolites and riboswitches. For this the RNA was
labeled at its 5’ end using in vitro GMPS transcription and subsequent fluorescein labelling
(Sections 6.4.1.1 and 6.4.1.3). All measurements were performed on the Monolith NT.115
(NanoTemper Instruments).
For every round of measurements 16 glass capillaries were prepared that contained 10 µl
of sample solution. This sample solution consisted of a final labeled RNA concentration of
20 nm (RNA was properly folded before addition to the mix), assay buffer (same as used in
i. e. glmS in vitro cleavage assays) and finally 1 µl of appropriate compound was added to
obtain the wanted final concentration. These components were mixed in 0.5ml tubes and
incubated for about 5min at RT till equilibrium was formed. Then capillaries are loaded and
optionally closed with putty at each side.
For fluorescein labeled RNA the blue LED laser was used (Laser on time: 40 s, Laserpower:
70%). For more detailed methods descriptions refer to the Bachelor thesis of Jens Hör (Hör,
2011).
6.4.1.1 GMPS-transcription
This transcription method allows the incorporation of a modified guanosine nucleotide at the 5’
end of the RNA. The guanosine monophosphate thioate can later react with iodoacetyl-moiety
of labelling molecule like biotin or fluorescein by a nucleophilic substitution.
Reagent Amount Stock Resultant
Tris pH 7.9 (or Hepes for glmS ribozyme) 20 µl 200mM 40mM
MgCl2 25 µl 100mM 25mM
DTT 5µl 100mM 5mM
NTP Mix 10 µl 25mM 2.5mM
RNasin 1.24 µl 40U/µl 0.5U/µl
Inorganic pyrophosphatase 0.2 µl 2U/µl 0.02U/µl
dsDNA template 10 µl 150-300 pmol 1.5-3 µl
T7 RNA polymerase 5 µl 50U/µl 0.5Uµl
GMPS 6.7 µl 150mM 10mM
water 11.86 µl
total volume 100 µl
Table 6.21: Pipetting scheme for GMPS-transcription
Reaction mix was composed as shown in Table 6.21. A positive control, approximately
100-200 nt long was transcribed as well to ensure activity of enzymes, proper salt and buffer
conditions. The transcription was run over night. Before samples were phenol-chloroform
extracted and precipitated according to Section 6.1.4.1, yield was checked running an agarose
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gel. The pellet was resuspended in 100 µl DEPC water and passed through G25 columns
(6.1.11.1) twice.
6.4.1.2 Biotinylation of RNA
Before the biotinylation was started RNAs were checked for integrity on an agarose gel. For
the labeling reaction the components listed in Table 6.22 were mixed and added to the GMPS
transcribed RNA. Whenever the glmS ribozyme was used in this protocol, Tris buffer was
substituted by Hepes buffer, since Tris increases the self-cleavage reaction of this riboswitch.
Since the pH can vary dramatically with different amounts of RNA being added, the pH was
measured. It was only preceded when the pH lay around 8 or after it had been adjusted
to 8. The mix was heated to 80 °C for 1min and immediately put on ice for 5min. In the
meantime a crumb of EZ-link PEO-iodoacetyl biotin (by Thermo Scientific) was dissolved in
100 µl DMF. 40 µl of biotin solution were added to the 360 µl of labelling mix at RT and then
incubated at 40 °C for 2 h, 300 rpm.
Reagent Amount Stock
TE (Tris 800mM, EDTA 500mM) pH 8 40 µl 10×
Urea 100 µl 8.3M
RNasin 4 µl 40U/µl
GMPS transcription 100 µl
DEPC water 116 µl
total volume 360 µl
Table 6.22: Composition of RNA labelling mixture
6.4.1.3 Fluorescein-labelling of RNA
For successful fluorescein-labelling reactions, the same protocol and procedure as stated under
Section 6.4.1.2 was followed, except for the use of iodoacetamido-fluorescein (4mM final)
dissolved in DMF as labelling substrate.
6.4.1.4 Ammonium acetate precipitation
Samples were split into 2× 200 µl and 1 µl of DNaseI was added. Incubation for 20min at
37 °C allowed the digest of remaining DNA templates. 100 µl 6M NH4OAc and 900 µl of
EtOH abs. were added. The tube was inverted to mix and frozen at -80 °C for 10min, spun
at 4 °C for 20min at 20817 rcf. The pellet was washed using 70% EtOH, centrifuged for 5min
and air-dried, then dissolved in 50 µl 1× sucrose PAGE loading buffer. Finally, the protocol
for RNA work-up was followed (Section 6.1.7), fluorescein-labelled RNA was run in the dark.
The resulting biotinylated or fluorescein-labelled RNA pellet was taken up in 20 µl DEPC
water. Whereas the yield and quality of biotinylated RNA was checked by gel shift assay
(Section 6.4.1.5), fluorescein-labelled RNA was run on an agarose gel and evaluated using the
fluorescence reading options of the phosphorimager or by simple absorption measurements at
494 nm and 260 nm.
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6.4.1.5 Gel shift assay
Biotinylated RNA was mixed in equimolar concentrations with streptavidin (SA-stock:
150mM) and incubated at RT for 15-25min before 2× RNA agarose loading buffer was
added. Samples were immediately loaded on an agarose gel of convenient percentage (Section
6.1.2). Positive and negative controls as well as unbiotinylated RNA were run for orientation.
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7.1 Solutions
Solution Ingredient
Agarose loading buffer 2× pH 8.0 Tris/HCl 50mM
EDTA 50mM
Glycerine 50% (v/v)
Assay buffer 2× sodium phosphate buffer, pH 7.3 200mM
MgCl2 2mM
β-mercaptoethanol 100mM
o-nitrophenyl-β-D-galactopyranosid 1.33mg/ml
Cleavage Buffer 10× Hepes pH 7.5 500mM
KCl 2M
DEPC water DEPC 1:500 (2ml for 1 l water)
LB media NaCl 5 g/l
yeast extract 5 g/l
tryptone 10 g/l
water ad 1 l
M9 medium 5× KH2PO4 15 g
NH4Cl 5 g
NaCl 2.5 g
Na2PO4 30g
ddH2O ad 1 l
PBS 10×, pH 7.4 NaCl 1.37M
KCl 27mM
Na2HPO4 65mM
NaH2PO4 14.7mM
Pfu PCR buffer 10× Tris/HCl pH 8.8 200mM
KCl 100mM
Triton X-100 1%(v/v)
(NH4)2SO4 100mM
BSA 1mg/ml
RNA loading buffer 2× pH 8.0 Formamide 9.5ml
SDS 10% 25 µl
EDTA 0.5M 10 µl
bromophenol blue crumb
water 0.5ml
Solution B Urea 8.3M in 10× TBE
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Solution Ingredient
Solution C Rotiphorese Sequenziergel Konzentrat
Solution D Urea 8.3M
Sucrose Loading buffer 2× Tris/HCl 45mM
Boric Acid 45mM
Urea 4M
Sucrose 10%
SDS 0.05%
EDTA 2mM
Sucrose Loading buffer 1× Tris/HCl 45mM
Boric Acid 45mM
Urea 4M
Sucrose 10%
SDS 0.05%
EDTA 100mM
SOC media Trypton 2% (w/v)
Yeast extract 0.5% (w/v)
NaCl 0.2% (w/v)
MgCl2 10mM
MgSO4 10mM
Glucose 20mM
TBE 10× Tris/HCl 890mM
Boric Acid 890mM
EDTA pH 8.0 20mM
Taq PCR buffer 10× Tris/HCl pH 9.0 100mM
KCl 500mM
Triton X-100 1% (v/v)
7.2 Equipment
Equipment Manufacturer
-80°C freezers, -20°C freezers, refrigerators AEG, Heraeus
96 well plates, half area, flat, black, medium binding Greiner Bio One
96 well plates, flat, black, medium binding Greiner Bio One
96 well plates, flat, clear Roth
Agarose gel camera BioRad
Agarose gel and equipment in house construction
Analytical balance Sartorius
Autoclave Systec
Balance Chyo
Beaker Schott
BioMate 3 photometer Thermo Spectronic
Centrifuges Eppendorf and Beckmann
Clamps Mauy
Counter for radioactivity Berthold
Cryo-vials Greiner Bio One
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Equipment Manufacturer
Cylinder Faust
Disposable cuvettes Roth
Drigalski applicator In-house construction
Electrophoresis apparatus and chambers BioRad and Fischer Scientific
Eppi racks Roth
Eppendorf concentrator 5301 Eppendorf
Eppendorf tabletop centrifuge 5417C Eppendorf
Erlenmeyer flask Schott
Fluorescence spectrometer Perkin Elmer
G25 columns GE Healthcare
Gel dryer BioRad
Glass plates for PAGE Baack
Glass bottles Schott
Glassplate with buffer chamber BioRad
Glassplate (sequencing gels) BioRad
Glasspipet tips (25ml, 10ml, 5ml) Hirschmann
Glasswool silanized Serva
Gloves Peske
Head-top-tumbler Heidolph
Heating blocks Bachofer
Hollow needles Roth
Hood (bacteria) Antares
Incubator shaker Innova
Incubator (37 °C-90 °C) WTC binder
Magnetic stirrer IKA
Membrane filters 45 µm, 25mm Sigma-Adrich
Microwave Bosch
Multichannel pipette Eppendorf
Multipette Eppendorf
NanoQuant infinite 200 Tecan
NAP5 columns GE Healthcare
NAP10 columns GE Healthcare
Parafilm Faust
PCR Thermocycler Biometra
Peristaltic pump LKB Bromma
Petridishes for LB-agar plates Faust
pH-meter Inolab
pH paper Macherey-Nagel
Phosphorimager screens & cassettes Fuji
Phosphorimager FLA-3000 Fujifilm
Pipets Eppendorf
Pipet tips Sarstedt
Pipetboy Acu-jet pro Brand
Power supply for PAGE Consort
Radioactivity protection gear (goggles, shields etc.) Sigma
Reaction tubes (2ml, 1.5ml, 0.5ml) Eppendorf/Sarstedt
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Equipment Manufacturer
Saran wrap Roth
Sequencing gel chamber & equipment BioRad
Serological pipettes Faust
Scalpel blades Labomedic
Shaker GFL
Sonification manifold Bandelin
Spacers/ Comb, thin ( 0.5mm) BioRad
SPR Biacore GE Healthcare Life Science
Sterile filters (syringe filter / bottle top) Merck Millipore
Sunrise plate reader Tecan
Syringe (60ml) Henke/Sass/Wolf
Tips for multipette; Combitips plus Eppendorf
Thermomixer Eppendorf Eppendorf
UV Transilluminator BioRad
VarioSkan Thermo
Vortex mixer Neolab
Water bath GFL
Water purification system Werner
Tecan Ultra reader Tecan
7.3 Chemicals
Chemical Manufacturer
Acetic acid (99,8%) Merck
Acetonitrile (ACN) Fluka
N-Acetyl-muramic acid (MurNAc) Sigma
N-Acetyl-α-D-Glucosamine-1-phosphate (GlcNAc1P) 95% Sigma
N-Acetyl-D-Glucosamine-6-phosphate disodium salt (GlcNAc6P) Sigma
N-Acetyl-D-Glucosamine (GlcNAc) 99% Sigma
Adenine Sigma
Agar Invitrogen
Agarose Merck
Ampicillin sodium salt AppliChem
Ammoniumacetate Grüssing
Ammoniumchloride (NH4Cl) ChemSolute
Ammomiumperoxodisulfate (APS) > 98% reinst Roth
Bis-Acrylamid, Rotiphorese Roth
Biotin Sigma-Aldrich
Boric acid Grüssing
Bovine Serum Albumin (BSA, nuclease and protease free) Calbiochem
Bradford-reagent BioRad
Bromphenol blue Merck
Calf intestine alkaline phosphatase (CIAP) Promega
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Chemical Manufacturer
CIAP Buffer Promega
Casamino Acids Vitamin assay Becton Dickinson
Chloroform Merck
Coenzyme B12 Sigma
Coomassie Brilliant Blue G250 Merck
Dichlormethane Merck
Dichlorodimethylsilane Acros organics
Dimethylformamide (DMF) Fischer Scientific
Diethylopyrocarbonate (DEPC) Sigma
Dimethylsulfoxide (DMSO) AppliChem
1,4-Dithiothreitol (DTT) Roth
di-Sodiumhydrogenphosphate-dihydrate Merck
DNase Roche
Ethanol abs. Merck
Ethidium bromide Roth
Ethylendiamintetraacetic acid (EDTA) p.A. AppliChem
EZ-link PEO-iodoacetyl biotin Thermo Scientific
Formaldehyde (36%) Fluka
D-Fructose-6-phosphate dipotassium salt Sigma
D-(+)-Glucose (Glc) Sigma
α-D-Glucose-1-phosphate dipotassium salt dihydrate (Glc1P) Fluka
D-Glucose-6-phosphate (Glc6P) Sigma
D-Glucosamine-1-phosphate (GlcN1P) Sigma
D-Glucosamine-6-phosphate (GlcN6P) Sigma
D(+)-Glucosamine-hydrochloride (GlcN) min 99% Sigma
L-Glutamine Merck
Glycerin Roth
Glycine Roth
Guanine Fluka
Guanosine-5’-thiophosphate disodium salt emp biotec
Hepes Pufferan 99,5% p.a. Roth
Hemin Sigma
Hydrochloric acid (HCl) Roth
Hyoxanthine 99% Sigma
Imidazole Roth
Iodacetamido-fluorescein Sigma
Iodacetamido-biotin (EZ-link PEG2) Thermo Scientific
Isoamyl alcohol Roth
Isopropanol Merck
Kanamycin sulfate Sigma
Lennox L Broth (LB) Sigma
Lysis Buffer 5× Promega
Lysostaphin Sigma-Aldrich
Magnesiumchloride-hexahydrate(MgCl2-6×H2O) 99% p.a. ACROS organics
Magnesiumsulfate (MgSO4×7H2O) Merck
Methanol VWR
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Chemical Manufacturer
β-Mercaptoethanol 98% Rad
Agarose gel and equipment in house construction
Analytical balance Sartorius
Autoclave Systec
Balance Chyo
Sigma
Monopotassiumphosphate (KH2PO4) Sigma-Aldrich
o-Nitrophenyl-β-D-galactopyranosid (ONPG) Roth
Phenol Roth
Potassium chloride (KCl) 99,5% p.a. Grüssing
Potassiumdihydrogenphosphate Riedel de Haen
Pyrithiamine hydrobromide Sigma-Aldrich
Pyridoxamine dihydrochloride Fluka
Pyridoxal hydrochloride Sigma
RNasin Promega
Rnase H Promega
RNA protect Bacteria reagent Qiagen
Rotiphorese Sequenziergel Konzentrat Roth
Salt optimized carbon medium (SOC) Sigma
Sodium Acetate Grüssing
Sodium carbonate Na2CO3 p. a. Riedel de Haen
Sodium chloride p.A. ChemSolute
Sodium dodecylsulfate (SDS) Roth
Sodium hydrogenphosphate Na2HPO4 ×2H2O p.a. Sigma Aldrich
Sodium hydroxide (NaOH) Grüssing
Sodium orthovanadate AppliChem
Sodium pyrophosphate AppliChem
Sodium trifluoroacetate 98% Alfa Aesar
Spermidine trihydrochlorid 98% Sigma
Streptavidin Sigma
Streptozotocin Sigma
Superscript Reverse Transcriptase II Invitrogen
T4 Polynucleotide kinase (PNK) NEB
T4 PNK buffer NEB
Tetrabutylammonium chloride Fluka
Tetracyclinehydrochloride 95% Roth
N,N,N’,N’ -Tetramethylethylendiamide (TEMED) Roth
Thiamine hydrochloride Sigma
Thiamine monophosphate chloride dihydrate Sigma
Thiamine pyrophosphate Sigma
Tris Ultra Quality 99.9% Roth
Triton X-100 Merck
Tween-20 Calbiochem
Urea AppliChem
XL10 Gold ultracompetent cells Stratagene
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7.4 Chemically defined media
Component Amount in mg
Group I
FeSO4×7H2O 5
Fe(NO3)3×9H2O 1
MnSO4 5
dissolve in 1ml H2O
Group II A
L-tryptophan 100
L-cystein 50
dissolve in 1ml 2N HCl at 55 °C
Group II B
L-leucin 100
DL-alanin 100
L-isoleucin 100
L-methionine 100
L-threonine 200
L-arginine 100
DL-histidine 100
L-valine 100
L-lysine 100
L-glutamine 100
dissolve in 10ml H2O
Group II C
L-asparagine 100
L-phenylalanine 100
L-serine 100
L-proline 100
L-hydroxyproline 100
L-glutamic acid 100
glycine 100
L-tyrosine 100
dissolve each amino acid in 1ml 2.5N NaOH at 55 °C
Group III
p-aminobenzoic acid 0.2
biotin 0.2
folic acid 0.8
nicotinamid 1
α-NAD 2.5
D-panthoic acid 2
pyridoxal HCl 1
pyrodoxamin-di-HCl 1
riboflavin 2
thiamine HCl 1
cobalamine 0.1
dissolve components in 10ml H2O and dropwise addition of
2.5N NaOH until the solution becomes clear
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Group IV
adenine 20
guanine HCl 20
uracil 20
dissolve in 3ml 2N HCl at 90 °C
Group V
K2HPO4 200
KH2PO4 1000
MgSO4×H2O 700
CaCl22×H2O 7
NaOAc 3×H2O 4500
NaHCO3 2500
D-glucose 1000
HEPES 13,000
dissolve components in 300ml H2O
H2O ad 500ml
7.5 Bacterial strains
Organism Mutations
E. coli MG1655 F−, lambda−, rph−1
E. coli DH5αZ1 laciq, PN25-tetR, Spr, deoR, supE44,
Delta(lacZYA-argFV169), Phi80 lacZDeltaM15, recA1,
hsdR17(rK- mK+), endA1, gyrA96, thi-1, relA1
E. coli XL10 GOLD endA1, glnV44, recA1, thi-1, gyrA96, relA1, lac,
Hte, Δ(mcrA)183, Δ(mcrCB-hsdSMR-mrr)173
tetR, F’[proAB lacIqZΔM15 Tn10(TetR Amy CmR)]
H. influenza DSMZ 11121 Rd [KW20] (Fleischmann et al., 1995)
S. aureus SG511-Berlin VSSA
S. aureus Mu50 VISA
Table 7.5: Microorganisms and their genetic background. deoR: Allows uptake of large
plasmids; regulatory gene mutation allowing constitutive expression of genes for deoxyribose
synthesis; endA1: Abolishes non-specific endonuclease I activity; improves quality of plasmid
DNA isolations; gyrA96: Resistance to nalidixic acid; DNA gyrase mutation; hsdR17(rK- mK+):
Restriction minus, modification positive; transformed DNA will not be cleaved by endogeneous
restriction endonucleases; laciq: lac promoter up-mutation; constitutive overproduction of Lac
repressor; DeltaM15: Allows α-complementation of β-galactosidase activity, partial deletion of
β-D-galactosidase gene; PN25-tetR: constitutive production of Tet repressor; recA1: Prevents
recombination between introduced DNA and host DNA; confers UV-light sensitivity; relA1:
Allows RNA synthesis in the absence of protein synthesis; rph-1: a 1 bp deletion that results in
frameshift over last 15 codons and has polar effects on pyrE, leading to suboptimal pyrimidine
levels on minimal medium; Spr: resistance to Spectinomycin; supE44: Suppresses amber (UAG)
mutations; thi-1: Requires thiamine for growth on minimal media; Hte phenotype allows high
transformation with large plasmid inserts.
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Kit Manufacturer
NucleoSpin Extract II Macherey-Nagel
NucleoSpin Plasmid kit Macherey-Nagel
NucleoSpin Xtra Midi & Maxi kits Macherey-Nagel
QuikChange Lightning Agilent Technologies Inc. (Stratagene)
PCR purification kit Fermentas
PrestoSpin D Bug Molzym
PrestoSpin R Bug Molzym
RNeasy Min Elute Clean-up Qiagen
Sequenase Version 2.0 PCR product sequencing USB
7.7 Standards, nucleotides and synthetic oligos
Type Length Manufacturer
DNA ladder 100-10,000 bp PeqLab
100-1,000 bp PeqLab
RNA ladder low range Fermentas
high range Fermentas
Table 7.6: DNA and protein ladders
Nucleotides/ radiochemicals Manufacturer
dNTP-Set Roche
NTP-Set Roche
α 32P-GTP P-ATP, 10mCi/ml NEN, Zaventem, Belgium
γ 32P-ATP P-GTP, 10mCi/ml NEN, Zaventem, Belgium
Table 7.7: Nucleotides and radiochemicals
Name Sequence (5’ to 3’)
GATC-pRS414.2 empty-555953 CTG CCA GGA ATT GGG GAT CG
GATC-5’ pRS414.2 Insert B-342112 GAA GCA ACG GCC CGG AGG
Table 7.8: Sequencing primers at GATC
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Name Sequence (5’ to 3’)
N25.47 AAT GCT AAT ACG ACT CAC TAT AGG GAG AGA GAG ACA GTC TAC GTA TT
N25.21 TGT ACC TAC GTC TGC AGT GAA
Oligo1 AAT ACG TAG ACT GTC TCT CTC TCC C
5’ TPP+T7 TCG TAA TAC GAC TCA CTA TAG GAA CCA AAC GAC TCG
3’ TPP TTG CGC TGG ATC CAG CAG GTC GA
5’ Sau glmS+T7 GATT AAT ACG ACT CAC TAT AGG GCA GTT AAA GCG CCT GTG CAA ATA
5’+T7 glmS Sau long
(5’Sau glmS rbzm long)
TCG TAA TAC GAC TCA CTA TAG GTA ATG ATT AAT GGA AAG GGG G
3’ Sau glmS neu ATC TTA TTA ACT TTG TCC ATT AAG TCA CCC
N25.1 mut1F AAT TCG CGC GGC ATA CCT GCT GCT CTG TGC CGC GCG
N25.1 mut R GAT CCG CGC GGC ACA GAG CAG CAG GTA TGC CGC GCG
N25.1 mut2 F AAT TCG CGC GGC ATA CCT CCT GCT CTG TGC CGC GCG
N25.1 mut2R GAT CCG CGC GGC ACA GAG CAG GAG GTA TGC CGC GCG
5’ glmS clvsite mut gg-
mittellang
GCA CAG GCG GGA ACT GTA CTG CCG
3’ glmS clvsite mut gg-
mittellang
CGG CAG TAC AGT TAA CCC GCC TGT GC
Aptamer 7 AGA GAG AGA CAG TCT ACG TAT TCC TAC CCG ACA CAA TTC TAA TCT ACT TCA CTG
CAG ACG TAG GTA CA
5’primiR
18a19a+bdgsite+T7
AAT GCT AAT ACG ACT CAC TAT AGG AGT GCT TTT TGT TCT AAG GTG C
3’ primiR 18a19a+bdgsite GGA GTG CTA CAG AAG CTG TCA CAT CA
5’ primiR 19a+bdgsite+T7 AAT GCT AAT ACG ACT CAC TAT AGG AAG TTA TGT ATT CAT CC
3’ primirR19a+bdgsite GGA AGC TGT CAC ATC AGA TAG ACC
3’ primiR19a+mut bdgsite GGA AGC TGT CAC ATC AGA TAG ACC AGG CAG ATT CTA CAT CAC TCC AAT AAA AGT
ACA CAA AAT T
5’ mutATG 1 GTT GAC GAG GAT TGA GGT TAT CG
3’ mutATG 1 GCA TAA CCT CAA TCC TCG TCA AC
5’ mutATG 2 GAA TTT TCG GCG GGT GCC TCC CGG
3’ mutATG 2 CCG GGA GGC ACC CGC CGA AAA TTC
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Name Sequence (5’ to 3’)
5’ mutATG 3 GAG AAA TCA CGT GAT CTT CC
3’ mutATG 3 GGA AGA TCA CGT GAT TTC TC
5’ mutATG 4 CCA AAA AAC GTG TAG GAA GGG GAC AC
3’ mutATG 4 GTG TCC CCT TCC TAC ACG TTT TTT GG
5’ mutATG 4LV CGT GAT CTT CCA AAA AAC GTG TAG GAA GGG GAC
3’ mutATG 4LV GTC CCC TTC CTA CAC GTT TTT TGG AAG ATC ACG
5’ glmS clvmut gg TAT TTA TTT GCA CAG GCG GGT TAA CTG TAC TGC CGA AC
3’ glmS clvmut gg GTT CGG CAG TAC AGT TAA CCC GCC TGT GCA AAT AAA TA
N25.1 LS FP (+T7) TCG TAA TAC GAC TCA CTA TAG GCG CGG CAT ACC TGG TGC TCT GGTG CCG CGC
N25.1 LS RP (+T7) GCG CGG CAC AGA GCA CCA GGT ATG CCG CGC CTA TAG TGA GTC GTA TTA CGA
5’ pNYL insert TCG TAA TAC GAC TCA CTA TAG GAT CAG CAG GCA CTG ACC G
3’ pNYL insert AAC AGA TAA AAC GAA AGG CCC AGT CTT TCG ACT GAG CC
N25.3 Apt FP (T7) TCG TAA TAC GAC TCA CTA TAG ACA CTT CGA GCG GGT ACG AGT GTC
N25.3 Apt.RP GAC ACT CGT ACC CGC TCG AAG TGT CTA TAG TGA GTC GTA TTA CGA
T7.glmSEGFP TCT AAT ACG ACT CAC TAT AGG GTC AGA TCC GCT AGC GCT ACC
glmSEGFP GCT TTA TTT GTA ACC ATT ATA AGC TGC
N25.1AptFP+T7 TCG TAA TAC GAC TCA CTA TAG GCA TAC CTG GTG CTC TGT GCC
N25.1AptRP GGC ACA GAG CAC CAG GTA TGC CTA TAG TGA GTC GTA TTA CGA
N25.3LS RP+T7 CGG ACA CTC GTA CCC GCT CGA AGT GTC CGC TAT AGT GAG TCG TAT TAC GA
N25.3LS FP TCG TAA TAC GAC TCA CTA TAG CGG ACA CTT CGA GCG GGT ACG AGT GTC CG
5’ pNYLins w/o T7 ATC AGC AGG ACG CAC TGA CCG
chempro3’SauglmSlo CAC TAT CCT CCT CGT CTA C
5’ BamHI pSil Apt7 ATT GAA CGG ATC CGA TAC GTA GAC TGT CTC TCT CTC CCG TAA
3’ HindIII pSil Apt7 CAA GTT AAA GCT TTT CCA AAA AAT CAC TGC AGA CGT AGG TAC ATT
5’ T7 Apt7w/ODN AAT GCT AAT ACG ACT CAC TAT AGA TAC GTA GAC TGT CTC TCT CTC CCG TAA
3’ Apt7w/ODN CAT TAC ATG GAT GCA GAC GTC ACT AA
Apt7 DNAw/ODN GAT ACG TAG ACT GTC TCT CTC TCC CGT AAG GGA GAG AGA GAC AGT CTA CGT ATC
CTA CCC GAC ACA ATT CTA ATC TAC TCA CTG CAG ACG TAG GTA CAG TAA TGT ACC
TAC GTC TGC AGT GAT TTT TTG GAA
3’ pNYLins 27 CAA CAG ATA AAA CGA AAG GCC CAG TC
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Name Sequence (5’ to 3’)
FP 16S rRNA ATT AGA TAC CCT GGT AGT CCA CGC C
RP 16S rRNA CGT CAT CCC CAC CTT CCT CC
N25.1m1 AptFP+T7 TCG TAA TAC GAC TCA CTA TAG GCA TAC CTG CTG CTC TGT GCC
N25.1m1 AptRP GGC ACA GAG CAG CAG GTA TGC CTA TAG TGA GTC GTA TTA CGA
N25.1m1LS FP+T7 TCG TAA TAC GAC TCA CTA TAG GCG CGG CAT ACC TGC TGC TCT GTG CCG CGC
N25.1m1LS RP GCG CGG CAC AGA GCA GCA GGT ATG CCG CGC CTA TAG TGA GTC GTA TTA CGA
N25.1m2 AptFP+T7 TCG TAA TAG GAC TCA CTA TAG GCA TAC CTC CTG CTC TGT GCC
N25.1m2 AptRP GGC ACA GAG CAG GAG GTA TGC CTA TAG TGA GTC GTA TTA CGA
N25.1m2LS FP+T7 TCG TAA TAC GAC TGA CTA TAG GCG CGG CAT ACC TCC TGC TCT GTG CCG CGC
N25.1m2LS RP GCG CGG CAC AGA GCA GGA GGT ATG CCG CGC CTA TAG TGA GTA GTA TTA CGA
T7+preQlong VAAT GCT AAT ACG ACT CAC TAT AGG TTG TAT ACT CCG TTC TAA ATG TG
5’ preQlngßgal CAC TAT AGG GAA TTC TTG TAT ACT CCG TTC TAA ATG TG
3’ preQ1 Mu50 TTT TGT AAT TGC TCC TAT CA
3’ preQ1 Mu50ßGal CGG GCA TGG ATC CAG GTC GAC TTG CAT AGT TTG CTC CTT TTT GTA ATT GCT CCT
ATC
5’ preQSauEcoRI CAC TAT AGG GAA TTC TAT TCA TCG TAC
Sau preQ1 AD TAT TCT ATT CAT CGT ACA TAA ATG AAT ATC AGA GGT TTC TAG CTG AAA CCC TCT
ATA AAA AAC TAG ACA TT
5’ preQSau+T7 AAT GCT AAT ACG ACT CAC TAT AGG GTA TTC TAT TCA TCG TAC
3’ preQ1 AAT GTC TAG TTT TTT ATA GAG GG
3’ preQ1 βGal rep CGG GCA TGG ATC CAG GTC GAC TTG CAT AGT TTG CTC CTA ATG TCT AGT TTT TTA
TAG AGG G
5’ pNYLins +T7NEW TCG TAA TAC GAC TCA CTA TAG GAT CAG CAG GAC GCA C
pNYL ins NEW AAC AGA TAA AAC GAA AGG CCC AGT CTT TCG ACT G
5’ NheI glmS ATG1234 ATT GAA CGC TAG CTC TTG TTC TTA TTT TCT C
3’ BglIII glmS ATG1234 ATT GAA CTC TAG AGT CCC CTT CCT ACA CGT TTT TTG GA
5’ KpnI glmS ATG 1234 ATT GAA CGG TAC CTC TTG TTC TTA TTT TCT C
3’ BamHI glmS ATG1234 ATT GAA CCC TAG GGT CCC CTT CCT ACA CGT TTT TTG GA
5’ Ad.RS TCG TAA TAC GAC TCA CTA TAG GGA AAT AGC TAT TAT CAC TT
3’ Ad. RS AAA AAA AAT CCT GAT TAC AAA AAA TGT C
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Name Sequence (5’ to 3’)
5’ TTPHHaz TAA TAC GAC TCA CTA TAG GGA GTC TCC TTC GGT ACA TCC AGC TGA TGA GTC CCA
AAT AGG ACG
3’ TTPHHaz 1.20 TCT CCT TCG TGG AAT CCA GGA ATA ATC CCT ACG CTG GCA TTA TCC AGA TCA GGT
GAT ACG GGT ATT TCT CAG CC
blck strand ATT TGG GAC TCA TCA GCT GG
3’ TTPHHaz2.5 TCT CCT TCG TGG AAT CCA GGA TCC ATC CCT ACG CTG GCA TTA TCC AGA TCA GGT
GAT ACG GGT ATT TCT CAG CC
5’ Ad.RS-xtd ATG AAC GGG AAT TCT CGT AAT ACG ACT CAC
3’ Ad. RS-xtd CTT GGC ATG GAT CCA GGT TTA CTT GCA TAT TTT GCT CCT AAA AAA
3’ tpp.91 CGT GAC TTC CCT ACG CTG GCA T
5’ T7 shp Apt 7 AAT GCT AAT ACG ACT CAC TAT AGG GAT ACG TAG TAA TAC GTA TCC TAC C
3’ shp Apt 7 AAT CAC TGC AGA TTC ATC TGC AGT GAG TAG
3’ Ad.RSxtd 1st AGG TTT ACT TGC ATA TGT TGC TCC TAA AAA AAA TCC TGA TTA CAA AAA ATG
3’ Ad.RSxtd 2nd CTT GGC ATG GAT CCA GGT TTA CTT GCA TAT GTT GCT C
pRS414.2 fw AGG AGC AAA CUA UGC AAG UCG
pRS414.2 rv GAA TTC CGA TCC CCA ATT
pRS414.2 empty fw CCG GGC AGG CCA T
5’ GLMS nt1 ATG TGT GGA ATT GTT GGT TAT ATT GGC
3’ GLMS nt916 CTG CAT GGT AGC TTG TAC CTG
5’ qPCR GLMS GCT GAT AGT AGC GAT TTT GAT GG
3’ qPCR GLMS GCA TAT GAA CCA TGT AAT AAT GAC AC
5’ glcA fmt1 BamHI ATT GAA CGG ATC CAC CAA CGT GTT ACT AAG TAA GAT TAG GC
3’ glcA fmt1 KpnI ATT GAA CGG TAC CCG ATT GCG ACA CCT AAT GCG
5’ glcA fmt 2 KpnI ATT GAA CGG TAC CAT GTT GAG GAA GGT CAA GAA G
3’ glcA fmt2 NcoI ATT GAA CCC ATG GAT AGC CTC GAA TAC AGT G
5’ ptsG fmt1 BamHI ATT GAA CGG ATC CAC TTG CGT GTT ACT GGT A
3’ ptsG fmtI XhoI ATT GAA CCT CGA GCT GCT GCT TCC ATG ACC G
5’ ptsG fmt2 XhoI ATT GAA CCT CGA GAA ACT GAA TGG TGA AGG ATT CG
3’ ptsG fmt2 NcoI ATT GAA CCC ATG GCT CGC TAC TTC GCA TAC GC
5’ ptaA fmt1 BamHI ATT GAA CGG ATC CGC CTA GGT GAC TAT AAC GGA G
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Name Sequence (5’ to 3’)
3’ ptaA fmt1 KpnI ATT GAA CGG TAC CTA TAG CTA CAC CAA TTG C
5’ ptaA fmt2 KpnI ATT GAA CGG TAC CGA ATA CGA TTG GTA GAG GTG
3’ ptaA fmt2 NcoI ATT GAA CCC ATG GTT AGA TTT GCG CTT TAG CTG
gyrB-297 TTA GTG TGG GAA ATT GTC GAT AAT
gyrB-547 AGT CTT GTG ACA ATG CGT TTA CA
Table 7.10: Synthetic oligonucleotides
142
8 Appendix
8.1 Supplementary Material
Activator EC50 S. aureus R2 EC50 B. subtilis R2
GlcN6P 3.6 µM 0.98
GlcN 189 µM 0.98
CGlcN6P 6.2 µM 0.98 2.1 µM 0.93
GlcN6S 160 µM 0.98
Table 8.1: EC50 values for glmS activating metabolites. To obtain these values, percent
glmS cleavage was plotted against the logarithm of metabolite concentration used in the cleavage
reaction. This sigmoidal dose-response curve was fitted as mentioned in Methods Section 6.2.4.2.
Goodness of fit is indicated by R2 values.
Figure 8.1: Dose-response curves for EC50 determinations. (A) Dose-response curve used
for EC50 determination of S. aureus glmS ribozyme cleavage in the presence of increasing GlcN6P
(dark blue), GlcN (magenta), CGlcN6P (light blue) or GlcN6S (purple) concentrations. Error bars
indicate standard deviation of at least three independent experiments. (B) Dose-response curve
used for EC50 determination of B. subtilis glmS ribozyme cleavage in the presence of increasing
CGlcN6P concentrations. Error bars indicate standard deviation of at least three independent
experiments.
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Figure 8.2: S. aureus glmS ribozyme characteristics. (A) Temperature dependency of
glmS self-cleavage. At physiological temperatures of 37 °C (black bars) cleavage is more prominent
than at RT (23 °C, gray bars). (B) pH dependency of glmS self-cleavage. With increasing
pH the ratio of cleaved glmS increases reaching a cleavage maximum at pH of about 7.5. (C)
Metabolite-induced cleavage assay using different sugar metabolites or a chemical analog of
GlcN6P, namely GlcN6S, as substrate. (D) Metabolite-induced cleavage assay using different
mono- and disaccharides (Glc= D-glucose, Glc1P= glucose-1-phosphate, Glc6P= glucose-6-
phosphate, Fru6P= fructose-6-phosphate, Suc= Sucrose, Man= Mannose) at a final concentration
of 2mM. (E) Salts were tested at 10mM final concentration. (F) Concentration dependent
analysis of MgCl2 and CaCl2 aided glmS cleavage.
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Figure 8.3: Metabolite induced self-cleavage assay of glmS ribozyme of S. aureus and
B. subtilis. (A) Metabolite induced self-cleavage of S. aureus glmS ribozyme upon addition of L-
glutamin (L-Gln, 200 µM) (B) Metabolite induced self-cleavage of the wildtype (wt) glmS ribozyme
of S. aureus in comparison to the cleavage mutant, which does not show any self-cleavage upon
addition of GlcN6P or GlcN. (C) Metabolite induced self-cleavage of B. subtilis glmS ribozyme
upon addition of CGlcN6P (200 µM). (D) Concentration dependent effect of compound 2 on
S. aureus glmS ribozyme cleavage. (E) Influence of increasing DMSO concentrations on metabolite
induced self-cleavage assay.
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Figure 8.4: Synthesis scheme of carba-glucosamine-6-phosphate. Methyl glycoside 30
was converted to carba-cycle 31 as described by Barton et al. (1990). Basic cleavage of the cyclic
carbamate gave diol 32 that could be selectively phosphorylated at the primary hydroxyl group
to yield 33. Catalytic hydrogenation gave carba-sugar 8.
Figure 8.5: Synthesis scheme of compounds 11-15. Synthesis of compounds 11-15 was
achieved using a “click” chemistry approach utilizing a common azide intermediate, 34. This
was obtained from thiamine itself in a substitution reaction with sodium azide which has been
previously reported by Erixon et al. (Erixon et al., 2008). Compound 34 was then reacted with
the appropriate substituted alkyne to generate the small library of six thiamine derivatives.
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Table 8.3: Reymond compounds and results of different screening approaches. If compounds appeared as hits in a screening
approach they are marked with an X. X* indicate compounds that appeared as hits from the band quantification data, but turned out to be
artifacts, when primary PA-gel appearance was considered. (X) indicate compounds that could be counted as hits, because they are very
close to the hit cut-off-line. X** marks compounds with unexpected effects on screening outcome, such as D4, which did not only show glmS
cleavage activation in the first screening, but also revealed increased glmS activation in the GlcN6P competition screening.
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Figure 8.6: Reymond compounds with concentration dependent inhibition of glmS
ribozyme cleavage. Graphs show metabolite-induced self-cleavage assays carried out in the
presence of 200 µM GlcN6P and increasing concentrations of Reymond compound B7 (A), C6
(B), C3 (C), C8 (D), D2 (E) and D4 (F). Compound concentrations ranging from 1 µM-2mM
were not sufficient to inhibit cleavage completely.
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Figure 8.7: Screening of Reymond compounds for activation of glmS ribozyme. For
this screening the glmS ribozyme was incubated with the Reymond compound library at a final
compound concentration of 20 µM in 2% DMSO. None of the compounds increased the cleavage
above background levels. Increase in glmS activation for compound E1 is due to unspecific RNA
degradation most likely due to an RNase contamination.
Figure 8.8: Growth curves of DH5αZ1 and MG1655 in M9 minimal medium in the
presence of PT and T. A) DH5αZ1 cells do not show diminished growth upon increasing
pyrithiamine concentrations, whereas OD600 of MG1655 cells decreases at concentrations higher
than 8mM (B). Graphs show bacterial growth at t=495min in the presence of PT or T in relation
to growth in the absence of any compound. Bacterial growth was determined by measurement of
OD600 over 15 minutes for 24 h (see Section 6.3.6 for details).
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Figure 8.9: kobs determinations for S. aureus glmS cleavage inhibition by aminogly-
cosides. Metabolite-induced self-cleavage of S. aureus glmS in the presence of 200 µM GlcN6P
and indicated concentrations of Tobramycin (A) and Neomycin (B). These kobs determinations
were performed by Anna Schüller.
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Figure 8.10: kobs determinations for S. aureus glmS cleavage inhibition by aminogly-
cosides. Metabolite-induced self-cleavage of S. aureus glmS in the presence of 200 µM GlcN6P
and indicated concentrations of Kanamycin B (A), Paromomycin (B) and Sisomycin (C). These
kobs determinations were performed by Anna Schüller.
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Figure 8.11: IC50 value determination for inhibition of glmS ribozyme cleavage
by aminoglycosides. Concentration dependent effect of Neomycin (A), Ribostamycin (B),
Kanamycin A (C), Kanamycin B (D) and Paromomycin (E) was investigated in the presence of
200 µM GlcN6P after incubation at 37 °C for 30min. Aminoglycoside concentrations ranging from
10 nM to 10mM were used. Concentration dependent inhibition by Kanamycin B was monitored
by Anna Schüller.
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Figure 8.12: Growth of S. aureus Mu50 and SG511 in the presence of increasing
Streptozotocin concentrations in 2×CDM and 0.5×MH. Graphs show optical density
measured at 600 nm plotted against the time. Bacterial growth without Streptozotocin added is
shown in magenta and contamination controls of medium alone are depicted in gray.
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Figure 8.13: Growth ratio of MG1655 in M9 minimal medium with compound versus
no compound added. Bacterial growth is shown as ratio of growth in the presence of TT-
compound versus growth in the absence of any compound. Graphs show assay results for indicated
compound (A-E) or thiamine (F). Compound concentrations between 500 µM- 32mM at 495min
are shown.
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Figure 8.14: Concentration dependent effect of TT compounds on β-galactosidase
expression in DH5αZ1 cells. Dose-response curves obtained by monitoring β-galactosidase
expression in DH5αZ1 cells with increasing compound concentrations (0.01-500 µM) for compound
10 (A), 11 (B) and 14 (C). Each experiment, of which one exemplary curve is depicted here, was
measured in duplicates and repeated at least two times. Mean and standard deviations of these
measurements are shown in Table 3.7.
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Figure 8.15: Concentration dependent effect of TT compounds on β-galactosidase
expression in MG1655 cells. Dose-response curves obtained by monitoring β-galactosidase
expression in MG1655 cells with increasing compound concentrations (0.01-500 µM) for compound
10 (A), 11 (B),12 (C) and 14 (D). Each experiment, of which one exemplary curve is depicted
here, was measured in duplicates and repeated at least two times. Mean and standard deviations
of these measurements are shown in Table 3.7.
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Figure 8.16: Individual HILIC/MS measurements of thiamine, thiamine monophos-
phate and thiamine pyrophosphate. Thiamine, thiamine monophosphate and thiamine
pyrophosphate can be separated using HILIC and analyzed and identified by MS/MS.
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Figure 8.17: HILIC/MS measurements of thiamine, thiamine monophosphate and
thiamine pyrophosphate mixture. Thiamine, thiamine monophosphate and thiamine py-
rophosphate can be properly separated using HILIC and analyzed and identified by MS/MS.
Figure 8.18: HILIC/MS measurements of samples 46, 51-54. All samples stem from
80ml compound isolations and a TPP double peak was detected in all samples.
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Figure 8.19: Rough quantification of samples 52 and 54 by HILIC. HILIC curves of
sample 52 (green) and sample 54 (blue) are shown. Refer to Table 3.8 for sample conditions. The
area under the curve is determined (see shaded region) as 405 (sample 52) vs. 280 (sample 54) and
can be considered a rough estimate of TPP amounts in these samples (personal communication
Giorgia Greco).
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Figure 8.20: HILIC measurements for TPP detection. HILIC measurement of sample 46
(green) and sample 46 spiked with 10 µM TPP (red) (A). Comparison of HILIC measurements for
samples 46 (red), 51 (green), 52 (blue), 53 (yellow) and 54 (pink) (B). The double peak is TPP,
which runs as double peak due to matrix effects or possibly the left peak resembles hydrolyzed
TPP species such as TMP.
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